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Abstract 
Whole genome and exome sequencing (WGS and WES) raise numerous ethical, legal and social 
issues (ELSI), such as related to informed consent and usage of sequencing data in research. 
These concerns may be amplified when genomic sequencing is offered direct-to-consumer 
(DTC) bypassing the traditional heathcare system. This thesis discusses ELSI related to 
WES/WGS and DTC genetic testing, provides an overview of current DTC genetic testing 
market, and analyses the impact of the recently adopted Regulation of the European Parliament 
and of the Council on in vitro diagnostic medical devices on DTC genetic testing. 
To provide insights into how ethical issues are addressed in DTC offer of WES/WGS, content 
analysis of websites of relevant DTC companies was conducted; the results were compared to 
relevant recommendations of expert groups. The analysis revealed the following concerns: lack 
of pre-test counselling, inadequate informed consent documents for genetic testing and/or for 
research activities on consumers’ samples and data, lack of relevant information and/or 
presence of potentially misleading descriptions in some of the companies studied. 
Consequently, consumers might not be aware of all the implications of undergoing WGS/WES, 
and their informed consent may be compromised. 
Another study presented in this thesis evaluated readability of informed consent forms for 
clinical WGS and WES using the SMOG and the Flesch-Kincaid formulas. All 36 forms studied 
failed to meet the average recommended reading grade level for informed consent forms, 
indicating that the content of the forms may not be comprehensible to many patients. 
In order to respect patients/consumers, the compliance with ethical standards when offering 
genetic testing should be strived for, also in the commercial DTC offer of WES and WGS. The 
findings presented herein indicate specific areas in which practices should be improved and 
provide reference and guidance for well-informed and potentially policy-relevant discussions 
between various stakeholders.   
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Introduction  
Introduction to the research field of ethical, legal and social implications 
(ELSI) of genomics  
‘Three profoundly destabilizing scientific ideas ricochet through the twentieth century, 
trisecting it into three unequal parts: the atom, the byte, the gene. Each is 
foreshadowed by an earlier century, but dazzles into full prominence in the twentieth. 
Each begins its life as a rather abstract scientific concept, but grows to invade 
multiple human discourses-thereby transforming culture, society, politics, and 
language.’ 
Siddhartha Mukherjee in: ‘The Gene: an Intimate History’ [1] 
Genetics – the study of heritability and variation of organisms, next to chemistry and 
information technology, has profoundly and in multiple ways impacted humanity in the last 
century. The milestones in development of genetics include the discovery of heritability units 
called genes in the XIX century, solving the structure of DNA (a molecule which makes up 
genes) in the 1950s, and finally development of technologies allowing ‘reading’ of DNA 
sequences (the order of the building blocks of DNA, called nucleotides, in which information 
about functioning of organisms is encoded) in the 1970s. These developments led to increased 
understanding of the etiology of many diseases, and consequently to provision of timely 
diagnosis and treatment to patients affected by genetic conditions. On the other hand, 
knowledge of mechanisms of heritability and evolution underlay the idea of eugenics, “science 
of improving stock” aiming to “give to the more suitable races or strains of blood a better 
chance of prevailing speedily over the less suitable than they otherwise would have had” [2]. 
Remarkably, the proponents of eugenics misunderstood the mechanism of heredity; they 
assumed that physical and mental traits are always passed on to offspring, whilst in reality the 
heredity mechanisms are far more complicated and are influenced by environmental factors. 
The eugenic movement reached its zenith in Nazi Germany in the 1940s, when compulsory 
euthanasia, sterilizations, and mass murder were employed as means of ‘racial hygiene’. After 
the end of the Second World War, the atrocities committed by Nazis, including their medical 
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doctors were judged in the Nuremberg trials (1945-1949). During the trials, U.S. doctors, 
Andrew Ivy and Leo Alexander drafted criteria of legitimate research, as a basis for the response 
to the defendants’ claims that Nazis’ practices were not distinct from medical research 
elsewhere [3]. In the verdict of the trials the points suggested by the doctors were reiterated and 
developed further into the currently known form of the Nuremberg Code. The first point of the 
Nuremberg Code outlines the requirement of voluntary informed consent for research, which 
in the coming decades gained significance not only in the practice of medical research, but also 
in clinical practice, gradually becoming part of international and national legislation [4,5]. 
Informed consent, together with the principle of confidentiality of health-related information 
became guiding principles in the subsequent practice of clinical genetics and genetic research, 
with aims to protect against the misuses of the science of heredity similar to those which left 
indelible scar on the history of the twentieth century [6,7].  
The relevance of the ethical reflection on the practice of medicine and medical research was 
also recognized decades later the Nuremberg Trials, in the context of the Human Genome 
Project (HGP) - an endeavour which aimed to sequence (or in simpler words, to obtain 
a ‘readout’ of) all the human DNA – the genome. The Human Genome Project was funded in 
1990 by the U.S. Congress with a of 3 billion dollars and a proposed timeframe of 15 years [8]. 
The efforts of international research groups to read the human genetic code were accompanied 
by the programme on related ethical, legal and social implications, the ELSI Program, for which 
between 3 and 5% of the U.S. National Institutes of Health and Department of Energy budgets 
for the Human Genome Project was allocated [9]. The ELSI Program was initially focused on 
the themes of: privacy and fairness in the use of genetic information, safe and effective 
implementation of genetic knowledge in clinical practice, education of professionals and public 
in genetics. The issues studied were meant to be closely related to the ongoing genetic research 
and informative to related policy developments [10].  
The HGP was successfully concluded in 2003 (two years ahead of a schedule) providing 
a freely accessible high-quality sequence of the entire human genome. This accomplishment 
fuelled further research endeavours for years to come, which eventually allowed, for example, 
to identify 1,800 genes related to diseases, improve diagnosis and treatment of many patients 
[11]. Furthermore, the HGP brought a ‘revolution’ to genetics research initiating new approach 
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in studying DNA - genomics, which involves large-scale studies of genome sequences using 
high-throughput technologies and collecting massive amounts of genetic data [12,13]. This is 
in contrast to the ‘traditional’ approach in genetics which was to study only one or a few specific 
genes at a time. As the research in genetics and genomics has been flourishing in the years after 
the completion of the HGP, an ELSI Program has continued to be funded by the U.S. National 
Institutes of Health influencing the way genomic research is conducted and the implementation 
of its results in medicine [14]. Moreover, research programmes with a similar scope were 
established in other countries, and ‘ELSI research’ started functioning as a term indicating a 
distinctive area of studies [14,15].  
Studies on ethical, legal and social implications of genetics and genomics may be classified as 
an area of research within bioethics – an interdisciplinary field of study dealing with ethical 
questions related to biomedical research as well as clinical practice, employing a variety of 
methods derived from disciplines such as philosophy, social sciences, media studies, legal 
studies, economics, and others. The research presented in this thesis falls within the area of 
ELSI of genomics studies as it tackles ethical, legal and social problems raised by new 
approaches employed in genomic studies, that is, whole exome and whole genome sequencing 
(WES, WGS). 
A novel approach in genetic testing - whole exome and genome sequencing 
and the related ethical issues 
As mentioned earlier, the sequencing of the first human genome took 13 years and cost 
2.7 billion of U.S. dollars. In the last decade, the capacities of sequencing technologies 
significantly advanced allowing for rapid ‘reading’ of many pieces of the genetic code 
simultaneously, in other words, sequencing DNA in high-throughput and massively parallel 
manner. Thanks to these next-generation sequencing (NGS) technologies, today it is possible 
to obtain a whole genome sequence (albeit without a complete interpretation) within a few 
weeks at a cost under 1000 U.S. dollars, with plans, by some companies, to further reduce this 
amount to just 100 U.S. dollars [16] (Figure 1). This magnitude of price reduction can be 
compared to a drop in a cost of an expensive car which could be purchased for around 400 000 
USD at the time of the Human Genome Project, and now would cost only 40 cents or less [17]. 
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Consequently, due to the higher availability of next-generation sequencing technologies, the 
approach of sequencing whole genome or whole exome (the part of genome containing only 
protein-coding regions) has been increasingly applied in the research and clinical setting. 
Furthermore, since about 2012 it has been advertised directly-to-consumers.  
Figure 1. A graph depicting reductions in DNA sequencing costs in years 2001-2015. "Cost 
per Genome" - the cost of sequencing a human-sized genome. Trend labelled ‘Moore’s Law’ 
illustrates hypothetical data based on Moore’s Law describing a trend in computer hardware 
technology, which involves doubling of ‘computer power’ every two years. The technologies 
which follow the predictions of Moor’s Law are considered to be developing very well. The 
reduction of price of DNA sequencing technology exceeds these predictions. Source: 
https://www.genome.gov/sequencingcostsdata/.  
 
Whole exome and genome sequencing generate unprecedented amounts of raw sequencing 
data. Raw exome or genome sequence may be analysed to obtain various types and amounts of 
results. Importantly, the genome analysis usually aims to provide certain type of information, 
which is defined priorly to the sequencing. For example, the goals of sequencing may be to 
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diagnose a neurological disease with unspecific manifestation, estimate predisposition to some 
diseases, determine presence of genetic variants which could cause a disease in one’s offspring. 
In each of these cases the analysis will focus on relevant, chosen aspects and parts of the 
genome/exome sequence. However, even if whole genome/exome sequence is analysed using 
such a targeted approach, there is a possibility of identifying  inadvertently usolicited findings, 
that is findings unrelated to the original indication for the sequencing. Additionally, a possibility 
of opportunistic screening can be considered, that is an approach in which a laboratory would 
analyse a set of genetic variants which are likely to be informative for healthcare of a patient 
(even if they are unrelated to the initial indication for the sequencing) every time a whole 
exome/genome is sequenced in clinic. Whatever the policy on the return of sequencing results 
is followed by a clinical laboratory, the patients should be informed about it and relevant 
choices should be made in informed consent process for WES/WEG. Given the wide-range of 
possible findings with various clinical significance, informed consent process seems to be more 
challenging in the context of genomic sequencing than in the ‘traditional’ approach to genetic 
testing focused on one or a few genes. The ethical issues related to unsolicited findings, 
opportunistic screening, and informed consent are addressed in Chapter 1: ‘Current ethical 
issues related to the implementation of whole-exome and whole-genome sequencing’, which 
provides background for the discussions presented in the subsequent chapters.  
Genomic data produced using whole exome and whole genome sequencing may be useful also 
in research, having potential of bringing benefits at societal level, for example by advancing 
medical care. At the same time, genomic data are sources of sensitive information about one’s 
health, therefore, their usage requires appropriate safeguards. The issues of informed consent 
and transparency in the context of secondary uses of genomic data for research (in direct-to-
consumer genetic testing companies) are discussed in Chapter 4: ‘Ethical issues in consumer 
genome sequencing: use of consumers' samples and data’. 
A novel context of offering genetic testing - direct-to-consumer genetic 
testing 
Whole genome and exome sequencing recently have been offered also outside the traditional 
healthcare system realm – in the direct-to-consumer (DTC) context. Companies offering direct-
16 
 
to-consumer genetic testing (DTC GT) target their advertisements at potential consumers of 
their products – individuals who would undergo the testing. Prior to such DTC companies, 
advertisements of genetic testing laboratories would be aimed primarily to health care 
professionals and/or health care institutes. DTC GT is usually purchased through e-commerce, 
over the Internet, often without any involvement of a medical professional, bypassing the 
traditional healthcare system. Some of the DTC genetic tests, however, must be ordered by 
a healthcare professional. After placing an order (usually online), a consumer receives saliva 
kit, which together with the consumer’s saliva sample is sent back to the genetic testing 
company. The test results are usually delivered online to the consumer. As noted by the 
Presidential Commission for the Study of Bioethical Issues (2013), by providing health 
information DTC GT companies “interact in both the business and medical realms, and could 
find themselves subject to the ethical principles pertinent to business transactions as well as 
those of medical care” [18]. Operating within e-commerce context, at the same time providing 
health-related information often without involvement of a healthcare-professional, DTC offer 
of genetic testing has received a lot of criticism since its appearance in 1997. The concerns have 
been raised mainly from the standpoint of medical ethics and are related to: the adequacy of 
informed consent, the clinical validity of the testing, advertising practices, impact on the 
healthcare system, and others.  
Chapter 2: ‘Current ethical and legal issues in health-related direct-to-consumer genetic 
testing’ provides an overview of the current offer of DTC GT and related ethical issues, based 
on the recent literature and observations of the DTC GT market. Furthermore, as the offer of 
DTC GT in Europe will likely be affected by the recently adopted Regulation (EU) 2017/746 
of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical 
devices (the IVD Regulation), the relevant content of the Regulation is discussed in the 
context of DTC GT.  
Empirical study of ethical issues in the offer of whole genome and exome 
sequencing in direct-to-consumer and clinical context 
The two relatively novel approaches, genomic testing and direct-to-consumer offer of genetic 
testing constitute the core of the objects for which the ethical, legal and social implications are 
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studied in this thesis. Given the ethical concerns identified in the context of whole genome and 
whole-exome sequencing (Chapter 1) as well as these raised by direct-to-consumer genetic 
testing (Chapter 2), a question arises regarding how the ethical issues are addressed in the offer 
of whole genome and whole exome sequencing directly-to-consumers - an area that had not yet 
been thoroughly investigated. To address this question the first empirical studies of the offer of 
whole genome and whole exome sequencing in the direct-to-consumer were conducted and are 
presented in this thesis (Chapter 3 and 4). These studies focus on the cornerstone principle in 
medical and research ethics, that is, informed consent, both to genetic testing and consent to 
usage of consumers’ biological samples and health-related data for research purposes. The 
following subquestions served to guide this research: 
A. What is the adequacy of informed consent process for WGS and WES offered 
directly-to-consumers? 
B. What are practices of companies offering WES/WGS directly-to-consumers regarding 
consumers’ samples and data use, including informed consent? 
To answer these questions, a qualitative approach was used incorporating content analysis to 
examine the relevant content of websites of DTC GT companies offering WGS and/or WES. 
Content analysis was established as a method in the field of media studies allowing for 
systematic examination of communicative texts [19]. In the study aiming to answer the first 
research question deductive approach to content analysis was applied, that is, the analysis was 
performed using pre-defined categories – essential elements of informed consent suggested in 
recommendations for informed consent for whole genome sequencing: pre-test counselling, 
benefits, and risks [20,21] (Chapter 3: ‘Content Analysis of Informed Consent for Whole 
Genome Sequencing Offered by Direct-to-Consumer Genetic Testing Companies’). The 
categories used in the second study were derived inductively, after initial analysis of the text 
and they are: purpose and period of samples and data storage, consumer consent, data access 
and sharing, identifiability and confidentiality of data, and proprietary claims (Chapter 4: 
‘Ethical issues in consumer genome sequencing: use of consumers' samples and data’). 
One of the observations encountered in the above outlined studies was that even though some 
elements of information were presented to consumers, they appeared as potentially difficult to 
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understand due to usage of complex vocabulary. This observation prompted the third research 
question regarding the ease of understanding of informed consent documents for whole genome 
and exome sequencing, namely: 
C. How readily understandable are consent forms currently being used for WGS and WES in 
a clinical setting?  
In this study, informed consent forms for clinical WGS and WES (that are used in the healthcare 
setting to inform medical care) were examined. Informed consent forms for WGS and WES 
advertised directly-to-consumer, however, stating explicitly that the test is clinical, were also 
included in this study. To answer the third research question, readability tests were used to 
determine what reading grade levels were required to comprehend a given text. These 
readability tests are based on the number of complex words and the length of sentences. The 
readability study of informed consent forms is described in Chapter 5: ‘Readability of informed 
consent forms for whole exome and whole genome sequencing’. 
Content of the following chapters was published as articles (Chapters 2-5) or as a book chapter 
(Chapter 1). Details of each publication are outlined in the beginning of each chapter. The 
contributions of each author to these publications are described in the section “Co-authors’ 
statements”, in the end of this thesis. 
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Abstract  
We have briefly discussed herein four of the many aspects that raise concerns in the context of 
implementation of whole-exome and whole-genome sequencing (mainly) in the clinical realm. 
Namely, we addressed issues surrounding: (1) the duty to hunt for variants known to have 
a health impact, (2) such “hunting” or opportunistic screening in children, (3) challenges to the 
consent process, and (4) the commercialization of genetic testing direct to consumer. 
Keywords: whole-exome sequencing (WES), whole-genome sequencing (WGS), genomic 
variants, genetic testing, opportunistic screening, hereditary diseases, informed consent, direct-
to-consumer (DTC) genetic testing, undiagnosed genetic conditions 
1.1 Introduction 
The Human Genome Project, a global collaborative effort aimed at sequencing the entire human 
genome, cost over $2.7 billion and took more than 10 years to complete. The first draft of the 
human genome was published in 2001 [1]. Since then, rapid advancements in next-generation 
sequencing technologies (NGS, i.e., new high-throughput and massively parallel DNA-
sequencing technologies) have led to a drastic decrease in both the price and time needed for 
genome sequencing. As of 2014, the National Human Genome Research Institute estimates the 
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average cost of whole-genome sequencing (WGS) at approximately $4,000–5,000 [2], while 
the time required for this (without interpretation of variants) has been reduced to several days 
[3]. For over a decade now, the target price of $1,000 per genome has been discussed, and 
recently some companies have announced having reached this goal, or of being very close to it 
[4]. Moreover, whole-exome sequencing (WES), which analyzes only 1 % of the genome, the 
protein-coding sections [5], entails lower costs, and for now appears to be preferred in the 
clinical diagnostic setting [6].  
The decreasing cost and time of sequencing have led to the expectation that WES/WGS will 
become commonplace in medical practice, including diagnostics, as well as in population 
screening [7, 8]. In the past few years, both WES and WGS have been successfully used to 
identify causative mutations in some highly selected patients with rare or undiagnosed diseases 
of genetic origin [7,9–12]. Although the relatively high costs of WES/WGS currently preclude 
large-scale adoption of genome sequencing in the clinical setting, it has been suggested that 
rapidly diminishing sequencing costs may soon make the techniques cost-effective in a broader 
range of clinical cases such as personalized diagnosis and personalized drug therapy. Moreover, 
some have predicted that sequencing technologies will also be applied in public health 
programs, such as newborn screening programs [13].  
Despite the potential promises of WES/WGS in clinical practice, a number of challenges have 
been identified with regard to the potential implementation of sequencing technologies in health 
care. Firstly, even though the analytic validity of WES/WGS has improved dramatically, current 
sequencing techniques remain imperfect. For example, a recent study reported that, depending 
on the sequencing platform used, WGS failed to sufficiently cover from 10 to 19 % of inherited 
disease genes of interest [5,14]. Imperfect analytic validity of WGS is worrisome, since given 
the large scale of the human genome (>3 billion base pairs), even a very small percentage of 
erroneous results would translate into a high number of incorrect variants in absolute terms [12].  
Secondly, owing to the present limited understanding of the human genome, many variants 
currently identified through WES/WGS are unclassified; that is to say that they are variants of 
unknown significance, and their potential effect or impact on an individual’s health is yet to be 
determined [7]. Indeed, debates have been ongoing regarding to what extent such findings 
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should be reported to patients. Although unknown or unclassified variants may be valuable for 
research purposes, in the healthcare setting, they might offer little benefit to the individual 
patient as long as their true meaning has not been correctly understood. Furthermore, a large 
number of genetic variants, when combined with other genetic variants or environmental 
factors, may be suspected of playing a role in an individual’s predisposition to multifactorial 
conditions, such as cancer, diabetes, and cardiovascular diseases. However, the predictive value 
of such results may be low [8]. Although this is not specific to the technique of WGS/WES, 
given the large amounts of data generated with these approaches, one could predict that there 
will be more of these variants found with uncertain meaning. Moreover, the use of WES/WGS 
may reveal variants unrelated to the primary indication for sequencing (i.e., unsolicited or 
incidental findings) and lead to the question of which findings should be communicated to 
patients [7], how, and by whom [15]. This issue becomes even more knotty when the individual 
tested is a child, and findings may be relevant only later in life or may be predominantly 
informative (at the time of testing) for family members (but not necessarily for the child being 
tested).  
Thirdly, the amount and variety of information obtained through WES/WGS have important 
implications for information provision and counselling to the patients undergoing the procedure. 
Due to the complexity of the procedure – including technical aspects of WES/WGS, diagnostic 
value, likelihood of unsolicited/incidental findings, and implications of the test results for other 
family members – pretest counselling involving the informed consent procedure could 
drastically increase the time of the counselling process [16, 17]. Such counselling sessions 
should, ideally, clearly distinguish among the types of expected results in order to facilitate an 
informed decision by the patient [18]. Notably, post-test counselling may be equally time-
consuming, especially if the patient chooses to receive extensive information on incidental 
findings [7]. Furthermore, additional counselling and consent sessions may be required in those 
cases where either the patient’s biological sample or data derived through WES/WGS are to be 
retained for future research purposes.  
Evidently, there are several concerns with respect to the implementation of WGS/WES; herein, 
we outline four important ethical challenges to the implementation of these approaches in 
clinical care (and the related commercial context). To begin with, the issues related to 
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unsolicited findings and opportunistic screening in WES/WGS will be discussed: first in more 
general terms and secondly with respect to a pediatric population. Next, problems with informed 
consent will be covered. Finally, ethical issues regarding direct-to-consumer genetic testing will 
be considered. 
1.2 Unsolicited Findings and the Duty to Hunt  
As alluded to above, the increasing use of high-throughput technologies and approaches in 
genomics, both in the research and clinical contexts, has increased stakeholders’ focus on the 
topic of unsolicited findings. Unsolicited findings have also been referred to as incidental 
findings, unsolicited variants, unanticipated results, secondary variants, unexpected or off-target 
results, unsought results, or unrelated findings [19], as well as non-incidental secondary 
findings, serendipitous, or iatrogenic findings [20]. The exact meaning of each term as well as 
their merits has, to some extent, been debated and could, arguably, be even further discussed 
[19,21,22]. However, for the purpose of this chapter, we will use the term unsolicited finding to 
mean a result found during research or clinical testing that is beyond the aims of the study or 
the original reason to conduct clinical testing.  
Although unsolicited findings are not specific to genomics, the phenomenon is viewed as 
needing particular attention given the fact that we can now generate unprecedentedly large 
quantities of sequencing data in a very short time and therefore have access to a lot of 
information, whether or not it is related to the initial question posed [23]. Many authors have 
discussed whether or how unsolicited results should be returned to patients in the clinic [24] or 
to research participants in a research study [25]. Although there remains a lot of discussion 
regarding details, there appears to be a consensus taking shape: should a clinician or researcher 
discover a medically actionable variant with established health impact, this information should 
be returned to patients/participants [26,27]. For example, the European Society of Human 
Genetics recommends “If the detection of an unsolicited genetic variant is indicative of serious 
health problems (either in the person tested or his or her close relatives) that allow for treatment 
or prevention, in principle, a health-care professional should report such genetic variants” [18]. 
This being said, the details regarding which variants have utility or impact and the criteria 
needed to make these decisions are still being debated [23].  
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Closely related to this topic is the notion of the “duty to hunt” for genomic variants that may 
have a health impact for patients; that is to say, when performing WES/WGS, do physicians 
and/or researchers have a duty to actively search the sequence data for variants known to have 
a health impact but that are not necessarily related to the indication for performing the 
sequencing in the first place? Although some authors have referred to the findings obtained 
through this “hunt” as incidental findings [20], others have commented that such intentional 
“hunting” or searching could not be described as “incidental,” at least not in the “usual sense of 
the term” and have described the phenomenon as “opportunistic screening” [28,29]. The 
discussion regarding the return of results, including the duty to hunt, differs somewhat 
depending on the context, clinical, or research [30]; herein, we focus on the issue of the duty to 
hunt in the clinical context.  
Perhaps, the most well-known stance supporting a duty to hunt in the clinical context comes 
from the American College of Medical Genetics and Genomics (ACMG) which, in the first half 
of 2013, published recommendations supporting “that laboratories performing clinical 
sequencing seek and report mutations of the specified classes or types in the genes listed here. 
This evaluation and reporting should be performed for all clinical germline (constitutional) 
exome and genome sequencing, including the “normal” of tumor-normal subtractive analyses 
in all subjects, irrespective of age but excluding fetal samples” [20]. The ACMG provided a list 
of 56 genes associated with 24 inherited conditions that should be screened whenever a patient 
(of any age) is offered sequencing. The list was developed based on what the ACMG called a 
“consensus-driven assessment of clinical validity and utility” and focuses on conditions with 
relatively high penetrance and for which an intervention may be possible. Importantly, the list 
does not include conditions that are already part of newborn screening. The initial 
recommendations proposed that patients could not refuse the testing of these 56 genes without 
also forfeiting the access to WES/WGS. However, in the face of criticisms concerning the lack 
of support for patient autonomy, shared decision-making, and for patients’ right “not to know” 
[28,31,32], the ACMG changed their stance on this point the following year [33]. The rationale 
for opportunistic screening is based mainly on the medical benefit for patients and their families, 
where the identification of a genetic risk could allow for the early adoption of prevention or 
treatment measures. Furthermore, it is based on the fiduciary duty of clinicians and laboratory 
personnel to prevent harm. It should be noted, however, that these recommendations are not 
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meant for sequencing done in the context of preconception, prenatal, or newborn sequencing, 
nor do they apply to the sequencing of healthy children and adults [20].  
A number of concerns have been raised in reaction to these recommendations, including a lack 
of evidence for establishing the list of genes and the lack of information about frequencies of 
variants in healthy or not-at-risk populations [28]. Such a lack of information could 
subsequently lead to erroneous classifications of variants as pathogenic, which could cause 
needless anxiety and cause patients to seek inappropriate and costly follow-up medical 
procedures [34]. The fact that important stakeholders, such as members of the public and 
primary care physicians, were absent from the discussion [32] has also been mentioned as a 
weakness. Of major concern is also the potentially extremely high costs in terms of time, 
resources, effort, and money to conduct such screening [32]. Furthermore, there has been 
criticism regarding the screening of children in this context, especially for adult-onset disorders 
(see below).  
Although other professional associations’ and policy groups’ guidelines have mentioned 
opportunistic screening, they have not outright recommended it [29, 35]. Moreover, the 
European Society of Human Genetics’ guidelines on the use of WGS in health care advise that 
approaches such as targeting and filtering be used to reduce the chances of even encountering 
unsolicited findings: “When in the clinical setting either targeted sequencing or analysis of 
genome data is possible, it is preferable to use a targeted approach first in order to avoid 
unsolicited findings or findings that cannot be interpreted. Filtering should limit the analysis to 
specific (sets of) genes. Known genetic variants with limited or no clinical utility should be 
filtered out (if possible neither analyzed nor reported)” [18]. Although only indirectly addressed 
within the context of the management of incidental findings in the clinical context, the 
Presidential Commission for the Study of Bioethical Issues recommends that “Medical 
educators, both in the classroom and clinic, should continue to cultivate ‘diagnostic elegance’ 
and ‘therapeutic parsimony’ amongst practitioners—ordering and conducting only tests and 
interventions necessary for addressing health concerns related to their patient” [36].  
In conclusion, currently, there is no general agreement regarding whether clinicians who use 
WGS or WES for diagnostic purposes also have a duty to hunt for other variants with health 
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impacts. There is, however, a large consensus that much more evidence is needed [20, 28, 34] 
regarding opportunistic screening and its potential impact on the healthcare system and on 
patients. Even the ACMG recognizes that “there are insufficient data on penetrance and clinical 
utility to fully support these recommendations, and we encourage the creation of an ongoing 
process for updating these recommendations at least annually as further data are collected” [20].  
1.3 Opportunistic Screening in Children  
As previously mentioned, the introduction of WES/WGS in the clinic may revolutionize the 
potential for finding the (molecular) diagnosis of genetic conditions, including movement 
disorders. Although this may confer benefits in terms of reducing the diagnostic odyssey, and/or 
improving patient management [7] as well as revealing potential risks for relatives, it also raises 
ethical issues in relation to genetic testing in children.  
Consider this scenario:  8-year-old Jack is referred to your clinic for investigation of the genetic 
cause of his progressive ataxia. His parents, who are considering having a second child, are 
keen to find out the genetic basis of his condition in order to avoid having a second affected 
child. Given there are several candidate genes, you decide whole-genome sequencing will be 
most cost-effective. Following testing, you receive the laboratory report which reveals the 
genetic cause for Jack’s progressive ataxia, as well as a result unrelated to diagnosing the 
ataxia – that he carries a variant in BRCA1. This variant is expected to be pathogenic and 
therefore has health implications for Jack, one of his parents, and potentially their extended 
family members. 
As described in the previous section, the use of WES/WGS raises the question as to whether 
laboratories should limit their reporting of results only to the findings that are relevant to the 
clinical question at stake or to “hunt” for other variants known to have a health impact. The 
previously mentioned ACMG guidelines, which recommend the active search of a selected 
group of genes, including those for conditions with adult onset, have led to a heated debate 
regarding whether these recommendations should also apply to children. The ACMG states that 
“masking or tailoring the reporting of such information according to the age of the patient could 
place an unrealistic burden upon laboratories facing increasing volumes of clinical sequencing. 
The Working Group also felt that the ethical concerns about providing children with genetic 
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risk information about adult-onset diseases were outweighed by the potential benefit to the 
future health of the child and the child’s parent of discovering an incidental finding where 
intervention might be possible. Therefore, the Working Group recommended that 
recommendations for seeking and reporting incidental findings not be limited by the age of the 
person being sequenced” [20].  
These recommendations appear to be in stark contrast to previous recommendations for 
predictive testing in children as well as to a set of guidelines which were jointly released by the 
American Academy of Pediatrics (AAP) and the ACMG in 2013 [37,38]. The AAP/ACMG 
guidelines recommend that children should generally not receive genetic testing for adult-onset 
disorders, particularly where no treatment is available [37,38]. It should be noted, however, that 
the contextual background of testing differs somewhat for each set of guidelines. The 
AAP/ACMG guidelines are generally situated in a clinical setting where parents may request 
predictive testing for their child for an adult-onset condition that is already known in the family 
[37,38]; no particular strategy or tool for testing is mentioned nor do they mention a situation 
of opportunistic screening. The ACMG guidelines, on the other hand, relate specifically to 
a situation such as Jack’s, described above, where WES/WGS is used as a diagnostic approach 
[20].  
This contextual difference translates to two important distinctions between the WES/WGS 
diagnostic approach from the standard predictive testing context [39]. First, the nature of the 
tools or approach used for diagnostic purposes in Jack’s case means that the sequence data is 
already available for the “hunt” rather than a specific test being performed only for the reason 
of testing an adult-onset condition. Second, the genetic predisposition Jack carries for BRCA1 
may not have been identified previously in the family, and reporting of the variant could, 
therefore, potentially lead to early detection of risk and implementation of screening for both 
Jack in the future and also for relatives. These are the primary drivers of the ACMG’s 
recommendations for reporting these variants [20].  
Although the reporting of results from opportunistic screening might result in health benefits 
for the children or their family, we must also consider the potential (harmful) impact when one 
of these variants is identified in a child and disclosed to the family. Standard genetic guidelines 
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for predictive testing in children often indicate that when there is no medical benefit from 
performing predictive testing, then it is in the child’s best interests to postpone testing until the 
child is able to make an autonomous decision [37,38,40–42]. That being said, the AAP/ACMG 
guidelines also leave some room for alternate routes when they state that “…after careful genetic 
counseling, it may be ethically acceptable to proceed with predictive genetic testing to resolve 
disabling parental anxiety or to support life-planning decisions that parents sincerely believe to 
be in the child’s best interest” [38]. One of the challenges in the context of genetic testing is that 
there are many different views regarding exactly what constitutes as being in the child’s best 
interests [43].  
One way of determining what is in the child’s best interests might be to assess the harms of 
reporting and not reporting the results from opportunistic screening (or unsolicited findings). 
Some authors have proposed that the harms of reporting such results in children are limited to 
the imposition of undesired genetic information on the child and their family [44]. They argue 
that this is outweighed by the potential harm of removing family members’ opportunities to 
avoid illness through screening [44]. Although genetic guidelines generally recommend against 
providing predictive testing in young children, few studies have investigated the psychological 
impact of testing [40–42,45]. There is, therefore, little in the way of evidence to suggest that 
identification of an unsolicited finding (or results from opportunistic screening) predisposing a 
child to a genetic condition would cause psychological harm. However, lack of evidence does 
not equate to evidence of a lack of harm, and therefore, additional empirical studies to 
investigate this are required.  
The ACMG has taken a more family-based approach to what is in the child’s best interests. 
They argue that identification of these pathogenic variants in children benefits the child, first by 
providing them with important information about their future health risks and, second, through 
the potential health benefits to their parents should they be detected prior to displaying 
symptoms of the genetic condition for which a mutation was detected. Therefore, the ACMG 
believes that the ethical concerns are outweighed by the “potential benefit to the future health 
of the child and the child’s parents” [20]. For this reason, their follow-up recommendations 
indicated that it could be viewed as unethical if laboratories do not report these unsolicited 
findings, because they are failing to allow parents to act in their child’s best interests and avoid 
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preventable harm [44,46]. This is in line with literature acknowledging that parents are best 
placed to consider all the factors that impact on their family and should therefore be allowed to 
make decisions in a way that takes the family’s best interests into account [47]. This being said, 
whether parents will be sufficiently informed regarding the unsolicited information they might 
receive in order to make decisions on behalf of their children and their broader family is unclear.  
One should consider what else is at stake for the child if we report the results of opportunistic 
screening (or unsolicited results). A commonly stated argument against predictive testing in 
children is that, as well as removing their right to privacy (regarding their genetic result), it 
impinges on their future autonomy, specifically the child’s ability to make his/her own decisions 
about whether they want to know their genetic status when they are older [42]. This concept has 
been referred to as “the child’s right to an open future” and rests on the notion that genetic 
testing would narrow the child’s future options [48,49]. Likewise, when the results of 
opportunistic screening are reported to the clinician and subsequently to Jack’s parents and Jack, 
we are removing the child’s right not to know whether he has a BRCA1 mutation. From this 
perspective, preservation of the child’s future autonomy would involve either not conducting 
the screening at all for adult-onset disorders or, in the case of a truly “stumbled upon” incidental 
finding, to not report it to the clinician. Alternatively, the result could be reported to the clinician 
and held in trust until the child is able to make an autonomous decision. However, one might 
also view that by disclosing the results of opportunistic screening to the family, we are in fact 
broadening the options available to Jack and his family by providing them with opportunities 
for further screening and preventative care.  
Debate continues as to whether laboratories should “hunt for” and report back results for a preset 
list of genes when WES/WGS is conducted in the clinical setting in children or whether 
reporting should be restricted to findings relevant to the quest for a diagnosis. Ultimately, it 
depends on the importance one places on the preservation of the child’s right not to know 
information about their genetic risks compared to the potential health benefits for the family. 
Given that once information is known, it cannot be “unknown,” perhaps the initial premise 
should be to remain cautious until more evidence is amassed regarding the impact of returning 
results to children for adult-onset disorders and limit reporting to the original clinical question 
and, in doing so, promote the child’s future autonomy. 
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1.4 Informed Consent for WES and WGS in Diagnostics  
Informed consent in clinical practice functions as a permission given for the performance of 
a medical procedure by a capacitated patient to whom the information about the procedure has 
been given, who understands it fully, and voluntarily consents to it. Informed consent has been 
integrated in most jurisdictions as a legal requirement and supported ethically as ultimate 
respect for the autonomy of individuals and their right to self-determination [17]. It has been 
argued that in order to obtain genuine informed consent, the information about the procedure 
(or in this context the genetic test) presented to a patient should be accurate, relevant, and 
understandable, and the patient should have the opportunity to freely withdraw consent [17,50]. 
Yet, obtaining valid and adequate informed consent for some medical procedures poses 
challenges such as those related to proper communication of the information and its 
comprehension, which is particularly relevant for informed consent for genetic testing. The fact 
that clinical genetic testing is usually offered with both pre- and post-test genetic counseling is 
an indication of how important and potentially complex communication can be in this context. 
Herein, we offer a list of issues that should be considered when planning for the informed 
consent procedure for WES/WGS.  
Indeed, the implementation of WES and WGS adds further challenges and amplifies those 
already existing related to the informed consent procedure for “traditional” genetic tests. This 
is primarily caused by the vast amount of complex information that may be extracted from 
whole-exome or whole-genome sequence data. This information varies with respect to the 
clinical significance and predictive value, which may influence the individual’s desire to obtain 
particular results [51]. Related to this, the potential for unsolicited findings is of particular 
concern in the informed consent process. Among others, they raise a question about the 
categories or types of genetic variants (i.e., those with high penetrance or clinical utility or 
health impact) that should be retrieved from a whole-genome sequence [18,20]  and what should 
be reported to patients. Even if sequencing is targeted and filters are applied to WES/WGS with 
the aim of obtaining only findings relevant to the medical indication in question, unsolicited 
findings may nevertheless appear in the process of sequence analysis and interpretation. 
Although unsolicited findings exceed the initial scope of the test, they may be clinically 
actionable, which poses questions about the obligation to disclose them [36]. Additionally, the 
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significance of sequencing data may change with time as our understanding of variants 
progresses through genomics research. Therefore, the storage of the data should be considered 
as well as the possibility of reanalyzing and reinterpreting data in the light of new scientific 
findings and whether the patient agrees to be recontacted for this information (or for any 
incidental finding). Furthermore, in the case where clinical whole- genome sequencing is 
coupled with research, this subject, including the issue of data sharing, should be discussed 
during the informed consent process [52]. Finally, as with other genetic tests, some of the 
outcomes of WES/WGS for hereditary diseases concern not only the patient but also the 
relatives or future offspring; thus, this introduces the dilemma of potential obligation to disclose 
some information to family members [25]. Additional difficulties appear in case of WES/WGS 
offered for children, whose “right not to know” regarding health prospects should be retained 
as much as possible [51] in the case of testing for adult-onset conditions. All of the issues 
outlined above make the process of designing appropriate informed consent procedures in the 
context of WES/WGS particularly challenging. It is crucial to communicate with the patient 
regarding these factors and, in particular, to communicate the meaning and implications of the 
different types of expected findings in an understandable way that would allow truly informed 
decision-making.  
Given these challenges, many societies and experts have attempted to face or overcome the 
difficulties of informed consent in this new context of WES/ WGS. Ayuso et al. specifically 
analyzed publications and guidelines concerning or related to informed consent for WGS in the 
clinical context [53]. The authors found a relatively high level of consistency among the 
guidelines and proposed a minimum list of information that should be provided to the patient, 
which are the management of incidental findings, the scope, a description indicating the kind of 
information to be obtained, the possible benefits and risks, the availability of alternative tests, 
the voluntary nature of the test, the possibility of refusal, the future use of the data, and the 
confidentiality of the outcomes. Pretest counseling has been underlined by the authors of the 
abovementioned publication as well as by other experts in various recommendations as a crucial 
element of informed consent [53]. Pretest counseling should prevent informed consent from 
being reduced to the mere signing of a document. It should be ensured through dialogue that the 
patient truly understands the information provided and is competent to make a choice. Fulfilling 
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these requirements in the context of WES/WGS will demand time-consuming counseling 
sessions provided by properly trained professionals [55].  
Various authors have also suggested new strategies of informed consent that may minimize 
information overload by introducing clinically relevant categories of diseases and traits, layers 
of indispensable and additional information, and informational and decisional phases of consent 
that require it to be stretched in time [56–59]. Dynamic models of consent, where the use of 
information technology interfaces places patients at the center of the decision-making process 
and allows them to be more engaged over the entire time span of use of their 
sample/information, may also help to ease the challenges of consent for WGS/WES [60]. These 
different strategies may facilitate the counseling and informed decision-making of the patient 
regarding the type of test they want to consent to and categories of results that will be returned.  
Concluding, informed consent is just one of the elements related to the ethical issues around 
WES/WGS. Its adequacy may not resolve the other ethical issues related to data handling and 
return of results; however, efforts should be made to implement the proposed recommendations 
and new strategies of informed consent for WES/WGS into clinical practice. Thereafter, studies 
may be conducted toward optimizing informed consent procedures so that it may fulfil its 
functions more adequately. 
1.5 Genetic Testing Beyond the Clinic: Commercialization of Genetic Tests  
Although not, strictly speaking, a part of the realm of “clinical” genetics per se, direct-to-
consumer (DTC) genetic testing, in many ways, brushes up to the activities of clinical genetics 
(e.g., some of the types of tests being offered and the inclusion of healthcare professionals in 
the process). Furthermore, as a relatively new phenomenon, which has sparked a great deal of 
debate in the last years, we chose to address these activities and their ethical dimensions herein. 
Unlike the previous sections, however, we do not confine the discussion only to WES/WGS and 
the companies offering these services DTC, as these are fairly recent, and the ethical issues 
surrounding companies offering genome-wide testing are very similar to those offering 
WES/WGS. Furthermore, it is important to note that all three previous topics discussed are 
relevant concerns, albeit with some variations, for companies offering WES/WGS DTC.  
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 For more than a decade now, several for-profit companies have been commercializing genetic 
tests through the Internet, often without involving a healthcare professional in their services 
[61]. Such tests are advertised directly to the public, and consumers may order and receive the 
tests themselves, or through a healthcare provider [62]. The majority of direct-to-consumer 
(DTC) genetic testing companies are based in the USA, although the number of companies 
established in Europe and Asia is also growing [63]. The DTC genetic testing market 
comprises a very heterogeneous spectrum of companies and products, while its size is still 
unspecified [64].  
Currently, a wide variety of genetic tests is available DTC, including tests for recreational 
purposes, such as athletic performance and ancestry tests and tests for health-related purposes 
such as tests for multifactorial or monogenic disorders, test for carrier status, and nutrigenomics 
and pharmacogenomics tests. While in previous years the most comprehensive testing was 
offered mostly by companies genotyping hundreds of thousands to millions of SNPs, more 
recently companies are now also offering whole-genome and whole-exome sequencing directly 
to the public.  
Specifically for conditions under the umbrella of movement disorders, various consumers might 
be able to find tests DTC, including tests for susceptibility to Parkinson’s disease [65] , Tourette 
syndrome [66] , and restless legs syndrome [67], as well as carrier tests for ataxia-telangiectasia 
(ATM) [68] and rare diseases such as myoclonus dystonia (DYT11) and Rett syndrome 
(MECP2) [68] . In the past, some companies have also offered susceptibility tests for essential 
tremor, tardive dyskinesia, and progressive supranuclear palsy [69] . Indeed, DTC genetic tests 
on offer are frequently subject to changes, as the DTC genetic testing market is a particularly 
dynamic field.  
Supporters of DTC genetic testing claim that such tests promote genetic education of 
consumers, empower them to improve their health by making their own healthcare decisions, 
and enhance their autonomy [70]. In addition, given that DTC genetic testing may potentially 
enable consumers to control who has access to their test results, this type of testing is considered, 
by some, to protect privacy of genetic information toward employers and insurance companies 
[71].  
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Nevertheless, DTC genetic testing has also been subject to a lot of criticism over the past years, 
and concerns have been raised by several authors and professional organizations regarding the 
potential risks stemming from such tests. One of the main concerns regarding this type of testing 
has to do with the uncertain clinical validity and utility of many of the tests offered DTC. When 
it comes to susceptibility testing for common complex disorders, such as Parkinson’s disease, 
where the development of the disorder is usually the result of several genetic mutations acting 
in combination with other nongenetic factors [72], the predictive value of individual genetic 
variants remains low [72], and the commercialization of such tests is often considered to be 
premature [73]. The clinical utility of such tests is also questionable in many cases, since the 
test results are often not clinically actionable, and the health advice provided along with them 
is usually generic [74]. When thinking of rare monogenetic disorders, some concerns also exist 
about the extent to which the pathogenicity of variants is known, as well as penetrance and 
expressivity, especially in healthy populations, which have traditionally not been studied for 
such disorders. Moreover, when using WES/WGS, the problems of reporting (or not) variants 
of unknown significance remain. 
In addition, it has been claimed that without genetic counseling and individualized supervision 
from a healthcare professional, consumers are more likely to misinterpret the test results and 
potentially take inappropriate healthcare actions or experience unnecessary anxiety [71]. The 
importance of medical supervision and pre- and post-test genetic counseling in the context of 
genetic testing for movement disorders is often underlined, since the test results are, in many 
cases, inconclusive, and their interpretation requires a high level of expertise in genetics [75,76]. 
Furthermore, in light of the limited clinical interventions available for disorders like Parkinson’s 
disease, performing the appropriate test for the appropriate person is particularly important, in 
order to avoid unnecessary distress and redundant visits to healthcare professionals [75]. It is 
important, therefore, that this type of testing is performed in the context of genetic counseling 
and that it is based on an informed decision of the patient [75]. Despite the fact that lately, many 
DTC genetic testing companies tend to involve healthcare professionals in their services, 
various concerns remain. Including a medical prescription on paper for genetic tests is not 
a guarantee of an adequate informed consent procedure and pretest counseling. In most cases, 
any physician seems to be allowed to order genetic tests regardless of whether he/she has 
adequate training to do so. Finally, some healthcare professionals may be employed or 
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otherwise collaborating or linked with some companies, raising doubts about their impartiality 
[62].  
Several professional organizations, genetic societies, and bioethics committees have addressed 
concerns related to DTC genetic testing, stressing in guidelines and recommendations the 
importance of medical supervision, genetic counseling, and informed consent and ensuring the 
quality of the tests [72,77,78]. Nevertheless, the effective regulation of this field remains a 
challenge, since the regulatory landscape both in Europe and the USA is rather fragmented and 
complex, leaving some important gaps [63]. Furthermore, the idea of a “one size fits all” 
regulation for all types of tests (e.g., ancestry, health related, etc.) may not be the most coherent 
approach. Finally, enforcement of national legislation may be problematic, given the global 
character of this industry which operates mostly through the Internet [79]. 
Conclusion  
We have briefly discussed herein four of the many aspects that raise concerns in the context of 
implementation of whole-exome and whole-genome sequencing (mainly) in the clinical realm. 
Namely, we addressed issues surrounding (1) the duty to hunt for variants known to have 
a health impact, (2) such “hunting” or opportunistic screening in children, (3) challenges to the 
consent process, and (4) the commercialization of genetic testing direct to consumer. Indeed, 
none of these are new issues per se, but each issue when brought into the context of WES/WGS 
has new particularities and appears to be exacerbated by these high-throughput approaches. 
Furthermore, it is clear that the ethical and procedural frameworks previously created to deal 
with these aspects for “traditional” clinical genetic testing (i.e., where one or few genetic tests 
were performed usually sequentially) are, at best being challenged by the use of WES/WGS, 
and at worse, completely inept to properly manage these areas and concerns.  
It is evident that, overall, more evidence is needed in order to pave the route to responsibly 
manage the implementation of WES/WGS in clinical care. Regarding the return of incidental 
findings and/or opportunistic screening, it will be important to closely study centers and pilot 
projects that currently offer these services to patients and to study the impact on patients. 
Additionally, with respect to programs for opportunistic screening, like that proposed by the 
ACMG, evidence is needed regarding the penetrance and mutagenicity of the 56 genes in 
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healthy populations. Evidence is also needed specifically regarding the return of results for 
children, especially for adult-onset disorders. Are children negatively impacted by such 
information? Is there a benefit to them knowing? With respect to the ACMG guidelines, there 
is also a need to discuss and reconcile the discrepancies between traditional guidelines that 
suggest no testing in children for adult-onset disorders unless action can be taken to reduce the 
chances of developing the disorder. This discussion should also address the fact that DTC 
genetic testing companies can, and do, test children for adult-onset disorders. Regarding 
consent, new models and procedures of consent need to be carefully planned to integrate all the 
aspects and information needed to obtain proper informed consent in the context of WES/WGS. 
These then need to be tested on patient populations and the impact on patients measured. Finally, 
the DTC offer of genetic testing should continue to be monitored, as this group of actors has 
tended to offer services that go well beyond what we have been used to in the traditional clinical 
context. 
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Abstract 
A variety of health-related genetic testing is currently advertised directly to consumers. This 
article provides a timely overview of direct-to-consumer genetic testing (DTC GT) and salient 
ethical issues, as well as an analysis of the impact of the recently adopted Regulation on In 
Vitro Diagnostic Medical Devices (IVD) on DTC GT. DTC GT companies currently employ 
new testing approaches, report on a wide spectrum of conditions, and target new groups of 
consumers. Such activities raise ethical issues including the questionable analytic and clinical 
validity of tests, the adequacy of informed consent, potentially misleading advertising, testing 
in children, research uses and commercialization of genomic data. The recently adopted IVD 
Regulation may limit the offers of predisposition DTC GT in the EU market. 
Keywords: direct-to-consumer genetic testing, genetic testing, consumer genomics, consumer 
genetics, informed consent, genetic counselling, IVD regulation  
2.1 DTC genetic testing and related services 
Direct-to-consumer (DTC) genetic testing (GT) (for the purpose of this article we will be using 
terms ‘genetic’ and ‘genomic' interchangeably) encompass a wide and heterogeneous range of 
offers, which have constantly been evolving since the emergence of DTC GT almost two 
decades ago. Given the dynamic nature of the DTC GT market and how it poses (new) ethical 
and regulatory challenges, in this article we aim to provide overview of the current offer of 
health-related DTC GT and the related salient ethical issues. Furthermore, as the offer of DTC 
GT in Europe may be affected by the recently adopted Regulation (EU) 2017/746 of the 
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European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices 
(the IVD Regulation), we discuss the relevant content of the Regulation in the context of DTC 
GT.  
This article focuses mainly on health-related testing, excluding testing with other main purposes 
such as ancestry and paternity. However, it is important to note that ancestry test results may 
reveal health-related information to consumers given the known associations between genetic 
ancestry markers and disease, some of which have been reported in mainstream media and 
received attention of ancestry testing consumers [1]. Furthermore, web-based interpretation 
services can provide health-related information on the basis of raw data received from ancestry 
genetic testing. 
2.1.1  Direct-to-consumer genetic testing definition  
Direct-to-consumer genetic testing is a commercial model of genetic testing provision whereby 
consumers can undertake a test without necessarily any involvement of a healthcare 
professional (HCP). A consumer can order a test via the Internet or buy it at a pharmacy, (s)he 
then receives a saliva or swab kit, which together with the consumer’s saliva sample is sent to 
the genetic testing company. The results are usually delivered online to the consumer. A number 
of DTC GT companies however, do advertise directly to consumers, but then, require that the 
test be ordered by a healthcare professional and/or that the results be returned to a HCP. This 
broader definition of DTC GT including testing advertised directly to consumers, but involving 
a HCP was recognized in ‘A Common Framework of Principles for direct-to-consumer genetic 
testing services’ issued by the UK Human Genetics Commission [2] as well as by researchers 
[3,4]. Supporting this definition is the fact that one of the crucial characteristics of DTC GT, 
that is to say, advertising directly to consumers, is retained in the model of DTC GT including 
a HCP. 
2.1.2 Current offer of DTC GT – expanded scope, audience and new technology 
The first health-related genetic tests marketed directly to consumers were identified almost two 
decades ago [5]. In 2002, as part of research aiming at identifying the availability of DTC GT, 
Gollust et al. identified 14 companies selling health-related DTC GT [6]. A recent study by 
Phillips (2015) revealed that the market of health-related DTC GT has grown significantly in 
the last decade reaching over hundred companies [7]. Considering that these studies (including 
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search terms) were performed in English, the total number of companies offering DTC GT may 
be assumed to be even larger.  
Importantly, not only has the number of companies grown in recent years, but their offer has 
expanded regarding the scope of the tests, technologies used, and the target audiences of the 
tests. The types of health-related tests offered by DTC GT companies include lifestyle (dietary 
and fitness) testing, pharmacogenomic tests (concerning reaction to drugs), carrier testing 
(revealing persons who carry a mutation that may cause a disease in their offspring), and tests 
providing diagnostic and disease predisposition information. The range of diseases for which 
companies provide results also varies greatly, starting from single-gene diseases with known 
genetic cause(s) (i.e. mendelian or monogenetic diseases, e.g. sickle cell anaemia) to conditions 
having a complex genetic background and for which development is usually the result of several 
genetic and non-genetic factors acting in concert (i.e. complex diseases, e.g. cancer, diabetes).  
Furthermore, the DTC offer of genetic testing varies regarding the amount of data/results 
provided. Some companies offer single gene tests (e.g. Graceful Earth) [8], others offer the 
testing of a group of genes relating to a type of disorder (e.g. cardiology-panels offered by 
Invitae) [9], while others offer genome wide testing of hundreds of thousands of single 
nucleotide polymorphisms (SNP) and offer a report on over a hundred conditions and traits (e.g. 
23andMe) [10].  In recent years, companies, have also been offering whole exome sequencing 
and whole genome sequencing [11]. Whole genome sequencing generates readouts of (almost) 
all the DNA present in cells, whilst whole exome sequencing provides sequence of all protein 
coding regions of DNA; in both cases the amount of genetic information obtained is 
unprecedented. Once sequenced, the exome or genome can then be analysed for specific, 
defined purpose(s) (e.g. using targeted gene approach where only a subset of genes is analysed), 
for example to identify variants relevant to a specific disease, variants related to responses to 
drugs, or variants associated to (complex) traits.   
Currently DTC GT is advertised not only to the (healthy) ‘worried-well’ (i.e. symptomless 
adults anxious about their health) and persons with higher education levels and disposable 
income. The decrease in price as well as the expansion of the types of tests offered resulted in 
the significant expansion of the consumer groups to which DTC GT is explicitly aimed. Namely 
this encompasses: couples considering having children (carrier screening, e.g. Counsyl) [12], 
pregnant women (prenatal testing, e.g. Veritas Genetics) [13], and individuals wanting 
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preimplantation diagnosis/screening tests, which allow for the selection of embryos that have 
(or not) specific genetic variants can be selected (e.g. offered by Illumina) [14]. Furthermore, 
parents of new-borns [15] and children [16] are being encouraged by companies, through online 
advertisements, to purchase the tests for their offspring. 
2.1.3 Interpretation and data sharing services for DTC GT consumers 
Some DTC GT companies (e.g. 23andMe) provide consumers not only a report describing 
results of the testing (i.e. the interpretation of genetic variants with respect to disease), but also 
non-interpreted raw data in a downloadable format [17]. These raw data can then be uploaded 
on several online genomic data interpretation services, for example: Promethease [18], 
LiveWello [19], Genetic Genie [20], Sequencing [21].  Such online services provide consumers 
with health-related information based on the analysis of the raw DNA data.  
 
Furthermore, there are also online services/platforms aimed at DTC GT consumers, to which 
they can upload their raw genetic data to make them accessible to others (e.g. general public or 
groups of researchers), for example openSNP [22], DNA.Land [23], Sequencing [21]. Apple 
has also announced adding a module to its ReasearchKit apps allowing consumers to share their 
genetic data from 23andMe with researchers [24]. Interestingly, there are also companies 
(Genos, Invitae, Portable Genomics) which are planning to provide consumers platforms for 
sharing their genetic data for which the consumers would be paid/compensated [25].  
2.2 Ethical issues in DTC GT companies 
Having originated from outside the traditional health care system, with a plethora of differences 
from the established clinical genetics offer of genetic testing, health-related DTC GT raises 
ethical, legal and social implications. These include a long list of issues: lack or problematic 
involvement of a HCP, adequacy of pre- and post-test counselling, scientific validity and utility 
of the testing, misleading advertising, potential burden on a healthcare system, testing in 
minors, secondary uses and privacy of consumers’ data, non-consensual uses of testing, and 
problems related to regulation of DTC GT [26,27]. Many of these ethical issues were identified 
and discussed to some extent already in the beginning of existence of DTC GT [28]. In the 
following years, a number of authors further discussed these issues and empirical studies have 
been conducted to explore the offer of DTC GT and views of different stakeholders (e.g. 
consumers and healthcare professionals) [29,30]. Furthermore, various expert societies and 
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advisory bodies such as the UK Human Genetics Commission [2], European Society of Human 
Genetics [31], European Academies Science Advisory Council [32], have issued 
recommendations and position statements addressing DTC GT. Moreover, actions were taken 
by a regulatory authority, the US Food and Drug Administration (FDA), to ensure quality of 
the offer of DTC GT [33].  
Recent literature, both more theoretical or empirical in nature indicates that ethical issues 
around DTC GT are still not resolved, they are potentially amplified as the technology is 
evolving and the scope of the offer is expanding [11,34–36]. The aim of the following section 
is to provide an overview of the current ethical issues of DTC GT and related services, with a 
focus on analytical and clinical validity of the testing, adequate pre-test counselling and 
informed consent, potentially misleading advertising, and research uses and commercialisation 
of genetic data.  In the subsequent section, we discuss these aspects from a legal standpoint, 
and in particular with respect to the changes that will be introduced by the Regulation (EU) 
2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic 
medical devices (IVD Regulation). 
2.2.1 Analytic and clinical validity of the services 
The analytic validity (the accuracy with which a genetic variant is identified), clinical validity 
(how well a variant is associated with a given phenotype/disease) as well as clinical utility 
(whether or not any intervention/test can improve the healthcare outcome) of many of the DTC 
genetic tests have been seriously questioned [4,37]. The scientific evidence for clinical validity 
of tests offered is very limited (especially for complex traits), therefore the commercialization 
of many of the predisposition tests has been criticized as being premature [37,38]. Furthermore, 
the disease risk predictions based on genetic data does not consider the environmental/lifestyle 
(e.g. diet) and family history factors which can modify the genetic risks of diseases to a great 
extent [37]. Similar concerns about the quality of the reported results may be raised regarding 
third-party interpretation services, whose interpretation reports may not be based on reliable 
scientific evidence and may not be understandable to consumers [39]. 
It is not only the various authors and societies that have been expressing concerns about the 
validity of DTC GT. 23andMe had been offering Personal Genome Service providing health 
reports on 254 diseases and conditions including carrier status, disease predisposition, and 
pharmacogenomic results [33]. In November 2013 the Food and Drug Administration (FDA), 
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in a warning letter sent to 23andMe, expressed, among others, its lack of ‘assurance that the 
firm has analytically or clinically validated the PGS [Personal Genome Service] for its intended 
uses’ and ordered that 23andMe stop marketing its health-related tests until it obtains marketing 
authorization from the FDA [33]. Consequently, 23andMe limited its offer in the US to ancestry 
tests, at the same time applying for the FDA marketing authorization for Bloom syndrome 
carrier status, which was subsequently granted to the company in February 2015 and the test 
was included in its offer together with other carrier status tests which FDA exempted from its 
premarket review [40].  Meanwhile, the company has been offering carrier, susceptibility and 
pharmacogenomic testing for a range of conditions and traits to consumers in countries where 
the current legal framework does not appear to pose any market barriers, such as Canada, the 
UK, Denmark, Finland, Ireland, Sweden, and the Netherlands [41]. Moreover, in April 2017 
the FDA completed pre-market review and allowed for marketing of another 23andMe genetic 
test - Personal Genome Service Genetic Health Risk which provides information about 
predispositions for 10 diseases and conditions [42]. Remarkably, in the related announcement 
the FDA stated that ‘Results obtained from the tests should not be used for diagnosis or to 
inform treatment decisions.’, which may indicate that the clinical utility of 23andMe’s tests is 
still limited [42].  Indeed, some of the variants currently offered by 23andMe are not advised in 
clinical context by professional recommendations. For example, the testing for APOE variant 
[10] which is associated with Alzheimer’s disease was described by the American College of 
Medical Genetics as ‘not clinically recommended due to limited clinical utility and poor 
predictive value’ together with an indication that in this context ‘DTC genetic testing is not 
advised’ [43].  
Additional problems emerge regarding the interpretation of genetic results. Questions arise as 
who should be responsible (and liable) for the validity of the results reported as well as who (if 
anyone) should recontact the patient/consumer if the significance of results changes in the light 
of new results of genetic research. Is this the responsibility of a physician (if there is one 
involved in the testing), the DTC GT company, the laboratory which analyses the sample, or 
database/platform operator used for result interpretation? These issues are regulated to some 
extent by professional standards (e.g. to be aware of current state of knowledge and/or care in 
a given profession), and may be addressed, to some extent in the company website descriptions, 
terms of use and submission agreements (describing the requirements and responsibilities of 
people adding new data to databases) [44]. This issue does not concern exclusively DTC genetic 
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testing and interpretation services; however, it may appear more complex in this context given 
the lack of (adequate) involvement of a HCP in the provision of DTC GT.  
One may argue that the limited clinical validity and/or utility of DTC genetic tests are not 
enough grounds to prohibit their offer outright, provided that these limitations are clearly 
outlined to consumers. Many companies, indeed, provide this kind of statement e.g. that their 
services ‘are for research, educational, and informational use only, and are not to be used to 
diagnose, prevent, or treat any condition or disease or to ascertain the state of health for any 
individual’ [45]. Doubts arise, however, regarding whether consumers ever read these 
statements of limitations, given that they are often included in ‘small print’ documents to which 
consumers agree by ticking ‘I agree’ boxes or by default when using the services [11]. 
Secondly, even if consumers were well informed about these limitations (indeed, some 
companies provide explicit well-visible statements about the limitations of testing) [18], 
questions about potential implications for (public) healthcare systems remain. Should the 
consumer who obtained results indicating increased probability of a disease contact a HCP 
within the public healthcare system given that the results are of doubtful validity? Not only may 
this pose interpretation problems for physicians, it can also result in unnecessary follow-ups 
and a (financial/resource) burden on a public healthcare system, especially if DTC GT will be 
gaining in popularity [37]. Notwithstanding, some DTC genetic tests of proven analytical and 
clinical validity could potentially be useful in clinical care. However, in order for HCP to 
distinguish valid genetic tests from non-valid tests and to effectively act upon these results if 
needed, healthcare professionals should be provided with appropriate support [46]. This could 
come in the form of educational resources like those created in the GENE-EQUIP project [47], 
or the guidance from the National Institute for Health and Care Excellence (UK) [48]. Adequate 
legislation setting requirements for solid scientific evidence for analytical and clinical validity 
of genetic tests entering the market and appropriate labelling of these tests would be desirable 
in this context. Additionally, placing responsibility on DTC GT companies to provide access to 
genetic counselling could diminish burden placed on traditional healthcare systems [49]. 
2.2.2 Informed consent and pre-test counselling 
Communicating about genetic information and obtaining valid informed consent for genetic 
testing is challenged by the complexity of genetic information, and in more recent years, given 
genomic testing, it is also challenged by the volume of data produced [50]. Therefore, pre-test 
counselling is recognized as a key element of the informed consent process for genetic testing, 
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in which relevant information is provided to a person undertaking the test and her/his questions 
are answered [31]. The lack of involvement of (an adequately qualified) HCP in the provision 
of genetic testing, as well as often inadequate provision of information about offered testing 
suggests that DTC GT consumers may not be undergoing this important process as originally 
described or expected in the traditional health care system [11]. Although a number of DTC 
genetic tests must be ordered by a HCP, this may not ensure the presence of adequate pre-test 
counselling given the potential lack of genetics expertise, and potential lack of impartiality if 
the HCP is hired by a company [3,11]. Furthermore, a study of DTC GT company websites’ 
sections relevant to informed consent (to which consumers agree in order to undertake the test) 
of companies offering WES/WGS revealed the presence of scarce and potentially misleading 
information on necessary elements of informed consent (benefits, risks, incidental findings) 
[11]. 
Related to informed consent is the issue of non-consensual testing i.e. unlawful testing of a third 
party using his/her sample without that person’s consent, for the purposes of benefiting others 
or to the detriment of a tested person [27]. The DTC GT context may facilitate this kind of 
action given the accessibility of testing and the fact that a consumer and not a HCP is 
responsible for collecting samples for testing (i.e. saliva) and sending it to a company. Although 
in certain contexts there are laws in place [51] prohibiting this activity and sometimes 
contractual documents provided by DTC GT company also state the prohibition of non-
consensual testing, in practice ensuring that a person whose sample is tested has voluntary 
agreed to this procedure poses problems [27]. These issues underline the importance of 
providing an adequate context for genetic testing provision so that a valid and genuine process 
of informed consent in which a HCP is involvement is secured. 
2.2.3 Advertising 
Given the problems with informed consent mentioned above, the potentially misleading 
advertising of DTC GT, not only via companies’ websites but also TV commercials and 
distribution of emails, seems to be particularly problematic in the context of DTC GT. 
Additionally, companies in their rhetoric sometimes conflate promotion with “information” or 
“education” complicating the matter (both for consumers and for regulators) of advertising even 
more.  
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Since they appearance on the market, DTC GT companies have been criticised for the 
potentially misleading claims present on their websites [28]. In 2010 the report of the U.S. 
Government Accountability Office (2010) revealed that 10 of the 15 DTC GT companies 
analysed were ‘engaged in some form of fraudulent, deceptive, or otherwise questionable 
marketing practices’ [52]. Furthermore, the analysis of the content of DTC GT websites by 
Singleton et al. revealed that the information presented on the websites was weighted toward 
encouraging consumers to purchase the test rather than supporting informed decisions [53]. 
Borry et al. draw attention to the presence of nonpropositional content of advertisements i.e. 
appealing pictures and design of DTC GT websites, which may impact consumers perceptions 
of value of the product and its desirability [54]. In the context of non-invasive prenatal testing 
advertised directly to consumers, Skirton et al. found that emotive language and misleading 
information was presented on companies’ websites [55]. 
2.2.4 DTC GT for ‘reproductive purposes’, newborns and minors  
The explicit advertisement of DTC genetic testing to potentially more vulnerable groups such 
as parents of newborns, minors, and prospective parents amplifies some of the known 
challenges related to genetic testing outlined in the sections above. In the context of the genetic 
testing for ‘reproductive’ purposes (i.e. carrier screening, pre-implantation genetic 
diagnosis/screening, non-invasive prenatal testing) the results can have important implications 
for the choices of (prospective) parents, for example deciding for an abortion based on genetic 
test results. In this context, the issues of validity of the testing, provision of information and 
informed consent as well as advertising are particularly significant. 
Moreover, the offer to each of these groups raises specific challenges such as those related to 
the right not to know of minors and obtaining their assent as well as the more fundamental 
question of the extent of parental authority in decision making in this new era of genomics [56]. 
Studies surveying DTC GT companies’ polices regarding testing of minors revealed that 
companies were performing testing on children’s samples for adult onset diseases, therefore 
clashing with professional norms, which state, among others, that minors can be tested for adult-
onset disorders only if therapeutic or preventative measures are available during childhood for 
the condition tested [57,58]. A more recent study by Borry et al. indicates similar issues, 
although in the context of a company explicitly offering testing for newborns [35]. 
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2.2.5 Research uses and commercialisation of consumers’ genetic information 
Genetic and genomic data are perceived as valuable and their sharing may facilitate diagnosis 
in patients and the progress of medical research [59]. However, potentially sensitive 
information about health and ancestry can be retrieved from genetic data; furthermore an entire 
human genome sequence is unique to each person, therefore in some cases it can be used to 
(re)identify a person when linked to his/her other personal information [60]. Therefore, using 
genetic information for research should be accompanied with adequate safeguards to protect 
privacy, ensure transparency about the uses and sharing practices, and adequate informed 
consent [61]. 
Several instances of DTC GT companies performing research have been reported [62,63]. One 
of the best known and biggest engagement in research by DTC GT consumers has occurred 
with the company 23andMe, for which over 80% of its 1.2 million customers have consented 
to participate in research [64]. Consequently, the company may own the largest research 
databank in the world consisting of genetic information of consented re-contactable subjects. 
The compliance of these research activities with research ethics requirements, in particular the 
adequacy of informed consent for participation in research and data privacy, has been 
questioned [62,63,65]. Similar issues were raised in recent studies of DTC GT websites (one of 
which investigated companies offering WES/WGS) exploring issues such as secondary uses of 
samples and data, data confidentiality and privacy. The studies revealed, among others, that 
some of the companies may perform research on consumers’ data and/or samples for which 
informed consent process seemed not to comply with some of the professional guidelines 
[36,66]. 
Interestingly, the company 23andMe not only uses consumers’ data for research, but has also 
sold access to consumers’ data affected with Parkinson to a biotech company Genentech for 
research purposes [65]. Selling access to consumers’ data seems to raise similar concerns to 
those outlined by Sterckx et al. (2014) when discussing patenting activities of 23andMe. In this 
article, the authors argued, that applying for patents seemed to contrast with company’s appeals 
to promote the public good and, the lack of transparency about it appeared to undermine 
consumers trust [67]. Furthermore, gaining profit from research performed on consumers’ 
databases, as noticed by Sharon (2016) may seem ‘particularly problematic when public money 
is channeled, indirectly or directly, to their development, as has been the case with 23andMe, 
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which recently secured a US$1.4 million research grant from the NIH to expand its database.’ 
[68] 
Moreover, the problems related to commercialisation of health-related data arise, also in the 
context of the platforms allowing consumers to share their data and receive compensation for 
it. On the one hand, paying consumers for access to their data may provide them with an 
incentive to contribute to research and may appear as a fair and respectful “compensation” for 
consumers given that the companies and researches (may) benefit financially from using 
consumers’ data [25]. However, ‘cash-for-DNA’ approach may discourage individuals willing 
to contribute data for altruistic reasons, while, at the same time being potentially coercive for 
financially vulnerable individuals, as noticed by Roberts and co-authors (2017) [25]. 
Furthermore, genetic data commercialisation activities seem to challenge the ideal of open 
science, data sharing framework based on solidarity and it may as well lead to disparities in 
research [68].  
2.3 DTC GT legislation in Europe  
DTC GT in Europe is currently regulated by various laws, both on the national and the European 
Union (EU) level. Aspects related to patients’ access to GT, the role of healthcare professionals 
in prescribing the test and/or counselling the patient, as well as the informed consent process 
are regulated largely by national laws. This is mainly because GT in Europe has been 
traditionally offered through the public healthcare services and the conditions under which such 
tests are offered are considered to be part of the clinical practice [69].   
The regulation of the clinical practice resides with the Member States rather than the EU, 
following the principles of subsidiarity and proportionality. These principles mandate that the 
EU may take legislative action beyond the areas of its exclusive competence, when a given 
objective may be more efficiently achieved on the EU rather than the national level [70]. As a 
result, the conditions and restrictions applying to DTC GT may vary across Europe. Currently, 
there are countries, such as Germany and France, which restrict the GT framework, by adopting 
strict laws regarding the type of tests that should be available to patients, the channelling of 
genetic tests through healthcare professionals, mandatory genetic counselling and requirements 
for informed consent in the context of GT [71]. Although these laws target primarily the 
provision of genetic tests within the public healthcare system, it has been argued that they also 
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essentially render illegal the provision of DTC GT [72]. However, there are also many countries 
in Europe where no specific laws on GT exist. Therefore, when it comes to restrictions related 
to the involvement of a HCP, genetic counselling and informed consent requirements, DTC GT 
companies face minimal constrains.  
As opposed to aspects related to the context within which genetic tests are provided, several 
other aspects affecting the governance of GT in Europe are regulated on the EU level.  European 
legislation aims, among others, to promote the harmonization of the internal market and free 
movement of goods [73], as well as to enhance consumer protection by promoting the fair 
treatment of consumers and high standards for products that enter the European market [74]. 
Currently, numerous EU laws are in place, aiming to protect the economic interests and rights 
of consumers. Such laws cover a wide set of policies, including unfair commercial practices 
[75], consumer contract law [76], product safety and data protection [74]. 
Especially with regard to product safety and data protection, recent changes in the regulatory 
framework are expected to have an impact on the activities of DTC GT companies that are 
directed to European consumers. The recent adoption of the Regulation (EU) 2017/746 of the 
European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices 
(IVD Regulation) and the General Data Protection Regulation are expected to influence 
respectively the safety and efficiency standards that DTC genetic tests have to meet when 
entering the European market and the research activities performed by DTC companies 
involving genetic information of European consumers. In this section, we will focus on the 
main changes introduced by the recent adoption of the IVD Regulation and their potential 
impact on DTC GT. 
2.3.1 IVD Directive 
Genetic tests with a medical purpose fall within the definition of IVD medical devices and the 
regulation of their safety and efficiency when entering the European market currently falls 
under the scope of Directive 98/79 EC on in vitro diagnostic medical devices (IVD Directive) 
[77]. Based on this Directive, IVD medical devices, unless considered to be ‘low risk’, have to 
go through a conformity assessment before entering the European market. This means that 
independent commercial entities called notified bodies, assess whether such devices fulfil the 
essential requirements of safety and efficiency imposed by the Directive and issue a certificate 
of conformity (CE mark), allowing devices to circulate in the European market [78]. 
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The impact of the IVD Directive in the effective governance of DTC GT has been questionable 
[79]. This may be partly because, currently, the vast majority of DTC genetic tests offered by 
companies are tests for predisposition to common complex disorders. Devices for the purposes 
of prediction and predisposition are not explicitly covered by the Directive, creating uncertainty 
regarding whether such tests would actually fall within the scope of the Directive [80]. 
In addition, under the Directive, most genetic tests are classified as low risk devices requiring 
only self-assessment by their manufacturer before entering the EU market. This classification 
has been considered to be particularly lenient in comparison to the respective regulations in the 
US, Canada and Australia, where most genetic tests are considered to be moderate to high risk 
devices and are required to go through a pre-market assessment before being placed on the 
market [80]. 
Finally, the Directive has caused uncertainty regarding the clinical evidence that must be 
provided by manufacturers during the pre-market assessment of their devices. In this regard, it 
has been unclear whether manufacturers are required to provide evidence of clinical validity in 
order to prove compliance with safety and performance standards, or whether evidence of 
analytical validity would be sufficient [81]. A clarification on that matter would be of particular 
importance when it comes to DTC GT. This is because, as mentioned above, most such tests 
currently available on the market are susceptibility tests to common complex disorders, which 
often have doubtful clinical validity [37]. Therefore, requiring only evidence of analytical 
validity during the pre-market assessment of the tests would set the bar of performance rather 
low.  
2.3.2 IVD Regulation 
The revision of the IVD regulatory framework has been a long process that has given rise to an 
animated debate among the EU institutions and different stakeholders. After two public 
consultations were held, the European Commission issued in September 2012 its proposal for 
a new Regulation on IVD medical devices. Following the ordinary legislative process, the 
European Parliament and the Council of the EU published their own versions of the proposal 
in October 2013 and June 2015 respectively. Finally, after negotiations among these three 
institutions, a compromise was reached in May 2016. After undergoing legal-linguistic review 
the final version of the Regulation was adopted by the European Parliament and the Council of 
the EU in April 2017. The regulation will apply in the member states of the EU and the 
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European Free Trade Association (EFTA), as well as Turkey, after a 5-year transition period. 
For the purposes of this section, when we are using the term “Europe” we refer to the countries 
where relevant EU legislation applies.  
When it comes to the governance of DTC GT, the final text of the IVD Regulation contains 
changes that may cover gaps in the previous regulatory framework and potentially raise 
standards of safety and efficiency of such tests when entering Europe. In this regard, the changes 
introduced by the IVD Regulation concern mostly the scope of tests covered, the risk 
classification system (which determines how much scrutiny an IVD device has to go through 
during the pre-market assessment), the clinical evidence required, advertising of IVD devices 
and the availability of genetic counselling for certain types of genetic tests.  
Scope of tests covered 
In respect to the scope, the final text explicitly recognizes IVD devices providing information 
on ‘predisposition to a medical condition or a disease’ (Article 2(2)) as being subjected to the 
Regulation [82]. This amendment eliminates uncertainties regarding whether the majority of 
DTC GT offered (namely genetic tests for predisposition to common complex disorders) are 
covered by the Regulation or not. Importantly, the Regulation also clarifies that all IVD medical 
devices offered through the Internet to a natural or legal person established in the EU must 
comply with the rules set by the Regulation (Article 6) [82]. This way, it becomes clear that 
companies also established outside the Union should still comply with the relevant EU rules 
when offering their products to consumers residing within the EU.  
Classification of IVD devices 
When it comes to the classification of IVD devices, the Regulation replaces the list-based 
classification system adopted by the Directive with a new, risk-based classification system. The 
way IVD devices are classified is particularly important, as it determines how strictly the 
devices may be assessed before entering the EU market. According to the Directive, the 
classification of devices was based on predetermined lists. These lists have been criticized as 
being inconsistent and outdated, and, for many products, as offering inadequate scrutiny [83]. 
This was particularly the case for the vast majority of genetic tests, which were considered to 
be low risk devices, requiring, as a result, only a minimum degree of scrutiny before being 
available to consumers. The risk-based classification system introduced by the Regulation, 
which will replace the existing list-based system, is largely inspired by the classification system 
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introduced by the Global Harmonization Task Force [84] and aims to address the inadequacies 
created by the previous framework. In this regard, according to the Regulation, IVD devices 
may be divided in four categories based on their intended purpose and potential risks [79]. In 
this context, the Global Harmonization Task Force has defined risk as ‘combination of the 
probability of occurrence of harm and the severity of that harm.’[84]. The categories vary from 
Class A (low risk devices), to Class D (high risk devices). Genetic tests fall under Class C, 
which means that they are considered to be moderate to high risk devices and they have to go 
through a pre-market assessment by a notified body before reaching consumers.  
Clinical evidence  
Furthermore, the IVD Regulation raises the bar for clinical evidence by stating that the 
assessment of conformity with general safety and performance requirements should be based 
on ‘scientific validity, analytical and clinical performance data providing sufficient clinical 
evidence’ (Article 56) [82]. This provision clarifies that evidence of clinical validity 
(incorporated in the notion of clinical performance) should be provided by the manufacturer, 
eliminating uncertainties created over the previous regulatory regime regarding whether 
providing such evidence was mandatory [80]. This amendment may make it more challenging 
for tests with low clinical validity (for example for many genetic tests detecting predisposition 
to common complex disorders) to enter the European market.  
Advertising 
A particularly interesting addition in the IVD Regulation is Article 7 under the title ‘Claims’. 
In this article, for the first time, European legislation specifically addresses the advertising of 
IVD medical devices. This article provides that labelling, instructions for use and advertising 
of such devices must not use misleading content with regard to the device’s purpose, safety or 
performance. Examples of misleading content for the purposes of this article are ‘creating a 
false impression regarding treatment or diagnosis, functions or properties which the device does 
not have’ and ‘suggesting uses for the device other than those stated to form part of the intended 
purpose for which the conformity assessment was carried out’ (Article 7) [82]. Even though the 
article does not seem to grant broader protection than that offered by more general laws on 
consumer protection [85], it grounds these laws in the specific context of IVD medical devices 
and its symbolic value should not be underestimated. Especially when it comes to DTC GT, the 
business model of which is largely relying on advertising, having a more specific definition of 
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what may constitute misleading advertising could potentially contribute in a more efficient 
regulation of the way such products are promoted to the public. 
Informed consent and genetic counselling 
During the ordinary legislative process, the European Parliament, in its proposal, had supported 
that all genetic tests under the Regulation should be classified as prescription-only medical 
devices and that they must only be advertised to health care professionals and not to consumers. 
In addition, according to the same proposal, pre- and post-test genetic counselling should be 
mandatory for predictive, prenatal and diagnostic genetic tests, while informed consent should 
be written [86]. The above mentioned suggestions gave rise to a heated debate regarding 
whether regulating such issues at the EU level infringes the principles of proportionality and 
subsidiarity [87]. Some stakeholders argued that if such provisions were eventually adopted 
this would result in the Regulation going beyond its purpose (namely to regulate product 
efficiency and safety) and would ultimately interfere with clinical practice and the way this is 
organized at the national level [88]. Ultimately these provisions were not included in the final 
text. Instead, the Regulation acknowledges that the current divergences in national rules on 
informed consent and genetic counselling do not seem to have a significant adverse impact on 
the smooth functioning of the internal market. As a result, the Regulation will only provide 
limited requirements respecting the principles of proportionality and subsidiarity. In this regard, 
Article 4 of the Regulation prescribes that individuals undergoing genetic tests in the context 
of healthcare and ‘for the medical purposes of diagnostics, improvement of treatment, 
predictive or prenatal testing’ should be ‘provided with relevant information on the nature, the 
significance and the implications of the genetic test’. In addition, in the same context, and 
specifically for genetic predisposition testing for untreatable conditions and diseases, Member 
States shall make sure that patients have access to genetic counselling [82]. In this regard, the 
final text seems to attempt to strike a balance between stressing the importance of informed 
consent and genetic counselling while respecting the principle of subsidiarity and the right of 
Member States to regulate clinical practice in their territory as they see fit. This provision, 
however, will probably have little value for tests offered outside the clinical setting as it is 
addressed to Member States and in this regard, its impact will likely be limited to the clinical 
context. 
Overall, it may be argued that, when it comes to genetic tests, the IVD Regulation attempts to 
address weaknesses and uncertainties of the existing regulatory framework, especially 
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regarding the scope of protection, the risk-classification and requirement for clinical evidence, 
therefore it is addressing some of the salient ethical issues of DTC GT. In this regard, and 
specifically with the points discussed above, the Regulation seems to be an improvement 
compared to the Directive. It is now clear that predisposition tests fall within its scope and the 
new risk-based classification system and the requirements for clinical evidence may raise the 
quality bar for genetic tests entering the EU. Furthermore, the Regulation, even though it does 
not move to harmonize the framework within which genetic tests are offered (and potentially 
render DTC GT illegal within Europe)- goes beyond the Directive in specifically regulating 
advertising claims and referring to the need for adequate information and genetic counselling 
to be available in the context of health-related GT. The Regulation also shows potential for 
limiting the circulation of DTC GT with low quality in the EU market and deter companies 
from making exaggerated and unsubstantiated tests. However, it should be kept in mind that 
the DTC GT industry is global and operating mostly through the Internet. This means that even 
if such tests fall within the scope of the Regulation, no matter where they come from, the 
compliance of companies sending their tests to private individuals may be hard to ensure. As a 
result, the real value of the IVD Regulation for DTC GT will be largely dependent on its 
enforcement. 
2.4  Conclusions 
DTC GT and related services raise numerous and complex ethical issues; these are evolving as 
the DTC GT market is changing and consequently posing (new) challenges to its adequate 
regulation. The well-known issues of analytic and clinical validity of the testing, inadequate 
informed consent, and potentially misleading advertising are still relevant and problematic in 
the context of the current offer DTC GT. Meanwhile, new ethical issues emerged, namely DTC 
GT targeted to (prospective) parents, “monetization” of genetic data, and quality of third-party 
interpretation services. In the European context, the recently adopted IVD Regulation addresses 
some of the ethical concerns related to DTC GT. Specifically, the Regulation raises the bar for 
clinical evidence required for the tests entering European market, prohibits misleading 
advertising, and clarifies that companies established outside the European Union should still 
comply with the relevant EU rules when offering their products to consumers residing within 
the EU. Other laws in the European context can also be relevant to DTC GT, for example, laws 
concerning unfair commercial practices and the new General Data Protection Regulation. The 
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GDPR, which will apply in the EU in May 2018, may require redesigning some of informed 
consent practices among DTC GT companies, for example to enable easy withdrawal of 
informed consent [89]. Their relevance to, and impact on DTC GT (e.g. in the context of third-
party interpretation services, usage and confidentiality of consumers’ genetic data) require 
further investigation and discussion. To allow well-informed discussion on the ethical and 
regulatory issues related to DTC GT, empirical studies monitoring the current offers and 
practices of DTC GT companies and related ethical issues are invaluable.  
2.5 Future perspective  
The development of the DTC GT market is influenced among others by availability of new 
technologies, their price and the relevant regulation. Advancements in genomic sequencing 
technologies and increasing understanding of human genetics has been enabling obtaining more 
genomic information faster and cheaper. DTC GT companies have been taking advantage of 
these trends and have been offering a wider range of genetic tests at lower prices. Recently, the 
US FDA announced its intention to facilitate quicker and least burdensome introduction of 
some DTC predisposition testing to the market [42]. All of these factors, as well as the general 
push to make genomics a more mainstream part of medicine, may help support, in the coming 
years the market expansion of DTC predisposition GT in the US. In the European context, 
however, the recent IVD Regulation which will apply in 5 years is likely to limit the offer of 
predisposition DTC GT including the tests offered by the providers based in the US.  
Importantly, the business model of the DTC GT companies has been evolving. Selling genetic 
testing results is no more the only source of profit for the companies. Genomic data have been 
recognized as useful not only to the individual consumers, but also to researchers; some DTC 
companies have been taking advantage by selling consumers’ data to interested third parties 
[68]. In this context, a novel genomic data sharing approach seeking to also entitle consumers 
to profit from sharing their genetic data emerged and may be further developed (e.g. Portable 
Genomics).  
Additionally, the popularity and intake of DTC genetic testing may be dependent to some 
extend on the way genetics is portrayed in media and perceived by the potential consumers. For 
example, the story of Angelina Jolie, who underwent a preventive double mastectomy based on 
genetic risk and a family history of cancer, received extensive media coverage and raised some 
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awareness about genetic testing. Media coverage, however, may not translate to the correct 
understanding of genetics [90]. In this context, educating about genetics, its limitations, related 
ethical issues and responsible communicating about science in media should be recognized as 
factors which may facilitate informed decisions about undertaking DTC GT and using one’s 
genetic information. The level of genetic literacy in public may influence intake and attitudes 
of public towards of DTC genetic services.  
Executive summary  
Direct-to-consumer genetic testing (DTC GT) and related services 
- A variety of health-related genetic tests is currently advertised directly to consumers. 
The tests employ new approaches (whole exome and genome sequencing), may report on a 
wide range of conditions, and are targeted at new groups such as (prospective) parents (carrier 
testing, preconceptional and prenatal testing, testing for children). 
- Third-party web-based genetic data interpretation and sharing services are available to 
DTC GT consumers (who have their genomic data downloaded in the required format). Some 
of the platforms may offer payments for consumers for sharing their data. 
Ethical issues in DTC GT companies 
- The currently salient ethical issues related to the offer of genetic testing and services 
include, among others: questionable analytic and clinical validity of the tests, adequacy of 
informed consent and pre-test counselling, potentially misleading advertising, the offer for 
children and reproductive purposes, research uses and commercialization of consumers’ 
genomic data. 
DTC GT legislation in Europe 
- The recently adopted IVD Regulation may render many of the predisposition DTC GT 
illegal in Europe as it raises the bar for clinical evidence required for the tests entering European 
market, prohibits misleading advertising, and clarifies that companies established outside the 
European Union should still comply with the relevant EU rules when offering their products to 
consumers residing within the EU. The regulation will apply after 5-year transition period. 
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Abstract 
Whole exome sequencing and whole genome sequencing have become increasingly available 
in the research and clinical settings and are now also being offered by direct-to-consumer 
genetic testing companies. This offer can be perceived as amplifying the already identified 
concerns regarding adequacy of informed consent for both whole exome/genome sequencing 
and the direct-to-consumer (DTC) genetic testing context. We performed a qualitative content 
analysis of websites of four companies offering whole exome/genome sequencing DTC 
regarding the following elements of informed consent: pre-test counselling, benefits and risks, 
and incidental findings. The analysis revealed concerns including the potential lack of pre-test 
counselling in three of the companies studied; missing relevant information in the risks and 
benefits sections; and potentially misleading information for consumers. Regarding incidental 
findings, only one company, which provides opportunistic screening, provides basic 
information about their management. In conclusion, some of the information (and related 
practices) present on the companies’ webpages salient to the consent process are not adequate 
in reference to recommendations for informed consent for whole genome or exome sequencing 
in the clinical context. Requisite resources should be allocated to ensure that commercial 
companies are offering high throughput sequencing under responsible conditions, including an 
adequate consent process. 
Key words: whole genome sequencing, whole exome sequencing, direct-to-consumer genetic 
testing, consumer genomics, informed consent 
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3.1 Introduction  
3.1.1 Whole exome and genome sequencing applications 
The relatively recent development of next generation sequencing (NGS) technologies has led 
to a significant decrease in the cost and time required to perform whole genome sequencing 
(WGS) and whole exome sequencing (WES) (i.e. the sequencing of only protein coding parts 
of the genome; for the purpose of this article, in which the high-throughput nature of NGS is 
most salient, both whole genome and whole exome sequencing may be denoted by ‘WGS’ or 
‘whole genome sequencing’). These technologies are more powerful and potentially cost-
effective than previous sequencing technologies and have brought a shift in testing approach 
from the traditional way of testing only one or a few specific genes to obtaining the sequencing 
information from hundreds or even all the genetic variants in a genome [1].  
To date, the use of genomic sequencing approaches has proved to be useful in both the research 
context and clinical context; for instance, in providing molecular diagnoses for Mendelian 
disorders [2], for disorders with complex phenotypic presentations such as intellectual 
disabilities, or neurological diseases [3,4], potentially enabling targeted therapeutic strategies 
in some cases [5]. WGS can also be used for disease risk predictions [6], preconceptional carrier 
testing [7] and prenatal testing [8]. In the short to medium-term future, other applications of 
WGS in health care may materialize, including for newborn screening [9], tissue matching [1] 
or screening of embryos [10]. Despite these technical possibilities, it is important to note that 
there are still concerns regarding the accuracy, interpretation of results, cost-effectiveness, as 
well as ethical issues [11]. 
Given the relative novelty of NGS in the clinic and the resulting uncertainty related to 
implementation, the ethical concerns are numerous, and include but are not limited to issues 
related to the informed consent (IC) process, unsolicited findings management, opportunistic 
screening, secondary use of data, data management and storage, privacy and confidentiality, 
duty to re-contact patients (once new information arises), responsibility towards and 
communication with family members. All these outstanding issues currently, challenge the 
effective and responsible implementation of genome-based approaches in health management 
[12] and need to be addressed. Herein we focus on ethical issues of the informed consent process 
 75 
 
in the more specific commercial context of direct-to-consumer high throughput sequencing, 
which overlap with many of the concerns related to the clinical context. 
3.1.2 Direct-to-consumer genetic testing (DTC GT) companies  
Relatively recently, whole genome sequencing services have also been advertised and offered 
directly to consumers by some companies. These private, for-profit companies operate outside 
of the conventional public health care system and advertise genetic tests directly to consumers 
predominantly via the Internet. However, the companies increasingly are requiring consumers 
to contact a health care professional (HCP) in order to obtain a test and/or the test results [13]. 
Such genetic tests which ‘are commissioned by the consumer but where a medical 
practitioner or health professional is involved in the provision of the service’ also fall in the 
scope of DTC genetic tests according to ‘A Common Framework of Principles’ on DTC 
genetic testing issued by the Human Genetics Commission (UK) [14]. 
The phenomenon of DTC GT, even before WGS was being offered in this context, has received 
a lot of attention regarding ethical issues, such as the questionable scientific validity and utility 
of the tests on offer [15], the adequacy of information provision and the informed consent 
procedure [16], the potential need for medical oversight and genetic counselling [17], the testing 
of children [18], the research activities conducted by DTC GT companies [16] and the potential 
burden on the health care system [15]. The adequacy of legislations concerning the activities of 
DTC GT companies has also been discussed [19].  Considering the vast amount of genomic 
data obtained in WGS as well as difficulties in being able to properly assess or interpret each 
variant, one could consider that many, if not all, of the ethical, legal and social implications 
previously addressed at the DTC GT field are amplified in the context of companies offering 
WGS directly to consumers. As such, this particular type of DTC GT deserves further attention 
and study. 
3.1.3 Informed consent for WGS 
Informed consent is a key component of any responsible research on human subjects or 
healthcare provision, including the offer of genetic testing (for health purposes), regardless of 
whether it is provided via a HCP in the conventional health care system or by a private for-
profit company. Informed consent constitutes a voluntary permission given by a competent 
patient to have the test performed after (s)he has been duly informed about the procedure and 
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purpose of the test, including the results it will generate, as well as the potential risks and 
benefits. The Additional Protocol to the Convention on Human Rights and Biomedicine 
concerning Genetic Testing for Health Purposes states that ‘A genetic test may only be carried 
out after the person concerned has given free and informed consent to it’. The document also 
outlines that the consent should be documented and it may be freely withdrawn at any time 
[20]. Furthermore, the European Convention on Human Rights and Biomedicinea, specifies in 
Article 5 that a person consenting to an intervention in the health field ‘shall beforehand be 
given appropriate information as to the purpose and nature of the intervention as well as on its 
consequences and risks.’ [21] Moreover, the importance of informed consent has been 
recognized in the recently accepted version of the Proposal for a Regulation of the European 
Parliament and of the Council on in vitro diagnostic medical devicesb:  
 ‘Member States shall ensure that where a genetic test is used on individuals, in the 
context of healthcare as defined in Article 3(a) of Directive 2011/24/EU and for the 
medical purpose of diagnostics, improvement of treatments, predictive or prenatal 
testing, the individual being tested or, where applicable, his or her legally designated 
representative is provided with relevant information on the nature, the significance and 
the implications of the genetic test, as appropriate.’ (Article 4a) [22] 
In the context of WGS, appropriate provision of information about the testing seems to be a 
particular challenge considering the complexity of the technology used, the volume of 
information generated, and the wide-ranging nature of findings. The entire sequence of the 
genome may provide an unprecedented amount of information of various clinical significance 
                                                 
a The Convention on Human Rights and Biomedicine is only legally binding for those countries who have signed 
and ratified it (http://www.coe.int/en/web/conventions/full-list/-
/conventions/treaty/164/signatures?p_auth=GV537xJS). While, not all countries have done this (e.g. Germany, 
UK, Belgium, etc.), the Convention nonetheless, remains a very important moral benchmark and/or ethical 
framework in Biomedicine for all countries.  
bOn 15 June 2016 the European Parliament and the Council of the European Union have agreed on the draft of 
the proposal, which will undergo legal-linguistic review and will be adopted by the European Parliament and the 
Council of the European Union, probably at the end of this year. The rules of the regulation will apply 5 years in 
the EU member countries after its publication (http://ec.europa.eu/growth/tools-
databases/newsroom/cf/itemdetail.cfm?item_id=8863&lang=en). 
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and predictive value, which may change with time [1]. Furthermore, these results may have 
profound implications for the (psychological) health (care) and reproductive choices of a patient 
as well as his or her relatives. 
Given these challenges, various authors have proposed models for IC and attempted to 
determine the necessary elements of an adequate IC process for WGS [23-28]. Ayuso et al. 
(2013) specifically analysed articles from the academic literature and guidelines from 
‘societies’ concerning IC for genetic studies and WGS. The authors found a high level of 
consistency among the documents reviewed and proposed a minimum list of information that 
should be addressed in IC for WGS:  the scope of the test, a description of the test process, the 
possible benefits and risks, the availability of alternative tests, the voluntary nature of the test, 
the possibility of refusal, the future use of the samples and the data, the confidentiality of the 
outcomes and management of incidental findings (IF), and pre-test counseling [27]. Moreover, 
the authors found that the majority of the documents they studied suggest that IC for whole 
genome sequencing should be given explicitly [27] (this is understood as being relevant in a 
context where WGS is only one of the tests being used for diagnosing a disorder, and so an 
explicit consent should be obtained specifically for the WGS). 
Jamal and co-authors (2013) also developed “core elements” of content and procedures for 
informed consent, data sharing, and results management for whole exome sequencing; even 
though conducted in a research context, the former overlap with core elements of informed 
consent identified by Ayuso et al. for the clinical context [28]. Furthermore, Jamal and co-
authors used the core elements to evaluate the practices and policies of 6 U.S. CLIA- certified 
labs offering clinical exome sequencing, including the presence of the suggested elements in 
informed consent forms and their readability. The analysis revealed that laboratory policies vary 
widely, indicating that developing standards for best practices among exome sequencing 
providers may be beneficial.  
Similarly, Henderson et al. (2014) [26] have analysed IC forms used in nine NIH-funded studies 
aiming to develop best practices for clinical applications of WGS. On the basis of the analysis 
the authors have proposed recommendations, which ‘can serve as a checklist to help identify 
gaps and resolve ambiguities in consent forms for sequencing’, and which are related to the 
issues outlined by Ayuso et al. (2013). For example, Henderson et al. suggest describing the 
meaning of positive, negative and uncertain results, outlining the role of CLIA (Clinical 
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Laboratory Improvement Amendments) certification, and stating the likelihood of obtaining 
incidental findings. Furthermore, IC forms for WGS have also been analysed in the context of 
cancer studies. The examination of these IC forms has revealed the tendency for using samples 
in other, unspecified types of studies and sharing data with other researchers [29].  
Furthermore, IC and the provision of information on company websites have been investigated 
in the context of DTC GT companies revealing the inadequacies of these practices [16,30,31]. 
None of the studies, however, specifically addressed IC for WGS in the context of companies 
advertising or selling WGS directly to consumers. Therefore, herein we present an exploratory 
qualitative study of the information salient to the IC process, which is provided on websites of 
companies offering whole genome sequencing in the commercial direct-to-consumer context. 
In particular, we present information regarding the following elements salient to IC: 1) pre-test 
counselling, 2) expected benefits and possible risks; and 3) management of incidental findings. 
The information from company websites is then further contextualized and discussed against 
the backdrop of guidelines such as those from the Presidential Commission for the Study of 
Bioethical Issues (PCSBI) [32], recommendations for IC for WGS by Ayuso and colleagues 
[27], and the American College of Medical Genetics (ACMG) recommendations for the 
reporting of secondary findings [33]. 
3.2 Methods 
This study is an explorative qualitative analysis of the informed consent information for whole 
genome and/or whole exome sequencing offered by DTC companies. We use a broad concept 
of DTC, including companies that offer genetic testing without involvement of a HCP, as well 
as those that aim marketing directly at consumers, while requiring a physician’s request to 
obtain the test. This approach is congruent with the scope of DTC GT given by the Human 
Genetics Commission, which included situations where ‘tests are commissioned by the 
consumer but where a medical practitioner or health professional is involved in the provision 
of the service’ [14]. 
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The number and content of DTC genetic and genomic testing companies is often changing; this 
includes information about informed consentc. Against this background, and since no other 
academic article has addressed the specific issue of consent in the distinct context of 
WGS/WES, we opted for a non-exhaustive explorative qualitative study of a convenient and 
varied sample of company websites, which were selected between November 2013 and 
January 2014. Companies were identified through the academic literature (mostly via articles 
addressing DTC genetics), as well as with a general Internet search in English using the search 
engine Google and terms including ‘genetic test’, ‘direct to consumer’, ‘whole genome 
sequencing’ and ‘whole exome sequencing’.  
Our qualitative analysis is focused on the websites sections and documents available online that 
are presented by the companies with which consumers should agree and/or sign in order to 
undertake the test. Specifically, these are the IC documents, statement of consent, terms of 
service, terms and conditions, disclaimer and privacy policy (Table 3.1).  
For the qualitative content analysis of the relevant documents on the websites, we build on the 
study of Ayuso et al. (2013) and used the following elements of IC as the major codes: 1) pre-
test counselling, 2) expected benefits and possible risks; and 3) management of incidental 
findings. These were underlined as being particularly important and relevant for IC in the 
context of WGS [27]. The website documents were accessed in October 2014. The documents 
were perused for all material relevant to the codes above and were organized under these 
headings initially by one author (EN); these initial results were reviewed by a second author 
(HCH) and disagreements were resolved until both agreed on the adequate organization. Final 
tables including representative quotes were reviewed by three authors. 
  
                                                 
c Indeed, some companies’ policies have already changed since our study, and as mentioned in the discussion, it 
is relevant that future studies return to these companies as well as include novel companies not addressed herein. 
For example, the version of Illumina’s consent form analysed herein is not available online any more. For a copy 
of the form please contact the corresponding author. 
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3.3 Results 
3.3.1 The DTC WGS companies identified and the studied website documents 
Four companies, Illumina, Gentle, Gene by Gene and Inneova, were identified for this study. 
At the time of this analysis they offer WES and/or WGS as well as provide different types/scope 
of data/results and analysis (e.g. carrier status, pharmacogenomics). The basic description and 
information regarding these four companies are outlined in Table 3.1.  
All the companies studied advertise their services directly to consumers on the Internet. 
However, some websites also contain sections dedicated to physicians, who are required to 
order the test, except for the company Gene By Gene’s offer of research and consumer testing, 
for which the company does not require a HCP. 
All companies’ websites analysed provide at least one document and/or a section on the 
webpage that needs to be agreed to or signed in order to undertake the test (Table 3.1). Three 
companies have documents on their website with ‘consent’ in the title; meanwhile, Gene By 
Gene only has a ‘Terms and Conditions’ section of the website and specifies that in case of 
‘Clinical Genetic Testing’ the physician has to obtain IC from the consumer; however it does 
not state whether this includes a physical document that must be signed by the consumer: ‘Prior 
to placing an order, the ordering physician or genetic counselor is responsible for obtaining 
the informed consent from the patient whose sample is being sent for testing (…)’ 
(https://www.genebygene.com/pages/terms). Such a statement is not included in the section for 
‘Research and Consumer testing’ in ‘Terms and Conditions’ of Gene by Gene 
(https://www.genebygene.com/pages/terms). 
The results of the content analysis regarding the following elements of IC: pre-test counselling, 
benefits and risks as well as incidental findings are presented below and shown in tables 3.2-
3.4.  
3.3.2 Pre-test counselling  
Only Illumina (seemingly) requires pre-test counselling as a condition for undertaking the 
test. In the IC form a consumer has to sign the following statements:  
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‘I have been offered the opportunity to ask questions and discuss with my 
healthcare provider the benefits and limitations of the test to be performed as 
indicated on the associated test request form. I have discussed with the medical 
practitioner ordering this test the reliability of positive or negative test results and 
the level of certainty that a positive test result for a given disease or condition 
serves as a predictor of that disease or condition.’ 
(http://res.illumina.com/documents/clinical/forms/form-test-req-undiagnosed-
disease.pdf) d  
Another company, Gentle, vaguely suggests some form of pre-test counselling to 
consumers in its IC section of the webpage: ‘If you still have unanswered questions, be 
sure to ask us or your physician before you agree to take the DNA test being offered by 
us.’ (https://www.gentlelabs.com/consent?content_only=true). No information about 
pre-test counselling was found on the studied websites’ sections of Gene by Gene and 
Inneova. 
3.3.3 Benefits and risks 
In the studied sections of the websites, all the companies provide general information 
about benefits and risks; however specific sections labelled ‘Benefits’ and ‘Risks’ are 
explicitly distinguished only in the IC documents of Illumina and Gentle. More specific 
subthemes were identified within the subjects benefits and risks information (Table 3.3, 
in bold in columns 2 and 3); these were used to classify the benefits and risks and were 
derived and modified from the classification outlined by Ayuso et al., 2013 [27].  
Three companies outline that the results may indicate disease risks and predispositions 
(Table 3.3). Moreover, Illumina and Gentle state that test results may help to make more 
informed healthcare choices; Gentle adds that the knowledge from the testing may 
empower persons to make ‘important life planning decisions’. Furthermore, Gentle 
outlines as a benefit, gaining knowledge about one’s carrier status, the possibility of 
                                                 
d At the time of submitting the article the link to this document was no longer functional. For a copy of 
the form please contact the corresponding author. 
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adjusting drug therapy based on the genetic results, and gaining insight into one’s 
ancestry. This company also mentions as a benefit the possibility of participating in 
research studies conducted by the company.  
All the companies provide, at least, a general and/or short description of risks related to 
undertaking WGS (Table 3.3). The types of risks and concerns mentioned include the 
following: medical and physical risks, psychological risks, discrimination risks, and 
implications for family members. Implications for reproductive choices are mentioned 
only by one company, Inneova: ‘I realize the possible far-reaching implications of the 
information obtained through predictive genetics testing in affecting my life choices as 
well as those of my relatives, children, and unborn children’ 
(http://www.inneova.com/contenu.php?page=terms.php). 
3.3.4 Incidental findings and categorization of genetic information 
Only one of the analysed companies, Illumina, directly addresses the issue of incidental 
findings (IF) in its IC form (Table 3.4). The company refers to the first version of the 
American College of Medical Genetics’ (ACMG) recommendations for reporting of 
incidental findings (2013) [33] and together with the results of Undiagnosed Disease Test 
provides an incidental findings report that may contain information on some of 57 variants 
unrelated to the indication for testing. Meanwhile, in the consent form for Illumina’s 
Predisposition Screen test the possible findings are categorized (into: childhood onset and 
adult onset; subcategories: medically actionable, not medically actionable, cancer, 
neurologic conditions) and the consumer has the possibility to opt out of some of them. 
Although Gentle does not mention IF, the company does emphasize that customers can 
choose to exclude any condition from the analysis: ‘It is important to mention that you 
can choose to exclude any of the tests from the results before submitting your sample.’   
3.4 Discussion  
3.4.1 Informed consent in the context of DTC WGS companies 
The content analysis of DTC companies described herein has been conducted using some 
of the elements of IC for WGS in the clinical setting recommended by Ayuso et al. (2013) 
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[27]. It should be noted that there are significant differences between the offers of WGS 
in a ‘traditional’ clinical genetics context versus the commercial DTC setting, even if the 
latter involves a healthcare professional. As explained in the recent guideline issued by 
the Presidential Commission for the Study of Bioethical Issues (PCSBI): ‘Clinicians owe 
stringent fiduciary duties to patients, which entail an obligation to act in furtherance of 
the patient’s best interests. Non-clinician DTC providers have less stringent duties, 
including duties that might be limited or circumscribed by contract. Consumers should 
be made aware of these distinctions prior to consenting to undergo DTC testing.’ (p.103-
104) [32]. Indeed, in the context of DTC companies the contract describing the conditions 
of the service is usually stated in terms of service to which a consumer has to agree prior 
to buying the test. However, if the purpose of the test is health-related, signing a contract 
cannot fully replace the function of IC, which aims, among others, to provide 
understandable and balanced information about the test [24]. The tests included in this 
study are advertised as having (to some extent) a health-related purpose or as clinical 
tests, therefore, the presence of adequate IC in the studied DTC companies appears to be 
advisable. 
3.4.2 Explicit informed consent and pre-test counselling 
Explicit informed consent, which is recommended by Ayuso et al. (2013) for clinical 
WGS, may be defined as one for which ‘Those who request consent must provide an 
explicit statement of the nature and purposes of a proposed course of action, its effects, 
risks and other features, to those whose consent is sought. Those who are asked to consent 
must show explicitly that they understand this information and agree to the proposal’ 
[34]. The process of explicit IC typically involves documents, signatures and formal 
statements [34]. Therefore, in this study we have focused on the documents or the section 
of the websites which the consumers have to agree to in order to be tested. However, in 
order to be genuinely informed consent should not be reduced to signing a document but 
rather through dialogue with a qualified HCP it should be ensured that the patient truly 
understands the information provided and is competent to make a choice [35].   
Although all four companies provide some form of document addressing consent, only 
Illumina requires pre-test counselling understood as face-to-face consultation with 
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a physician. In the other companies studied, most of the tests have to be ordered by the 
physician meaning that the consumer has to contact one in order to be tested. This, 
however, does not guarantee that adequate counselling takes place, given the concerns 
about the expertise in genetics and impartiality of the health care professionals [13]. 
Indeed, including a third party HCP in the process raises the question of who bears the 
(fundamental) ethical and legal responsibility for taking adequate consent? Of course, the 
HCP must adhere to the general medical code of conduct, but depending on her/his 
specialty, is (s)he aware of the specific guidelines for genetic testing?  
Another important result that brings attention to the involvement of healthcare 
professionals in testing is a lack of involvement of a physician in undertaking the 
consumer test in Gene By Gene company. Although ‘Terms and Conditions’ state that 
the services listed in ‘Research and Consumer Testing’ section ‘are not to be used to 
diagnose, prevent, or treat any condition or disease or to ascertain the state of health for 
any individual’ (https://www.genebygene.com/pages/terms), the description of the test 
suggests that it may provide health-related information: ‘Sequencing of the exome can 
help identify variants that may be the genetic cause of a wide range of traits and 
conditions.’ (https://www.genebygene.com/pages/research#). Therefore, the involvement 
of a genetics professional seems to also be advisable in the case of ‘Research and 
Consumer Testing’ of Gene By Gene, which could prevent misinterpretation of the results 
or unnecessary follow-up care.  
In addition, although the non-clinician DTC provider may have less stringent duties as 
stated by the PCSBI [32], the full role of a clinician in the DTC context still remains 
blurry. It is unknown to what extent physicians in the DTC context follow the same 
protocol as geneticist follow in the traditional health care system. 
Another aspect related to informed consent is the potentially low readership of the consent 
documents analysed herein. It has already been shown that most of the consumers read 
very little of the terms of service agreements (e.g. when purchasing software [36] or 
accessing Wi-Fi). This may suggest that although the documents have the word ‘consent’ 
in the title and/or are aimed to be read and agreed to, the consumers are not acquainted 
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with their content. This issue requires further analysis to assess the accessibility and 
readability of such documents. 
3.4.3 Information about benefits and risks  
The content analysis of the sections of companies’ websites reveals that the information 
regarding possible risks and benefits is scarce, general and omits some relevant elements 
such as description of the implications for the reproductive choices, which has been 
recommended for IC for WGS [27].  Furthermore, some of the outlined information about 
benefits may be misleading such as regarding the possibility to participate in research 
studies (Table 3.3), which, in fact, does not necessarily benefit participants per se and is 
associated with various risks. Similarly, knowing the information about the carrier status 
is mentioned as a benefit in Gentle’s IC website section, but the implications for 
reproductive choices of having this knowledge are not described (Table 3.3). What is 
more, the information provided in the documents that need to be signed differs from the 
information placed in other sections of the website, which seem to be more encouraging 
about the possible results. For example, in the ‘Why do a genetic test?’ section of the 
Inneova website they state that:  
‘The objective of predictive genetics testing from Inneova™ is to determine each 
person’s specific genetic features – and notably vulnerabilities – in order to allow 
highly-qualified practitioners in anti-aging and preventive medicine identify 
appropriate measures designed to counter-balance weaknesses and maintain 
good health, as well as help prevent the development of specific diseases or at 
least to delay their onset’ 
(http://www.inneova.com/tout.php?page=prev_why.php&menu=2, under 
bookmark ‘Predictive Genetics’).  
This may be misleading as consumers may not read the sections ‘Terms of Service’ or 
‘Terms and Conditions’ [16], but rather take the decisions based on the information 
available on the main webpages. Finally, the information about the potential risks in the 
documents of Inneova and Gene By Gene may make an impression that it was designed 
or written more in a way to protect the company from any liability rather than to explain 
and inform about potential disadvantages, e.g. ‘I agree that ICL (…) assumes no liability 
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for any stress, strain, hardship, adverse medical condition, financial loss, or other 
circumstances that I may suffer as a result of the receipt or reference to any predictive 
genetics test results and/or interpretations thereof supplied to me by ICL’ 
(http://www.inneova.com/contenu.php?page=terms.php). 
Some of the findings presented herein are in line with the results of the study of Singleton 
et al, 2012 on informed choice in DTC GT companies, which focuses on the websites of 
the DTC GT companies containing consumer-focused content excluding terms and 
conditions and privacy statements, therefore being to some extent complementary to this 
study. Singleton et al. found that the amount of information describing benefits 
outweighed risks statements and that the websites presented conflicting information 
stating that the tests can help to prevent diseases, simultaneously giving information that 
the test cannot be used for diagnosis or treatment [30]. Similarly, Skirton et. al found that 
misleading, conflicting or incomplete information was present on the websites of DTC 
companies offering non-invasive prenatal testing [37].  
3.4.4 Incidental/secondary findings 
The last, but not the least element of IC analysed in this study is the management of 
incidental findings. The term ‘incidental findings’ refers to ‘results that are outside the 
original purpose for which a test or procedure was conducted’ [32], while secondary 
findings are results being sought deliberately because of the recommendations of 
an expert body as it has been defined by the PCSBI in the report on incidental and 
secondary findings [32]. The issue of incidental and secondary findings appears 
particularly relevant in the context of WGS generating vast amount of data for analysis 
[38]. Therefore, this topic has been discussed at great length and various expert societies 
have addressed it in recommendations. The PCSBI emphasizes the role of IC, and for the 
particular context of DTC companies suggests that the providers should develop adequate 
procedures to manage IF and provide consumers with understandable materials 
explaining these procedures [39]. The American College of Medical Genetics (ACMG) 
also has issued recommendations for the reporting of secondary findings obtained in 
WGS (although they use the term incidental findings, this is misleading since what they 
describe is opportunistic screening and not the strictly ‘unsolicited’ findings) [33]. This 
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policy statement of the ACMG suggests that secondary findings concerning 24 indicated 
conditions (related to 56 gene variants affecting function) should be sought and reported, 
however the patient may refuse the analysis of some of these genes if they are unrelated 
to the indication for testing, which should be done during the process of IC [33,40]. In 
contrast, the recommendations of the European Society of Human Genetics which address 
incidental findings, do not provide a specific list of reportable conditions but rather 
suggest narrowing the scope of the sequence analysis and developing guidelines and 
protocols [41] in order to reduce the chances of encountering IF all together. Finally, 
some authors propose models of stratification of information derived from WGS, 
including incidental/secondary findings, which will help the discussion with, and the 
decision-making by the patient [27,42]. 
Only one company out of the four studied addresses the issue of incidental/secondary 
findings and provides a report on IF complying with the recommendations of ACMG [33] 
(hence conducting opportunistic screening). However, the company does not indicate in 
the informed consent form for the TruGenome Undiagnosed Disease Test whether the 
consumer has an opportunity to opt out of the analysis of some of the genes listed by the 
ACMG. Furthermore, according to the report on the IFs issued by the PCSBI [32] as well 
as the recent update of the recommendations for reporting secondary findings in genome-
scale sequencing [40] the term ‘incidental findings’ used by Illumina is not adequate and 
in order to comply with the guidelines mentioned it should be replaced by the term 
‘secondary findings’. Nevertheless, in the IC for Undiagnosed Disease Test Illumina 
seems to implement the recommendations included in the primer on IFs for DTC 
providers, which advise to prepare a plan for the management of incidental and secondary 
findings and to provide easily accessible information for consumers about this procedure. 
The IC form for Illumina’s Predisposition Screen test introduces categories of genetic 
information which consumer may choose not to receive exercising his/her ‘right not to 
know’ some of the medical information. The categories of genetic information introduced 
by Illumina are to some extent in line with those suggested by Ayuso et al. (2013) as they 
arrange the conditions according to the time of onset and medical actionability facilitating 
the choice of consumers [27].  
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3.5 Conclusions  
Concerning the elements studied herein the consent forms and documents on companies’ 
websites do not appear to fulfil the requirements for genuinely explicit and informed 
consent for WGS in the clinical setting as suggested by Ayuso et al. (2013). This 
highlights the present need to develop and implement ‘best practices’ for the DTC GT 
context with regard to IC and the provision of information about testing being offered. 
Moreover, the specific context of the commercial DTC GT companies which involve 
healthcare professionals could benefit from developing guidelines that specifically 
address this practice. 
This explorative qualitative study has some limitations. Since it considers a small and 
convenient sample of DTC WGS/WES companies’ and a subset of their written policies, 
it does not provide an exhaustive overview of all companies, their practices and associated 
ethical issues involved in the consent process. Indeed, we stress that the goal of this article 
is not meant to be an exhaustive, or generalizable (in a quantitative statistical way) 
analysis of DTC WGS companies, but rather a qualitative exploration of the activities that 
exist with respect to consent. Moreover, information provided on other pages of 
companies’ websites not analysed herein may also be relevant to IC process, which 
requires further investigation. Furthermore, other information such as that related to 
storage and future use of consumers’ samples and data pertain to IC and their presence in 
the process of IC in DTC companies also needs to be discussed. Finally, it is important to 
note that the nature of the DTC genetic and genomic testing market is very dynamic and 
the practices of companies are continuously evolving, thus it is important to monitor and 
continue to study and reflect on these activities. 
In conclusion, we acknowledge that informed consent is just one of the elements related 
to the ethical issues around WGS. Its adequacy may not resolve the other ethical issues 
related to the companies that offer WGS, however, as stakeholders in genetics, we should 
expect and aim to support and provide an adequately informed consent process in order 
to respect individuals in their health-related decisions.  
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Tables (Chapter 3) 
Table 3.1 Basic information about the four companies selling WGS included in this study. 
The websites were accessed on 23 October 2014. HCP = healthcare professional. 
Company name, 
country and 
website address 
Description of service 
Who can 
order the 
test
a
 
Sections of the websites 
studied 
 
 
Illumina, USA 
(http://www.illumina
.com/clinical/illumin
a_clinical_laboratory
.html) 
 
 
WGS: 
TruGenome Undiagnosed 
Disease Test –  with analysis 
and interpretation based on 
clinical indication; 
TruGenome Predisposition Screen 
–  with analysis and interpretation 
of 1,600 genes that have 
established associations to a set of 
conditions or diseases caused by 
single genes 
TruGenome Technical Sequence 
Data – raw data without 
interpretation 
 
only HCP 
Informed Consent 
(different form for each 
test, at the time of 
submitting the article the 
versions of forms studied 
were no longer available 
online; for the copies of the 
forms please contact the 
corresponding author) 
Gentle, Belgium 
https://www.gentlela
bs.com/ 
WES - with analysis and 
interpretation of genetic variants 
related to carrier status, health 
risks and response to medications 
(in the time since this analysis was 
completed, Gentle has stopped 
selling to “end users”)b 
only HCP 
Informed 
Consent 
(https://www.gentlela
bs.com/consent), 
Terms of Service 
(https://www.gentlela
bs.com/terms) 
Gene By Gene, 
USA 
https://www.geneby
gene.com/# 
Clinical testing 
WES - with 
analysis, search 
for the variant(s) 
of potential 
causative effect 
for the described 
phenotype 
only HCP 
Terms and Conditions 
(https://www.genebygene.
com/pages/terms) 
Research and 
consumer 
testing 
WES and WGS 
- raw data or 
with analysis 
HCP and 
non-HCP 
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Table 3.1 Continuation 
aAccording to ‘A common framework of principles for DTC GT services’ issued by the 
Human Genetics Commission (UK)
 
the type of genetic tests which ‘are commissioned by the 
consumer but where a medical practitioner or health professional is involved in the provision 
of the service’ also fall in the scope of DTC genetic tests. 
b
At the time of submitting this article Gentle stated on its company website “In order to focus 
all our efforts on the clinical diagnostics market, we are no longer selling the Gentle test to 
end users. If you are interested in our clinical interpretation services, please contact us.” 
(https://store.gentlelabs.com/)
Company name, 
country and 
website address 
Description of service 
Who can 
order the 
test
a
 
Sections of the 
websites studied 
Inneova, Canada 
http://www.inneova
.com/ 
WGS – with analysis and 
interpretation concerning 
interaction of genes with ageing, 
nutritional and lifestyle choices 
and diseases 
 
 
only HCP 
Statement of consent 
(http://www.inneova.co
m/contenu.php?page=te
rms.php), Disclaimer 
and privacy policy 
(http://www.inneova.co
m/contenu.php?page=di
sclaimer.php 
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Table 3.2 Information about the pre-test counselling for WGS offered by the 
studied companies. The information was accessed on 25 October 2014. 
Company name Pre-test counselling 
Illumina Not provided by the company but 
required for IC 
Gentle Not provided by the company but 
recommended in IC 
Gene By Gene No information 
Inneova No information 
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Table 3.3 Information about the possible benefits and risks of WGS included in the studied 
sections of the companies’ websites. Words in bold in ‘Benefits’ and ‘Risks’ columns are 
identified subthemes. The websites were accessed on 25 October 2014. 
Company Benefits Risks 
Illumina 'Your test results may help you 
and your physician make more 
informed choices about your 
healthcare. It is also possible that 
your test results will not provide 
any benefit.' 
Medical and/or physical risks: 'Side 
effects of having blood drawn are 
uncommon, but may include dizziness, 
fainting, soreness, bleeding, bruising, 
and, rarely, infection.' Psychological: 
'Your test results may reveal 
information about yourself, or your 
relatives, that you would rather not 
know. For example, you may learn 
information about genetic 
risks/predispositions to disease, 
including ones that might not be 
curable; ancestry; etc.' Implications 
for family members: 'In a trio or 
parent/child analysis, it may be 
uncovered that a family member is 
unrelated to the patient, such as in the 
case of adoption or non-paternity. It 
may not be possible to prevent learning 
such information through this test.' 
Discrimination risks: 'Genetic 
information could be used as a basis of 
discrimination. (…) The laws may not 
protect against genetic discrimination 
in other circumstances such as when 
applying for life insurance or long-term 
disability insurance.' 
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Table 3.3 continuation 
Company Benefits Risks 
Gentle Knowledge about disease risks and 
predispositions: ' A person found to have an 
increased risk of disease might want to 
choose preventive or therapeutic medical 
treatments. 
Having this knowledge can empower a person 
and family members to make important life 
planning decisions, even if a cure is not 
available at the time of testing. (...) Knowing 
the genetic predisposition to these conditions 
allows you to take action, even before 
symptoms occur.' Information about 
carrier status: 'DNA-testing can inform a 
person about his/her carrier status for 
thousands of genetic conditions. 
Many genetic conditions are inherited in a 
recessive way. Being a carrier will usually 
not affect the health of the person him/herself, 
but might affect the health of future children. 
Screening your carrier status for diseases 
allows to check whether you might pass on 
severe conditions to your children.' More 
tailored drug therapy: 'Another benefit of 
DNA-testing is that you and your physician 
can make informed decisions on which 
medication is best for you.' Possibility to 
enroll in research studies: 'Having a 
specific diagnosis could qualify a person to 
enrol in research studies, which may lead to 
new treatments.' Insight into ancestry: 
'DNA-testing can provide insight into a 
person’s ancestry. 
Examination of DNA variations can provide 
clues about where a person’s ancestors 
might have come from and about 
relationships between families.' 
Psychological: 'The greatest 
concern pertains to the way 
a DNA test result might 
change a person’s life. The 
decision to have DNA testing 
can be stressful. You may 
have emotional reactions to 
learning that you do- or do 
not— carry a gene change 
for a certain condition.' 
Implications for family 
members: 'Sometimes a test 
result may not only affect 
you, but also your family 
relationships. A person who 
decides to have DNA testing 
needs to consider whether to 
tell other family members. 
Sometimes the result for one 
family member can disclose 
information about the 
genetic makeup of other 
relatives, even if they have 
not been tested.' 
Discrimination risks: 'In 
some countries a DNA test 
result may also affect a 
person’s ability to obtain 
health, life, disability or 
long-term care insurance. It 
could also affect the ability 
to obtain or keep a job.' 
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Table 3.3 continuation 
Company Benefits Risks 
Gene 
By 
Gene 
Knowledge about disease risks and 
predispositions, information about 
carrier status, only for 'Clinical 
Genetic Testing': 'The purpose of 
clinical  genetic testing is to evaluate 
the presence of the predisposition to 
genetic diseases, to assess the risk for 
developing a genetic disease, or to 
determine the carrier status of a known 
disease-causing mutation.' 
Psychological, discrimination 
risks for 'Clinical Genetic 
Testing' only: ' Gene By Gene, 
LTD. is not responsible for legal, 
material, social, psychological, or 
moral consequences related to the 
results of genetic testing.' Only for 
'Research and Consumer 
Testing': ' The customer is aware 
that some of the information 
received may be unexpected, and 
the customer takes responsibility 
for all possible consequences 
resulting from test data and sharing 
this data.' 
Inneova Knowledge about disease risks and 
predispositions: ' I understand the 
basic concept of predictive genetics 
testing and how it may result in the 
discovery of genetic predispositions 
that could indicate an increased or 
decreased risk of developing certain 
medical conditions and diseases. I 
realize the possible far-reaching 
implications of the information 
obtained through predictive genetics 
testing in affecting my life choices as 
well as those of my relatives, children, 
and unborn children. (...) ICL is 
obliged to (...) provide me with 
predictive genetics test results, as well 
as an indicative, preliminary 
personalized report for each test 
performed based on statistical genetic 
research into the behaviour and 
interaction of genes with factors such 
as aging, nutritional and lifestyle 
choices, as well as various diseases 
and how they could affect my health 
and well being.’ 
 
Medical, psychological risks, 
implications for family members, 
discrimination risks:  'I realize the 
possible far-reaching implications 
of the information obtained through 
predictive genetics testing in 
affecting my life choices as well as 
those of my relatives, children, and 
unborn children. (…) I agree that 
ICL (together with its medical, 
scientific, and other service 
partners, subsidiaries and related 
business entities, legal advisors, 
agents, or appointees) assumes no 
liability for any stress, strain, 
hardship, adverse medical 
condition, financial loss, or other 
circumstances that I may suffer as a 
result of the receipt or reference to 
any predictive genetics test results 
and/or interpretations thereof 
supplied to me by ICL.' 
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Table 3.4 Information regarding the management of incidental findings resulting from WGS 
included in the studied sections of the companies’ websites. The websites were accessed on 
25 October 2014. 
Company, type of test 
Incidental 
findings 
Categorization 
of the genetic 
information 
Right not to 
know 
Illumina 
TruGenome 
Undiagnosed 
Disease Test 
Provides 
'incidental 
findings' report of 
variants located in 
the genes 
recommended by 
ACMG 
No information No information 
TruGenome 
Predisposition 
Screen 
No information 
Yes, categories: 
childhood onset and 
adult onset; 
subcategories: 
medically 
actionable, not 
medically 
actionable, cancer, 
neurologic 
conditions 
Yes, option for 
excluding some 
of the categories 
from the test 
results 
TruGenome 
Technical 
Sequence Data 
Not applicable Not applicable Not applicable 
Gentle No information No information Yes 
Gene By Gene No information No information No information 
Inneova No information No information No information 
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Abstract 
High throughput approaches such as whole genome sequencing (WGS) and whole exome 
sequencing (WES) create an unprecedented amount of data providing powerful resources for 
clinical care and research. Recently, WGS and WES services have been made available by 
commercial direct-to-consumer (DTC) companies. The DTC offer of genetic testing (GT) has 
already brought attention to potentially problematic issues such as the adequacy of consumers' 
informed consent and transparency of companies' research activities. In this study, we analysed 
the websites of four DTC GT companies offering WGS and/or WES with regard to their policies 
governing storage and future use of consumers' data and samples. The results are discussed in 
relation to recommendations and guiding principles such as the “Statement of the European 
Society of Human Genetics on DTC GT for health-related purposes” (2010) and the 
“Framework for responsible sharing of genomic and health-related data” (Global Alliance for 
Genomics and Health, 2014). The analysis reveals that some companies may store and use 
consumers' samples or sequencing data for unspecified research and share the data with third 
parties. Moreover, the companies do not provide sufficient or clear information to consumers 
about this, which can undermine the validity of the consent process. Furthermore, while all 
companies state that they provide privacy safeguards for data and mention the limitations of 
these, information about the possibility of re-identification is lacking. Finally, although the 
companies that may conduct research do include information regarding proprietary claims and 
commercialisation of the results, it is not clear whether consumers are aware of the 
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consequences of these policies. These results indicate that DTC GT companies still need to 
improve the transparency regarding handling of consumers' samples and data, including having 
an explicit and clear consent process for research activities.  
Keywords: whole-genome sequencing, whole-exome sequencing, direct-to-consumer genetic 
testing, consumer genomics, human genome research, consent 
4.1 Introduction 
Direct-to-consumer (DTC) genetic testing (GT) companies operating outside of the traditional 
healthcare system have attracted numerous critiques of their practices over the last decade [1]. 
Beyond questioning the clinical validity and utility of the tests, the appropriateness of medical 
supervision and genetic counselling, some of the concerns centre on the storage and use of 
consumers' samples and data. These include a number of inter-related issues such as what 
consumers are told (e.g., during the consent process) about storage and use of samples and data; 
proprietary claims stemming from secondary uses of sample and data; as well as the coupling 
of companies' genetic testing offer with research activities. Indeed, an earlier explorative study 
of DTC GT companies has shown that for some companies the consent to participation in 
research may not be adequate; it questioned whether the information provided by the companies 
about their research activities was clear and explicit enough for consumers to understand what 
they were agreeing to [2]. Furthermore, it highlighted that such ambiguous presentations of 
information for testing and research activities blur the lines between consumers and research 
participants, undermine the informed choice of consumers and may potentially undermine 
public trust in research in general [2,3]. 
Recent advancements in sequencing technologies have resulted in a significant decrease in the 
price of whole-exome and whole-genome sequencing (WES, WGS), which has allowed for 
a greater use of these approaches in both the clinical and research domains causing a shift in 
testing approach from analysing one or a few genetic variants to the study of an entire 
exome/genome sequence. WES/WGS generates an unprecedented amount of sensitive health-
related genomic data useful in healthcare management and powerful in the research setting [4]. 
While much of the discussion surrounding the ethical, legal and social implications (ELSI) of 
these high-throughput approaches has been focused on these settings, much less attention has 
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been paid to commercial companies offering sequencing services DTC. Given that WES/WGS 
is likely to become increasingly more available and there is the potential for these services to 
be coupled with research activities using consumers' data 
(http://www.technologyreview.com/news/540711/inside-illuminas-plans-to-lure-consumers-
with-an-app-store-for-genomes/), the ELSI of DTC genomics are particularly important to 
address now. We therefore studied the websites of companies advertising WGS and/or WES 
DTC to shed light on the information they provide to consumers. More specifically, we analysed 
webpage documents that consumers should sign and/or agree to when undertaking the test 
(i.e., depending on the company, sections entitled informed consent, terms and conditions, 
statement of consent, disclaimer and privacy policy; Table 4.1). We focused on information 
relevant to storing and using consumers' data and samples. These issues include: i) purpose and 
period of samples and data storage; ii) consumer consent; iii) data access and sharing; iv) 
identifiability and confidentiality of data; and v) proprietary claims. Four companies were 
identified (circa mid-2015) which offer and/or advertise WES and/or WGS DTC: Illumina, 
Gene by Gene, GeneYouIn, and Inneova. Each stated that they offer WGS and/or WES, 
although the scope and focus of data analysis and interpretation varied from providing only raw 
sequencing data to the diagnosis of Mendelian disorders. Moreover, they had different models 
of provision (e.g., with or without physician referral; Table 4.1). We defined direct-to-consumer 
genetic/genomic testing as the offer and/or advertisement of testing direct-to-consumers. We 
considered companies that required a health care professional to order the WGS or WES 
services also as DTC companies since they were still advertising directly to consumers, and this 
can have a significant impact on the demand and ultimate use of a product or service. This is 
congruent with the scope of DTC GT given by the UK Human Genetics Commission, which 
included situations where “tests are commissioned by the consumer but where a medical 
practitioner or health professional is involved in the provision of the service.” [5]. 
4.2 Purpose and period of samples and data storage 
Three of the four analysed DTC companies (Illumina, Gene By Gene, GeneYouIn) stated on 
their websites that they may use consumers' data and/or samples for purposes beyond 
performing the genetic test ordered by the consumer (Table 4.2). Illumina stated that “leftover 
specimen and results may be used by Illumina for purposes of quality control, laboratory 
operations, and laboratory improvement” (http://www.illumina.com/content/dam/illumina-
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marketing/documents/clinical/forms/form-test-req-predisposition.pdf). This suggested that the 
company performs internal quality assurance, for which specific consent is not necessarily 
required as long as some conditions are met (e.g., actively informing individuals of this use) 
[6,7]. The period for which the results and specimen would be stored was not specified in the 
analysed document. 
Meanwhile, GeneYouIn indicated that it would store the samples for 90 days and that after this 
period they would be discarded; the company did not specify the period for data storage. 
GeneYouIn also stated explicitly that it may use consumers’5  data for research, providing 
a general description of the type of research on its informed consent page: 
“You provide your consent for research in which we analyse your genetic data and 
phenotype information in order to discover or validate associations between certain 
genetic variations and diseases.” (https://www.geneyouin.ca/informed-consent) 
Gene By Gene indicated in its terms and conditions that it would store consumer data for 
30 days or longer; after this time the data might be permanently deleted, however, the consumer 
could request storage for a longer period. Regarding the storage of the samples, the company 
indicated: “After testing is complete, remaining sample material is stored for 180 days, unless 
otherwise specified by regulatory agencies.” However, in the following sentence it stated: 
“After 3 months, the sample will be discarded or de-identified and retained for in-house 
laboratory use”, making it unclear for what period the samples would be actually stored. 
Furthermore, Gene By Gene provided a few statements concerning the use of samples and data 
that appear contradictory: “Any sample material sent will be used only to perform the 
specifically ordered testing.” Meanwhile, a few paragraphs below on the same page, it was 
written: “After 3 months, the sample will be discarded or de-identified and retained for in-house 
laboratory use.” And: “The customer specifically understands that they will not receive 
compensation for any research or commercial products that include or results from your 
sample, results, or personal record” (https://www.genebygene.com/pages/terms). The last two 
                                                 
5 The companies GeneYouIn and Gene By Gene use a word "customer" in the analysed texts. However, as 
implied in these texts, a customer (meaning a person who buys a test) is simultaneously a consumer (meaning a 
user of a test). Therefore, we use the word "consumer" throughout this article, also when referring to the 
quotations on the webpages of GeneYouIn and Gene By Gene. 
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statements imply that consumers' samples and data may be involved in research beyond quality 
assurance, which, without further information, appears to contradict the first statement that 
samples would be used only for the ordered testing. This information is ambiguous and 
confusing. 
The fourth company studied, Inneova, stated that biological samples would be destroyed after 
performing the test, but did not describe what would happen to the data. 
The incomplete information provided by the companies regarding the storage and use of 
consumers' data and samples is incongruent with the “Statement of the ESHG (European 
Society of Human Genetics) on direct-to-consumer genetic testing for health-related purposes” 
[8], which recommends that companies should “explain what will happen to the sample and the 
data when the testing process is concluded”. Furthermore, in case of research activities being 
performed on the consumers' data or samples, the ESHG (2010) recommends that more detailed 
information should be provided: “Informed consent documents for participation in research 
should disclose the procedures for storing and disposal of samples and genetic information, the 
time period and conditions for storing them” [8]. In addition, DTC GT companies should “have 
a clearly laid-out plan as to what will happen to the samples and data should the company be 
sold or go bankrupt” [8]. None of the web-documents/webpages studied from these four 
companies provided a description of what will happen in such situations. This echoes results of 
a study of DTC GT companies conducted by Zawati et al., 2011 [9], in which the authors called 
for “clearer institutional frameworks on the issue of closure.”  
Overall, our results show that two companies indicated may perform research on consumer data 
and/or samples, while two other companies did not make reference to research activities. 
Furthermore, only one company specified the period of storage for data, while the period of 
storage for samples was stated clearly by two of four companies. None of the companies made 
reference to what would happen if the company were sold or went bankrupt. 
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4.3 Consumer consent 
4.3.1 Consent for services 
Based on the websites studied, consumers give their consent for the services purchased, 
including agreeing to the information in the aforementioned documents by ordering the test 
(https://www.geneyouin.ca/terms-
conditions/;https://www.genebygene.com/pages/terms;http://www.inneova.info/contenu.php?
page=disclaimer.php) or by signing the form which is sent to the company together with the 
sample for analysis (http://www.illumina.com/content/dam/illumina-
marketing/documents/clinical/forms/form-test-req-predisposition.pdf). In the case of the 
informed consent from GeneYouIn, it was not made explicit how exactly consumers provide 
consent to the testing (e.g., via signature, a verbal agreement) 
“We ask you to provide your informed consent to ensure that, before purchasing 
GeneYouIn's genetic testing and consulting services, you are not only aware of the 
benefits, but also understand the limitations and potential risks. Please carefully review 
the information described below before you purchase any of our services.” 
(https://www.geneyouin.ca/informed-consent/) 
The provision of information and the manner of consenting in the DTC GT context may raise 
the question of whether consumers have read and fully understood the information to which 
they agree and thus whether their decision is truly an informed decision. The low readership of 
sections such as the “terms of service” has already been discussed in the context of online 
transactions e.g. when purchasing software [10]. However, as noted by the Presidential 
Commission for the Study of Bioethical Issues (2013), by providing health information DTC 
GT companies “interact in both the business and medical realms, and could find themselves 
subject to the ethical principles pertinent to business transactions as well as those of medical 
care” [11]. Therefore, DTC GT companies, depending on the types of tests they sell, can be 
subject to the e-commerce legal framework, as well as fall within the scope of ethical 
requirements related to genetic testing in the clinic context and/or in the realm of research 
participation. One of these requirements is to obtain informed consent for testing and research, 
which has different functions than the terms of service of a consumer contract [12]. The 
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informed consent process involves providing consumers certain types of information about 
testing (e.g. benefits and risks) in an understandable manner. Furthermore, as explained in the 
Statement of the ESHG the process of informed consent should “ensure that individuals 
understand the disclosed information, are legally competent and cognitively capable of acting 
without external pressure, and give their agreement to all the elements involved.” [8]. It should 
also protect against involuntary testing [8,12]. 
4.3.2 Consent to research 
The information about the possibility of performing research on consumers' samples (i.e., for 
the companies GeneYouIn and Gene by Gene) was not included on the front pages of the 
companies' websites or the main pages including the description of what the companies offer 
(Table 4.1). Therefore, it is not clear whether the consumers have been aware of the companies' 
research activities and if they have been genuinely consenting to them. Furthermore, the 
provision of information about research activities raises concerns about clarity and 
understandability of this information for consumers, as mentioned earlier. This type of unclear 
and non-explicit way of “recruiting” consumers as research participants appears to be in 
contradiction of the requirement for informed consent. The importance of informed consent for 
research has been articulated by various guidelines and legal documents, for instance the 
Statement of the ESHG specifies: “If samples or data are to be used in any research, this should 
be clear to consumers, and a separate and unambiguous consent procedure should take place.” 
[8]. This recommendation underlines another concern about the adequacy of consent for 
research activities of the companies, namely the presence of a separate consent procedure. This 
practice has been acknowledged and supported as it “enhances autonomy by drawing the 
customer's attention to the change in the use of their samples and data” [13]. Neither of the two 
companies that may conduct research and were examined here offered a separate informed 
consent form for research. What is even more troubling, they also did not provide a possibility 
to opt-out of their potential research activities, which has been criticised as a practice 
undermining the autonomy of consumers [13]. 
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4.3.3 Additional information needed in the consent process 
The recommendations for informed consent for research specify that besides information 
regarding the destination of the consumers' data and samples after performing the test, the 
consent should include additional elements. For example, the ESHG states: 
“Informed consent documents for participation in research should disclose the 
procedures for storing and disposal of samples and genetic information, the time period 
and conditions for storing them, inform participants of the identity of any third parties 
who may be granted access to data or samples, and include also information on the fact 
that the research may lead to commercialization and patents, on any customers' rights 
to commercial benefits and on the property of biological samples and data.” [8] 
The Global Alliance for Genomics and Health suggests similar types of information to be 
provided in order to respect the responsible sharing of genomic and health-related data in 
general, and specifically to support the principle of transparency: 
“Provide clear information on the purpose, collection, use and exchange of genomic 
and health-related data, including, but not limited to: data transfer to third parties; 
international transfer of data; terms of access; duration of data storage; identifiability 
of individuals and data and limits to anonymity or confidentiality of data; 
communication of results to individuals and/or groups; oversight of downstream uses 
of data; commercial involvement; proprietary claims; and processes of withdrawal 
from data sharing.” [14]  
Similarly, the recommendations on WGS issued by the US Presidential Commission for the 
Study of Bioethical Issues suggest the presence of particular elements in informed consent, 
which also apply to commercial WGS: 
“Researchers and clinicians should evaluate and adopt robust and workable consent 
processes that allow research participants, patients, and others to understand who has 
access to their whole genome sequences and other data generated in the course of 
research, clinical, or commercial sequencing, and to know how these data might be 
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used in the future. Consent processes should ascertain participant or patient 
preferences at the time the samples are obtained.” [15] 
In the remainder of this article we discuss some of the elements that have been highlighted in 
the above documents as being important to communicate to persons undergoing genetic or 
genomic testing. 
4.4 Data access and sharing 
All companies stated that they may grant access to consumers' data to a third party that is legally 
authorized or if it is required by law (e.g., by a court order) (Table 4.3). Illumina, GeneYouIn 
and Gene By Gene also specified that, with the consumer's consent, they may grant access to 
the healthcare provider to whom the test results would be released. In addition, GeneYouIn 
indicated that consumers may withdraw this type of consent and request deletion of their 
records. Moreover, the company specified that it might share consumers' data with research 
organizations and that consumers would have an opportunity to opt-out of their data sharing by 
checking a box in the informed consent. 
Inneova, although somewhat indirectly, also mentioned the possibility of sharing data: 
“I understand that ICL will not disclose my identity, contact details, or test results to 
third parties (except to its medical, scientific, and other service partners, subsidiaries 
and related business entities, legal advisors, agents, or appointees for the purpose of 
performing genetic testing or interpretation services, as well as any associated 
administrative transactions, as deemed necessary by ICL in the normal course of 
business under the terms of this Agreement as well as under its Disclaimer and Privacy 
Policy).” (http://www.inneova.com/contenu.php?page=terms.php) 
Although the first clause stated no disclosure, the list of exceptions in brackets was long and 
vague. 
Gene By Gene stated that the samples may be “retained for in-house laboratory use” and did 
not specify any third parties with which sharing would happen other than to state that third-
party access will only be given with proper “authorization in accordance with the Health 
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Insurance Portability and Accountability Act”. However, the statement: “The customer 
understands that by providing any sample (…) or providing personal information, that the 
customer acquires no rights in any research or commercial products or services that may be 
developed by Gene by Gene, LTD. or its collaborating partners.” 
(https://www.genebygene.com/pages/terms) suggests that consumers' data, in some way, may 
be indeed, used by “collaborating partners” and hence shared in some way. 
Importantly, the companies did not specify the detailed conditions (except mentioning “legal 
authorization”) under which third parties would gain access to consumer data. Also lacking was 
information regarding whether the transfer of data would be international and information about 
oversight of downstream uses of data, both of which are elements suggested in the “Framework 
for responsible sharing of genomic and health-related data” (called further Global Alliance 
Framework) in order to respect and support transparency in data sharing [14]. Similarly, the 
Presidential Commission for the Study of Bioethical Issues recommends: 
“Funders of whole genome sequencing research; managers of research, clinical, and 
commercial databases; and policy makers should maintain or establish clear policies 
defining acceptable access to and permissible uses of whole genome sequence data. 
These policies should promote opportunities for models of data sharing by individuals 
who want to share their whole genome sequence data with clinicians, researchers, or 
others.” [15] 
Although both of these documents highlight the importance of sharing data for maximising 
research potential, and they encourage making data accessible to researchers, they also stress 
that sharing should be conducted in a responsible way. Based on our findings, this may not be 
fully respected by some DTC WGS companies. 
4.5 Data security: identifiability and confidentiality 
All four companies stated that they provide privacy safeguards for consumers' samples and/or 
data (Table 4.4). Illumina stated that consumers need the code provided to their healthcare 
practitioner in order to access their results. Meanwhile, GeneYouIn described generally that it 
employs “commercially validated and reasonable computational and organizational 
safeguards” (https://www.geneyouin.ca/terms-conditions/). Similarly, Gene By Gene stated 
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that it “implements administrative, physical and technical safeguards to secure our client's 
protected health information as defined by HIPAA” 
(https://www.genebygene.com/pages/terms). Furthermore, Illumina, Gene By Gene and 
Inneova specified that the samples and/or data would be de-identified. GeneYouIn stated 
specifically that consumers' genetic and health data would be anonymised. The information 
provided by the companies seemed, at least to some extent, to fulfil the requirement articulated 
by the Statement of the ESHG: “companies offering DTC genetic tests should preserve the 
customer's privacy, keep their data confidential, inform them about their security procedures 
(…).” [8]. They also concur with the recommendations of the PCSBI which states that 
“Accessible whole genome sequence data should be stripped of traditional identifiers whenever 
possible to inhibit recognition or re-identification” [15]. The Global Alliance Framework, 
additionally, suggests provision of information about “limits to anonymity or confidentiality of 
data” [14]. GeneYouIn, Illumina and Gene By Gene stated that there are limitations to the 
privacy safeguards, which may be breached by, for example, the use of malicious software 
(Table 4.4). Yet information about the possibility of re-identification of anonymised genomic 
data was missing from the web documents/webpages studied for all four companies. The 
relevance of this element for informed consent for genome testing was highlighted by Chow-
White et al.: 
“(…) the consent form should contain language/disclaimer that privacy is not absolutely 
guaranteed. The unstableness of digital networks and uncertainty of genomic 
information creates the conditions of privacy without guarantees. The consent form 
should (…) provide details of data release and sharing, including potential public 
databases where data could be disseminated and explain the potential of re-
identification of anonymized data.” [16] 
Moreover, one may argue that using the term “anonymised” is misleading and disingenuous as 
it has been shown that anonymised genomic data may be re-identified by linking information 
from different databases [17]. Indeed, the term “pseudonomisation” may be more accurate in 
the context of genomic data, however it may be too vague for "lay" consumers to fully 
understand its meaning [18]. To clarify this issue, companies should explain to consumers that 
although their data will be stripped of personal information (de-identified) there is still a chance 
of reidentification. 
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The Statement of the ESHG also suggests that “possible consequences related to their [results] 
disclosure to third parties, such as insurance companies and employers, should be discussed” 
[8]. Illumina and GeneYouIn stated that there is a risk of discrimination in case of disclosure 
of the results (Table 4.4). Illumina also mentioned the limitations of legal protections against 
discrimination: “The laws may not protect against genetic discrimination in other 
circumstances such as when applying for life insurance or long-term disability insurance.” 
(http://www.illumina.com/content/dam/illumina-marketing/documents/clinical/forms/form-
test-req-predisposition.pdf). GeneYouIn and Gene By Gene also cited the US Genetic 
Information Nondiscrimination Act (GINA), which “prohibits health insurers and employers 
from discriminating based on genetic information” 
(https://www.genebygene.com/pages/terms). Furthermore, GeneYouIn mentioned the 
limitations of current Canadian law: “While there are different laws in place across the globe 
that prevent companies from discriminating against people based on race, age, handicaps, and 
genetic predispositions such laws are not yet fully implemented in Canada.” 
(https://www.geneyouin.ca/informed-consent). Gene By Gene outlined possible consequences 
of disclosure, including: “misuse, mishandling, or misrepresentation” 
(https://www.genebygene.com/pages/terms). 
4.6 Proprietary claims 
GeneYouIn and Gene By Gene stated that consumers would not receive any compensation for 
being involved in research (Table 4.5). Gene By Gene also added that a consumer “will not 
receive compensation for (…) commercial products that include or results from [customer's] 
sample, results, or personal record.”; and “customer acquires no rights in any research or 
commercial products or services that may be developed by Gene by Gene, LTD. or its 
collaborating partners.” (https://www.genebygene.com/pages/terms). Meanwhile, GeneYouIn 
explained that it is a custodian of consumers' genetic and health data; however, it did not appear 
to explicitly outline the implications of this fact. The presence of these elements of information 
seems to comply with the recommendations of the Global Alliance Framework [14] and the 
Statement of the ESHG, which suggests inclusion of “information on the fact that the research 
may lead to commercialization and patents, on any customers' rights to commercial benefits 
and on the property of biological samples and data.” [8] 
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However, the fact that Gene By Gene consumer's sample could actually be part of a commercial 
product raises particular ethical concerns including whether it is ethically acceptable to sell 
products that incorporate consumers' samples potentially without providing any benefit-sharing 
for the consumers [19]. 
In addition, given the concerns about overall adequacy of the consent process for the companies 
that may conduct research, we can question whether consumers are well informed about 
potential commercialisation of research results and their biological material. It has been 
reported that at least some of the consumers of the DTC GT company 23andMe were not aware 
of the possibility of commercialising research results, although the company provided 
a statement about it in its online consent form [20]. Importantly, the information about the 
potential commercial uses has been shown to be a relevant factor for deciding about whether to 
participate in research [21]. Therefore, this element of information should be provided to 
consumers in explicit and clearly understandable form in order to secure their informed choice. 
4.7 Conclusions 
Our study of particular sections of companies' websites indicates that some DTC WGS/WES 
companies might have conducted research with consumer data. Moreover, information about 
these activities, as well as general information about data and sample storage and specific 
information about data sharing were found to be lacking. For example, we found multiple 
instances where disclosures did not comply with guidelines of the ESHG concerning the offer 
of DTC GT [8] or with the recommendations outlined in the “Framework for responsible 
sharing of genomic and health-related data” [14]. This lack of transparency in the provision of 
information to consumers could undermine their informed consent. On the bright side, 
companies were relatively good at providing information about general data security. However, 
they failed to address the possibility (even if small) of re-identification. Finally, the companies 
did provide information about proprietary claims and commercialisation. 
We recognize that this study is based on a particular set of web documents/webpages sampled 
at a particular moment in time. As such there is a chance that some of the missing information 
might have been found elsewhere on the companies' websites. This being said, since the 
documents we chose are specifically aimed at consumers to read and agree to, we would argue 
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that the necessary information for data and sample storage, secondary use, and potential data or 
sample sharing should be included in these documents.  
Some of the ethical concerns regarding the research practices of DTC WGS companies 
discussed herein have been raised previously [3,22]. Furthermore, earlier this year, it was 
reported that the DTC GT company 23andMe together with the biotechnology company 
Genentech was to perform WGS on 23andMe consumers' samples, raising concerns about 
informed consent, data privacy, management of incidental findings and availability of the data 
to other researchers [23]. Although the ethical and legal study of DTC GT companies has been 
ongoing for almost a decade, it would appear that some of the ethical concerns about these 
companies and their research activities have not been resolved, but rather amplified as new 
sequencing technologies are implemented. Meanwhile, one of the DTC GT companies, 
23andMe, has been remarkably successful in recruiting research participants 
(http://www.forbes.com/sites/matthewherper/2015/10/14/23andme-prepares-a-comeback-
raising-115-million-at-a-1-1-billion-valuation/), thus gaining a significant share of the general 
community of biobank research and in doing so, potentially influencing the public perception 
of research. Noncompliance with ethical standards or recommendations by well-known 
companies could have significant negative implications for biomedical research in general. 
Therefore, it is particularly important to examine the behaviour of DTC GT companies and to 
promote the awareness and adherence to the ethical standards currently accepted and/or aspired 
to by the research community. In order to achieve this, it would be constructive to have the 
community of commercial companies weigh in on the development of best practice guidelines 
for the commercial realm along with relevant stakeholders such as consumers, patients and 
health care professionals.  
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Tables (Chapter 4) 
Table 4.1 Information about the companies, their WES/WGS services, model of provision of testing, and the website documents studied 
Company 
name & 
country 
Description of service Model of provision of testing 
Sections of the 
websites 
studied 
Illumina, 
USA 
 
WGS:                                                                                                                                                                                              
TruGenome Undiagnosed Disease Test – “intended to provide 
information to physicians to aid in the diagnosis of inherited 
diseases of single-gene etiology (Mendelian diseases)”.                                                                                                                 
TruGenome Predisposition Screen – “analysis and interpretation 
are performed on 1691 genes that have well-established 
associations to a set of 1232 conditions (...), and 11 medically 
actionable genes associated with response to 16 different drugs”                                                                                                               
TruGenome Technical Sequence Data – “whole-genome sequencing 
data in two formats: a gVCF and a BAM” 
(http://www.illumina.com/clinical/illumina_clinical_laboratory/t
rugenome-clinical-sequencing-services.html) 
“must be ordered by a licensed 
physician” 
(http://www.illumina.com/clinical/
illumina_clinical_laboratory/how-
to-order.html) 
Informed 
Consent 
(different form 
for each test) 
GeneYouIn, 
Canada  
WES: VitaSeqTM: “With VitaSeqTM, assess your risk of cancer, heart 
disease, autoimmune or neurological diseases.” PregnaSeqTM: “With 
PregnaSeqTM, genetic testing can help you optimize your fertility 
treatment and find out if you and your partner are at risk for 
passing on preventable diseases.” (https://www.geneyouin.ca/)  
do not require HCP for ordering 
(although 30 minute phone 
consultation is required before 
ordering) 
(https://www.geneyouin.ca/how-it-
works/how-to-order/) 
Informed 
Consent,                 
Terms and 
Conditions 
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Table 4.1 continuation 
 
 
 
 
 
 
 
* HCP: health care professional 
 
Company 
name & 
country 
Description of service Model of provision of testing 
Sections of the 
websites 
studied 
Gene By 
Gene, USA    
WES/WGS - raw data or with “alignment and variant calling” 
(https://www.genebygene.com/pages/research#) or (only for 
WES) with “professional RUO [research use only] interpretation” 
(https://www.genebygene.com/pages/research?goto=whole-
exome-with-interpretation#) 
for Clinical Testing service a clinician 
orders the test 
(https://www.genebygene.com/page
s/genetics#how-to-order); not 
available for "Research and 
Consumer" services  
Terms and 
Conditions 
Inneova, 
Canada                              
WGS – “screening risk factors and sensitivity to particular 
molecules which can help a client’s physician recommend specific 
check-ups as well as optimize the administration of medications 
and diets” (http://www.inneova.com/tout.php) 
“accept test requests from licensed 
medical professionals only” 
(http://www.inneova.com/tout.php) 
Statement of 
consent,    
Disclaimer and 
privacy policy 
  
 
1
2
3
 
Table 4.2 Information about consumers’ samples and data storage, use and research activities 
Company 
name  
Information on storage and use 
Period of 
samples and 
data storage 
Information about 
research activities 
Illumina 
 
Informed consent*: "Pursuant to best practices and clinical laboratory standards, 
leftover specimen and results may be used by Illumina for purposes of quality 
control, laboratory operations, and laboratory improvement. All such uses [will be 
de-identified]**, and in compliance with applicable law." **the phrase found only 
in the informed consent for TruGenome Predisposition Screen 
not available not available 
GeneYouIn 
Informed consent*:  
“You provide your consent for research in which we analyze your genetic data and 
phenotype information in order to discover or validate associations between 
certain genetic variations and diseases. These studies will improve the accuracy of 
our predictions for you and other customers. As the number of our customers 
grows, our ability to study their combined genetic data and phenotype information 
further advances scientific and medical research, thus improving health care." 
Terms and conditions: “Your genetic data will be stored in Your Account, and you 
appoint GeneYouIn as a custodian of your genetic and health data. By accepting 
these Terms you agree that your anonymized genetic and health data can be used 
for research purposes. (…) All biological samples and DNA will be destroyed after 
90 days following obtaining the test results, however the information of your 
genetic code will be stored in Your Account, and you appoint GeneYouIn as a 
custodian of your genetic and health data. By accepting these Terms you agree 
that your anonymized genetic and health data can be used for research purposes.” 
samples - 90 
days;  
data - not 
available 
research may be 
performed on 
consumers’ data 
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Table 4.2 continuation 
 
 
 
 
 
 
 
 
 
                 
* These denote the specific documents/sections of websites where the quotes can be found. 
 
Company 
name 
Information on storage and use 
Period of 
samples and 
data storage 
Information about 
research activities 
Gene By 
Gene 
Terms and conditions*: “Any sample material sent will be used only to perform the 
specifically ordered testing. After testing is complete, remaining sample material is 
stored for 180 days, unless otherwise specified by regulatory agencies.  After 3 
months, the sample will be discarded or de-identified and retained for in-house 
laboratory use. (…) The customer specifically understands that they will not 
receive compensation for any research or commercial products that include or 
results from your sample, results, or personal record”. 
data - 30 days 
or longer; 
samples – 
unclear: at 
least 90 or 
180 days 
contradictory 
statements: research 
will not be performed 
on consumers samples 
and research may be 
performed on 
consumers’ samples 
and data (inexplicit 
statement) 
Inneova                       
Disclaimer and privacy policy*: "The DNA is used only for the purpose of 
predictive genetics testing. Once processed, each DNA sample is discarded 
following a secure protocol." 
samples - 
discarded 
after testing; 
data and 
results - not 
available 
no research on 
consumers’ DNA 
samples; no 
information about 
research on data 
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Table 4.3 Information about consumers’ data access and sharing 
Company 
name 
Information on data access and sharing 
Illumina 
Informed consent*: "Illumina keeps test results confidential. Illumina will only 
release your test results to your healthcare provider, his or her designee, other 
healthcare 
providers involved in your medical care, or to another healthcare provider as 
directed by you (or a person legally authorized to act on your behalf) in 
writing, or otherwise as required or authorized by applicable law." 
(http://www.illumina.com/content/dam/illumina-
marketing/documents/clinical/forms/form-test-req-predisposition.pdf) 
GeneYouIn 
Informed consent*: "You authorize GeneYouIn to use and share your anonymized 
genetic and clinical data with research organizations. If you decide that you do not 
want us to share your anonymized genetic and clinical data, please initial the check 
box next to this bullet point.  “(...) Please note that GeneYouIn will not disclose your 
health information without your explicit consent or a legal order. (...) Through our 
electronic tools, you can grant your physician or other trusted health care provider 
secure access to your report. If at any time you decide to withdraw your consent, you 
may request deletion of your records.” (https://www.geneyouin.ca/informed-
consent) Terms and conditions*: “Access to you biological sample and health data 
by a court-appointed order will be granted according to the Privacy laws of Canada 
and Ontario." (https://www.geneyouin.ca/terms-conditions/) 
Gene By 
Gene 
Terms and Conditions*: "Test results will be released only to the ordering clinician 
or genetic counselor. Gene By Gene, LTD will not release results to a third party 
without proper authorization in accordance with the Health Insurance Portability 
and Accountability Act (HIPSS) of 1996. (...)The customer understands that by 
providing any sample, having your sample processed, accessing results, or providing 
personal information, that the customer acquires no rights in any research or 
commercial products or services that may be developed by Gene by Gene, LTD. or 
its collaborating partners.” (...) "The customer understands that Gene By Gene, LTD. 
is not responsible for misuse, mishandling, or misrepresentation of this data by the 
customer or other third parties who have been given rightful access to the 
aforementioned data or materials." (https://www.genebygene.com/pages/terms) 
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Table 4.3 continuation 
* These denote the specific documents/sections of websites where the quotes can be found 
  
Company 
name 
Information on data access and sharing 
Inneova 
Statement of consent*: "I understand that ICL will not disclose my identity, contact 
details, or test results to third parties (except to its medical, scientific, and other 
service partners, subsidiaries and related business entities, legal advisors, agents, or 
appointees for the purpose of performing genetic testing or interpretation services, 
as well as any associated administrative transactions, as deemed necessary by ICL 
in the normal course of business under the terms of this Agreement as well as under 
its Disclaimer and Privacy Policy). I understand that ICL will be absolved of this 
responsibility to a limited extent as stated in its Disclaimer and Privacy Policy in the 
case of any legal action, court order, or legislation requiring it to do otherwise." 
(http://www.inneova.com/contenu.php?page=terms.php)  
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Table 4.4 Information on samples’ and data identifiability and confidentiality 
Company 
name 
Samples' and data identifiability and confidentiality 
Illumina 
Informed consent*: "You will need to obtain a unique code from your doctor to 
download your test results. (...) The Internet and wireless services may not be 100% 
secure. There is always a risk that you may lose the device or the security on the device 
may be breached and someone else may then gain access to your test results. (...) 
Discrimination Risks. Genetic information could potentially be used as a basis of 
discrimination. To address concerns regarding possible health insurance and 
employment discrimination, many U.S. states and the U.S. government have enacted 
laws to prohibit genetic discrimination in these circumstances. The laws may not 
protect against genetic discrimination in other circumstances such as when applying 
for life insurance or long-term  
disability insurance.” (http://www.illumina.com/content/dam/illumina-
marketing/documents/clinical/forms/form-test-req-predisposition.pdf) 
GeneYouIn 
Informed consent*: "The Genetic Information Nondiscrimination Act (known as 
GINA) was signed into law in May 2008 in the United Sates. This legislation offers 
federal protection against discrimination based on an individual’s genetic information 
in health insurance and employment settings. While there are different laws in place 
across the globe that prevent companies from discriminating against people based on 
race, age, handicaps, and genetic predispositions such laws are not yet fully 
implemented in Canada." (https://www.geneyouin.ca/informed-consent)  
Terms and Conditions*: "We are not responsible for maintaining security and 
confidentiality of copies of Your Reports stored outside of GeneYouIn’s databases. We 
are not and cannot be responsible for any personally identifiable information about 
you that you release on your own, or that you request or authorize us to release. (...) 
We employ commercially validated and reasonable computational and organizational 
safeguards against unauthorized disclosure or access to your genetic data or other 
personally identifiable information about you according to our Privacy & Security 
Policy. You acknowledge that security safeguards, by their nature, are capable of 
circumvention and GeneYouIn does not guarantee that your personal identifiable 
information will not be accessed by unauthorized persons capable of overcoming such 
safeguards. In particular, our site may be used to access and transfer information, 
including personally identifiable information about you over the Internet. You 
acknowledge and agree that GeneYouIn does not operate or control the Internet and 
that unauthorized users may use malitious software (viruses, worms, trojan horses, 
and other software) to obtain access to personally identifiable information about you. 
GeneYouIn will not be liable to you for any damages in connection with unauthorized 
dissemination of your personal information in accordance with this paragraph.” 
(https://www.geneyouin.ca/terms-conditions/) 
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Table 4.4 continuation 
* These denote the specific documents/sections of websites where the quotes can be found 
  
Company 
name 
Samples' and data identifiability and confidentiality 
Gene By 
Gene 
Terms and conditions*: “However, Gene By Gene, LTD implements administrative, 
physical and technical safeguards to secure our client’s protected health information 
as defined by HIPAA. (...) Gene By Gene, LTD. will handle all sample specimens in 
compliance with all applicable laws and regulations. All data received from the 
customer and data generated will be created, stored, and transferred according to 
HIPAA guidelines. The customer understands that Gene By Gene, LTD. is not 
responsible for misuse, mishandling, or misrepresentation of this data by the customer 
or other third parties who have been given rightful access to the aforementioned data 
or materials.” (https://www.genebygene.com/pages/terms)  
Inneova 
Disclaimer and privacy policy*: "ICL uses a specific tracking system to identify your 
sample as soon as it enters our facilities. Molecular biologists in charge of your sample 
do not know who the actual sample belongs to, but only see each sample as a number. 
This tracking number is associated with your name and contact information only 
within our secure database, which is not accessible by the lab or anyone outside of our 
company."  
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Table 4.5 Information on the proprietary claims found on the studied pages of the companies’ 
websites 
Company 
name 
Proprietary claims 
Illumina not available 
GeneYouIn 
Informed consent*: “You understand that you will not receive any compensation 
as a result of having your DNA analyzed, Your Genetic Data, or your Phenotype 
Information analyzed, or from any other research performed using your Genetic 
Data or your Phenotype Information.” (https://www.geneyouin.ca/informed-
consent) Terms and conditions: “(…) you appoint GeneYouIn as a custodian of 
your genetic and health data.” (https://www.geneyouin.ca/terms-conditions/) 
Gene By 
Gene 
Terms and conditions*: “The customer understands that by providing any 
sample, having your sample processed, accessing results, or providing personal 
information, that the customer acquires no rights in any research or commercial 
products or services that may be developed by Gene by Gene, LTD. or its 
collaborating partners. The customer specifically understands that they will not 
receive compensation for any research or commercial products that include or 
results from your sample, results, or personal record.” 
(https://www.genebygene.com/pages/terms) 
Inneova not available 
* These denote the specific documents/sections of websites where the quotes can be found. 
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Abstract 
Whole exome and whole genome sequencing (WES, WGS) can generate an unprecedented 
amount of complex information, making the informed consent (IC) process challenging. The 
aim of our study was to assess the readability of English IC forms for clinical whole- exome 
and genome sequencing using the SMOG and Flesch-Kincaid formulas. We analysed 36 forms, 
most of which were from US providers. The median readability grade levels were 14.75 (the 
SMOG formula), and 12.2 (the Flesch-Kincaid formula); these values indicate the years of 
education after which a person would be able to understand a text studied. All forms studied 
seem to fail to meet the average recommended readability grade level of 8 (e.g. by Institutional 
Review Boards of US medical schools) for IC forms, indicating that the content of the forms 
may not be comprehensible to many patients. The sections aimed at health care professionals 
in the forms indicate that HCPs should be responsible for explaining IC information to the 
patients. However, WES and WGS may be increasingly offered by primary care professionals 
who may not (yet) have sufficient training to be able to communicate effectively with patients 
about genomics. Therefore, to secure an adequate, truly informed consent process, the task of 
developing good, legible examples of IC forms along with educating HCPs in genomics should 
be taken seriously, and adequate resources should be allocated to enable these tasks. 
Keywords: informed consent, readability, whole genome sequencing, whole exome 
sequencing, genetic counselling 
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5.1 Introduction 
5.1.1 The challenge of informed consent  
Informed consent (IC) was introduced into research practice as an instrument enabling choice 
about participation in a study, with the aims to prevent coercion and respect autonomy of 
research participants, mostly in response to research malpractices that occurred in the last 
century [1]. The Declaration of Helsinki written in 1964 and amended in subsequent years set 
the standards for more explicit, documented, and specific (i.e. containing a defined set of 
elements) informed consent in research [2]. These requirements were gradually implemented 
both in research and in the clinical context, becoming an integral part of routine research and 
medical care, as well as a legal requirement in many national legislations [1]. However, the 
process of adopting the requirements for informed consent in different contexts has not all been 
smooth sailing. As a consequence of the growing complexity of medical procedures and 
knowledge about the associated risks and implications, informed consent documents have often 
become lengthy and difficult to understand [3]. Reaching the standards of explicit, specific, and 
simultaneously truly informed consent may be often very difficult to achieve - a topic which 
has been widely debated in academic literature [3]. Many studies have reported low levels of 
readability and/or understandability of informed consent forms in the USA, which is 
particularly worrisome given the prevalence of low levels of (health) literacy in the population 
[4,5]. Furthermore, the importance of providing legible informed consent documents has been 
supported by medical and research malpractice law cases [6]. Importantly, recognition of the 
relevance of patients’ perspectives and needs, as well as the provision of adequate information 
by a physician, has given rise to concepts and practices such as shared decision making 
(i.e. between physician and patient), patient-centered care, and reasonable-patient informed 
consent standards, which have been implemented in the US and UK healthcare systems [7,8]. 
While these approaches stress the role of communication processes between a physician and 
patient, they do not diminish the importance of providing written documents, which should 
facilitate the discussion, and can be taken home by a patient in order to be considered and 
reflected upon at the patient’s own pace [7]. Therefore, adequate readability and 
comprehensibility of informed consent forms remain vital elements of the informed consent 
process. 
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5.1.2 Informed consent in genetics and genomics 
Genetics is a relatively advanced subset of biology, and the task of successfully communicating 
genetic concepts to a public unfamiliar with the subject can be challenging [9]. Explaining 
issues related to genomics, including the use of next generation sequencing in order to perform 
whole exome and whole genome sequencing (WES, WGS), adds to this complexity. These 
approaches generate an unprecedented amount of information, potentially about thousands of 
phenotypes, including diseases that may also hold relevance for family members of probands. 
In addition, the interpretation of these findings may change with time [10]. Whole genome and 
exome sequencing are being increasingly used in research, clinical and direct-to-consumer 
settings and their use is predicted to expand [11]. A number of recommendations for informed 
consent for WGS have been issued to address this challenge. These documents outline and 
discuss the elements that should be included in the informed consent process and emphasize 
the crucial role of pre-test counselling [12–15].  
A few studies analysed the content of IC forms for WGS and/or WES and discussed the 
presence (or absence) of a list of core elements [16–19]. Two of these studies also report on 
readability of IC forms [16,19]. Henderson and co-authors analysed nine informed consent 
forms for WES and WGS studies funded by the US National Human Genome Research Institute 
(NHGRI) and National Cancer Institute (NCI). Readability was evaluated by the Flesch-
Kincaid formula giving a median of 10.8 grade level, which indicates that after 10.8 years of 
education, an average student would understand most of the text present in the forms [16]. Jamal 
et al. (2013) analysed six informed consent forms provided by US based laboratories offering 
clinical exome sequencing. The median readability score (Flesch Reading Ease) among 
documents was 40 (corresponding to high school to some college grade level) [19–21]. Both of 
these studies indicate that the readability grade level is above the average recommended grade 
level of 8 for IC forms as stated by Institutional Review Boards of US medical schools [22]. 
These results suggest that even if the forms include the required elements of information, they 
may not be comprehensible to many patients since almost half of Americans read at or below 
grade level of 8 [22]. 
Given the particular challenges of communicating information about WGS and WES, their 
increasing use in health care and the importance of providing the information in a readable 
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manner, we aimed to provide additional insights into the readability level of a larger sample of 
informed consent forms for WGS and WES in the clinical context using two readability tests.  
5.2 Methods 
5.2.1 Search and inclusion criteria for IC forms 
The authors searched for informed consent forms using Google search engine 
(www.google.com) applying 12 combinations of terms from the following groups: (“informed 
consent”, “consent document”, “consent form”) and (“whole genome sequencing”, “whole 
exome sequencing”, “next generation sequencing”, “genome wide sequencing”). The search 
was performed between March and April 2016. Two pairs of authors independently conducted 
the search using the above search terms combinations. One hundred links retrieved in each 
search-term-combination were accessed and reviewed. Documents meeting the criteria of 
consent forms for clinical WGS/WES in English were included in this study. Consent forms 
developed primarily for research projects and forms that did not have a space for the patient’s 
signature were excluded. Additional consent forms that were not retrieved in the search, but 
that were known by the authors from other sources, were also included. The final collection of 
forms was read and studied for a number of different aspects, including information on return 
of results, use of samples and data in research, as well as readability. Herein we present only 
the results of the readability study. 
5.2.2 Characteristics of the forms 
The following information about the IC forms was extracted from the forms and/or websites of 
WGS/WES providers: name of provider, country of origin, type of provider (type 1: 
universities/hospitals/medical centres and their “in-house” and/or owned laboratories; type 2: 
laboratories/companies not related to a university/hospital/medical centre), for what type of test 
a form is used (WES/WGS), and who can be tested (child, adult). This information was obtained 
independently by two authors and discrepancies were resolved in discussion. 
 135 
 
5.2.3 Readability 
Preparation for analysis 
The forms were prepared for the readability analysis by directly converting files from 
an original portable document format (pdf) to a docx file format or by copying and pasting 
information from the original document into a Word docx file. Final versions of converted or 
copied files were verified for accuracy with the original file and any discrepancies were 
corrected. Additional sections included in the original files with the informed consent forms 
were excluded for this analysis (e.g. requisition forms, tables for patient information, sample 
information, address, payment options, clinical information, physician’s statements, text 
explicitly aimed at physicians). Sections of forms addressed to family members submitting 
a sample for validation of patient’s results were included. Headings were also included and each 
was treated as a complete sentence, even when there was no period in the end. The following 
phrases and words not constituting the main part of the informed consent form text were 
removed so that the program would not treat them as full sentences and consequently conflate 
the resulting readability scores: address and contact information of a provider; indications of 
fields for signatures, initials, names, addresses and dates of birth; dates of updating/creating 
forms; pages numbers.  Website addresses found anywhere in the text were also removed. 
Numerals were fully syllabized (i.e., sounded out) in the tests used. 
Readability measures 
A number of different readability tests have been developed for evaluating reading grade levels. 
These are based on evaluating parameters, such as word and sentence length, and the number 
of syllables in words. The reported grade level indicates the number of years of education that 
a person must have completed to understand the text assessed. In this study, two tests were used 
to assess the readability: the SMOG formula developed by McLaughlin (1969) and the Flesch-
Kincaid formula [23,24]. Basic characteristic of the formulas is shown in Table 5.1. The Flesch-
Kincaid formula is the most commonly used for analysis in recent health care literature (years 
2005-2008), which is likely to be the result of the embedding of this formula in Microsoft Word 
software [21]. However, the Flesch-Kincaid formula is expected to predict only about 75% of 
comprehension (when validated on multiple choice test), meaning that a person who completed 
the grade level obtained in the test will be able to comprehend 75% of the text [24,25]. 
Distinctively, the SMOG formula was developed to predict 100% comprehension (validated 
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using McCall-Crabbs Standard Test Lessons in Reading) [23]. For this reason, the SMOG 
appears to be a more adequate test to evaluate informed consent forms for which 100% 
comprehension is expected [21]. Hence, we used the SMOG test as the main evaluative 
calculation, although we also employed the Flesch-Kincaid formula to obtain results 
comparable to other studies using this test. Calculation of readability for the two groups of IC 
forms (type 1 and type 2, Table 5.3) were conducted using SMOG test. The results obtained for 
these two groups were compared using Mann-Whitney statistical test.  
Both tests were performed using the software Readability Studio Professional Edition for 
Windows, version 2015 (Oleander Software Ltd, Vandalia, Ohio). The calculations were based 
on the whole text (and not subsamples of the text) and standardized if needed. Additionally, we 
calculated the word count of informed consent documents as a rough indicator of the time 
required to read the text. 
5.2.4 Information about the informed consent process 
In order to have some insight into the informed consent process we also report on the presence 
of statements mentioning pre-test counselling as well the sections of the forms aimed directly 
at health care professionals (HCPs). 
5.3 Results 
5.3.1 Characteristics of forms 
We identified 36 informed consent forms for clinical WGS/WES in English: 32 forms were 
retrieved through the Google search; 4 forms were identified from WES/WGS providers with 
which the authors were familiar. The majority of forms come from various types of providers 
in the USA, are used for WES, and are targeted at both adult and children patients. The complete 
list of form characteristics is outlined in Table 5.2. 
5.3.2 Readability results 
Figures 1 and 2 illustrate the results of the SMOG and the Flesch-Kincaid formulas. The range 
of grade level scores for the SMOG formula was 12.7-18.4, with a mean grade level of 14.8 and 
median of 14.75. For Flesch-Kincaid, the range was 10.3-16.4; mean 12.5 and median of 12.2. 
The word count ranged between 204 and 3017 words; with a mean of 1679 words and median 
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of 1489. Figure 3 and Table 5.3 include the values for the SMOG formula and word count 
obtained in two groups of IC forms: universities/hospitals/medical centres and their “in-house” 
and/or owned laboratories (type 1) and laboratories/companies not associated with 
a university/hospital/medical centre (type 2). No significant differences were found between 
the two groups with respect to word count or readability grade levels. 
5.3.3 Information about informed consent process 
Thirty-two of the forms mentioned some form of pre-test genetic counselling outlining, for 
example, that patients should consider, seek and/or obtain pre-test genetic counselling, or that 
pre-test genetic counselling is recommended/required. Twenty-one forms included text aimed 
at a HCP stating that a HCP has provided/discussed relevant IC information and/or 
offered/ensured providing of pre-test counselling.  
5.4 Discussion 
5.4.1 Very low readability of IC forms 
All of the 36 forms studied have a higher reading grade level than that recommended (by 
US medical school Institutional Review Boards) for IC forms, which is, on average, a grade 8 
level [22].  The values obtained in the SMOG calculation are higher than those from the Flesch-
Kincaid.  This result is expected as the SMOG formula aims to predict 100% comprehension, 
while the Flesch-Kincaid formula would predict only about 75% comprehension (when 
validated using multiple choice test)  [23,24]. Our results correspond with the relatively high 
reading grade levels of informed consent forms obtained by Jamal et al. (2013) and Henderson 
et al. (2014) (which indicated the median grade level of high school to some college in the 
Flesch Reading Ease formula; and median of 10.8 grade level with the Flesch-Kincaid formula, 
respectively) [16,19]. The word count of the IC forms we studied ranged from 204 to 3017 
words; with a mean of 1679 words and median of 1489, suggesting that a person would need, 
at least, between 1-15 minute to read the informed consent form content aimed at patients 
(assuming the pace of reading of 200 words per minute) [26]. However, given the fact that the 
readability of the texts studied is low, an average patient would probably need much more time 
to assimilate the content of an IC form. These findings are in line with those of Jamal et al. 
(2013), which indicate the median word count among the six studied IC forms for WES is 1154 
and the range is 724 to 3429 words [19]. Both the results herein and Jamal et al.’s word count 
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results are lower than the values obtained by Henderson et al. (2014) in a study of 9 IC forms 
for WES/WGS (mean = 4588 words, range 2917-5757 words) [16,19]. This difference may be 
related to the fact that Henderson et al. (2014) analysed consent forms used in a research 
context, and these may have contained additional information such as about the study design 
(Henderson et al. 2014). 
The results indicating low readability of IC forms are not surprising, particularly when 
comparing them to studies of IC forms in the context of other medical procedures [4]. However, 
it is interesting that none of the forms in this study, or other previous studies investigating IC 
for WGS reaches the average recommended readability level of 8th grade [16,19]. This 
indicates that IC forms may fail to fulfil their intended function of providing understandable 
information to patients and facilitating communication. The high scores obtained in the SMOG 
and Flesch-Kincaid formulas indicate that the documents studied use many complex, long 
words, which are often technical and therefore difficult to understand to an average reader. 
Indeed, some sections of IC form text were difficult to understand even for the authors; one 
could imagine that it would be even more complicated for a person not familiar with vocabulary 
used in genetics, for instance:  
‘Diagnostic findings not related to phenotype in childhood onset conditions - a single 
pathogenic or likely pathogenic variant in genes that are known to cause autosomal 
dominant or X-linked childhood onset conditions, as well as two pathogenic or likely 
pathogenic variants in genes that are known to cause autosomal recessive childhood 
onset conditions, even if they are unrelated to the patient's phenotype, will be reported.’ 
(IC form number 18. The length of this sentence is 64 words; the score in the SMOG 
formula is 19).  
This lack of adequate provision of information in IC forms appears particularly worrisome 
given that some of the companies offering WES/WGS included in this study also advertise the 
tests directly-to-consumers. In the direct-to-consumer advertising context, consumers may be 
provided with encouraging information about the benefits of the testing on the companies’ 
websites, and unless explained in the IC process, they may not be aware of all the limitations 
and risks of the testing [27]. The need for legible IC forms seems to be even more relevant when 
WGS and WES is offered to minors; if possible consent or assent should be obtained from 
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children when testing is offered [28]. Therefore, clear and informative content of IC forms can 
be very valuable in this context. 
Since we hypothesized that the potentially greater presence and involvement of HCPs in 
designing IC forms might result in increased readability of the forms, we assigned the IC forms 
to two different groups, assuming that the involvement of HCPs is higher in the first group: 
group 1 - university/hospital/medical centres and their “in-house” and/or owned laboratories; 
group 2 - companies/laboratories not associated with a medical center/hospital/university. 
Readability and word count was compared among these groups (Table 5.3 and Figure 3). No 
statistically significant differences were found between these two IC forms types with regard 
to readability scores and word count. These results suggest that involvement of healthcare 
professionals/genetic counsellors with experience in communication may be similar in these 
two groups. Indeed, the recent data indicate that an increasing number of genetic counsellors 
work in diagnostic laboratories [29]. The process of designing informed consent forms, 
including the involvement and roles of various experts, may be worth investigating further.   
5.4.2 Role of a HCP in the informed consent process 
The requirement or suggestion to undergo pre-test counselling present in many forms studied, 
as well as the sections of text stating that a HCP has provided relevant information to the patient 
(which often should be signed by a HCP) seem to place an obligation on HCPs and genetic 
counsellors. These statements imply that the physician is responsible for ensuring that the 
patient is adequately informed and understands the information provided, even if the consent 
form is not easy to comprehend. Consequently, given the low readability of the forms and the 
stated obligation of a HCP to explain the relevant information, IC forms in this context may 
take a role of a “checklist” for a HCP indicating which elements (s)he should explain to 
a patient, rather than being a sole explanatory material for a patient. Indeed, a study by 
Bernhardt et al. (2015) showed that during pre-test counselling sessions for genomic 
sequencing, genetic counsellors and research coordinators modified and adjusted (depending 
on the context) the information provided to the patients from that presented in the IC forms 
[30]. Moreover, the study reported that genetic counsellors and research coordinators 
“recognized that most patients and participants cannot attend to, let alone understand, all of 
the information contained in the consent documents.” [30]. Undoubtedly, the HCP’s role (and 
often obligation) to communicate and provide information is vital for the IC process, not only 
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for genomic testing, but in the context of all clinical procedures or tests requiring informed 
consent. However, considering the predictions that genomics is likely to become part of 
mainstream practice in medicine, WGS and WES may be increasingly offered by primary care 
professionals who may not yet have sufficient training or experience to be able to communicate 
effectively with patients about genomics [31]. In such cases, primary care professionals may be 
more dependent on IC forms as a communication tool to explain WGS/WES to patients. 
Consequently, in these circumstances, the explanatory and educational role of informed consent 
forms should not be underestimated.  
The appropriate means of communicating about genomics in IC forms (e.g. usage of 
understandable vocabulary, length of document etc.) need to be explored, implemented, 
monitored and revised as needed. To obtain more comprehensive evaluation of the functionality 
of informed consent forms additional methods such as Suitability Assessment of Materials 
could be applied [32]. Furthermore, insights from health professionals who have experience in 
obtaining informed consent for genomic testing could help improve the quality of informed 
consent forms. For example, the issues indicated by genetic counsellors as most important for 
patients and most likely to be misunderstood could gain more attention when designing 
informed consent forms. In addition, reducing the length of other sections of IC forms such as 
descriptions of technical aspects of sequencing, might potentially increase the readability of the 
forms [30]. Furthermore, investigating patients’ needs and understanding when communicating 
about genomics could be another important element in the effort to design adequate informed 
consent information [33]. 
5.5 Limitations 
The limitations of this study include, firstly, that the consent forms were collected at one given 
point of time, in one language (English) using a specific strategy aimed at finding documents 
available online. We acknowledge that we may have missed some documents that are currently 
in use but not publicly available online, and that the studied forms we found may no longer be 
in use. The study of additional forms in other languages than English could also be of value. 
Secondly, there are limitations inherent to the readability formulas used. For example, not all 
the (potentially) difficult words have more than two syllables (for instance “genome”). 
Furthermore, the readability formulas do not evaluate all the elements influencing readability, 
for example, graphic design, font type and size, and document layout. Finally, readability and 
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comprehension are distinctive measures. However, the SMOG and Flesch-Kincaid formulas 
were validated in tests aiming at evaluating comprehensibility, it has been questioned whether 
some of them accurately reflect comprehension [21]. Therefore, the readability results only 
provide an estimation of comprehensibility of informed consent forms. In order to evaluate 
factual understanding of the documents, a study surveying patients should be conducted. 
5.6 Conclusions 
Based on the 36 IC forms identified, our results suggest that the IC forms for use in WES/WGS 
in the clinic may not adequately fulfil their function of explaining relevant information to 
patients. This function seems to be transferred to some extent to genetic counsellors and/or 
health care professionals, which may be problematic if a HCP does not have sufficient training 
in genomics to be able to explain the information to patients. Therefore, moving forward, along 
with educating HCPs in genomics, it will be essential for good examples of informed consent 
forms to be developed that will communicate relevant information effectively and facilitate the 
process of informed consent. Engaging expert groups including clinical geneticists, genetic 
counsellors, communication professionals, and patients may facilitate this task. In order to 
ensure responsible implementation of genomic technologies securing an adequate, truly 
informed consent process should be taken seriously and adequate resources should be allocated 
to enable fulfilling this task. 
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Tables (Chapter 5) 
Table 5.1 Information regarding the readability formulas used to analyse consent forms 
 Flesch – Kincaid formula SMOGa formula 
Original development 
and reference 
The formula has been 
designed for evaluating 
readability of technical 
texts for US military by 
Kincaid  [24] 
McLaughlin  [23] 
Analysis based on  
sentence length and syllable 
count 
Number of complex words 
(3 or more syllables) 
Easier formula for 
manual calculation (not 
used in this study) 
G=(12*(B/W)) + 
(0.4*(W/S)) – 16 
G - grade level 
W – number of words 
B – number of syllables 
S – number of sentences 
G = FLOOR(√C) + 3 
Where:  
G - grade level 
C - number of complex 
words (3+ syllables) 
FLOOR - round the result 
of (√C) down to the closest 
perfect square.  
Higher precision 
formula used by the 
software in this study 
G = (11.8*(B/W)) + 
(0.39*(W/S)) – 15.59 
G = 1.0430*√C + 3.1291   
a Originally, McLaughlin recommended using 10 consecutive sentences from the beginning of 
the text, 10 sentences from the middle and 10 from the end; the formula was meant to 
facilitate manual calculations. In our study, the calculations were based on the whole text (and 
not subsamples of the text) and standardized. 
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Table 5.2 Information about IC forms: the country of origin, provider, type of test, groups to 
which it is offered. 
Characteristics Number of forms 
Total number of forms 36 
Country of origin  
USA 29 
Germany 2 
The Netherlands 2 
Australia 1 
Canada and Germany 1 
Finland 1 
Provider  
Type 1: university/hospital/medical centre and their “in-house” 
and/or own laboratories 
18 
Type 2: company/laboratory not related to a 
university/hospital/medical centre 
18 
Type of test  
WGS 5 
WES 24 
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Table 5.2 continuation 
WGS and WES 4 
WGS, WES and another genetic test 3 
Target group  
Only adults 3 
Only children 1 
Adults and children 30 
Not specified 2 
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Table 5.3 Grade levels obtained for two categories of IC forms. The Mann-Whitney test was 
used for comparison of results between these two groups of test providers.
 
 
  
 
 
type 1: 
universities/hospitals/medical 
centres and their “in-house” 
and/or owned laboratories 
type 2:  
laboratories/companies not 
associated with a 
university/hospital/medical 
centre 
p-value 
and 
Z-score 
Grade level 
SMOG 
Range: 12.9 - 17; 
Median: 14.5 
Range: 12.7 – 18.4 
Median: 15.4 
Z=1.61 
p=0.1 
Word count 
Range: 204 - 3017; 
median 1405 
Range: 544 - 2785; 
median 1541 
Z=0.17 
p=0.85 
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Figures (Chapter 5) 
Figure 1 Results of the SMOG calculation for all the forms studied. The indicated ranges include the 
scores that are equal to or greater than the lowest bound and less than the largest bound for the range. 
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Figure 2 Results of the Flesch-Kincaid calculation for all the forms studied. The indicated 
ranges include the scores that are equal or greater than the lowest bound and less than the 
largest bound for the range.
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Figure 3 Comparison of readability between groups of IC forms using the SMOG formula. 
Type 1: universities/hospitals/medical centres and their “in-house” and/or owned laboratories; 
type 2: laboratories/companies not associated with a university/hospital/medical centre. The 
indicated ranges include the scores that are equal or greater than the lowest bound and less 
than the largest bound for the range. 
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Conclusions and indications for future research 
Revealed concerns regarding informed consent for WES and WGS 
Involvement of a HCP in the provision of WGS/WES offered directly-to-consumers 
The work conducted for this doctoral degree presents the first empirical studies of the offer of 
whole genome and whole exome sequencing (WGS and WES) in the direct-to-consumer 
context (Chapter 3 and 4). The analyses provide insights into informed consent process for 
WGS and WES offered directly-to-consumers revealing a few concerns. Firstly, the lack or 
limited involvement of a healthcare professional (HCP) in the provision of testing, including 
potential absence of pre-test counselling. However, all but one tests (for which informed 
consent was studied) had to be ordered by a physician, this does not guarantee that adequate 
counselling takes place, given the concerns about the expertise in genetics of general 
practitioners. Pre-test counselling is a crucial element for an adequate informed consent process 
for genetic testing, in which individual’s questions may be answered and a qualified HCP may 
ensure that the patient truly understands the information provided and is competent to consent 
to testing [1]. Recently, Middleton et al. argued that DTC GT companies should make adequate 
genetic counselling available to their consumers to avoid misinterpretation of genetic test results 
and unnecessary follow-up care [2].   
Another issue related to the involvement of a HCP in the context of DTC genetic testing 
concerns the obligations of a HCP when a consumer contacts her or him with a request to order 
a genetic test. After undergoing direct-to-consumer genetic testing, a consumer concerned with 
the results of testing may contact a health-care professional within a public health care system 
requesting for a follow-up care. Given the doubtful clinical validity of some of direct-to-
consumer genetic tests (as discussed in Chapter 2), should a healthcare professional take 
medical decision on basis of such test results? Indeed, this kind of follow-up care might be 
futile and be burdensome for the already scarce resources of public healthcare system. On the 
other hand, a scenario could be considered where a consumer took a genetic testing meeting 
high standards of clinical and analytical validity and received results indicating need for further 
medical interventions. Considering these two scenarios, the diversity of genetic tests offered 
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directly-to-consumers as well as their growing popularity, a help in a form of guidelines from 
professional societies concerning the issues mentioned above for healthcare professionals 
would be desirable.   
The process of IC in DTC WES/WGS companies 
Some of the companies studied did not seem to provide adequate informed consent documents 
for genetic testing and for research activities on consumers’ samples and data. In some instances 
(company Gene By Gene), an individual could agree to undergoing WGS and/or participating 
in research activities, just by placing an order and accepting a ‘clickwrap’ contract by clicking 
an ‘I agree’ box (Chapter 3 and 4). Although these practices are common in the e-commerce 
environment, the fact that the companies offered health-related testing may make them a subject 
to ethical principles pertinent to medical care [3]. From the standpoint of medical and research 
ethics, replacing the process of informed consent (which normally consists of dialogue with a 
HCP as well as a written document) with ‘clickwrap’ agreement seems to be unacceptable.  
One may argue that additional informed consent documents may be provided to the consumer 
at another stage of provision of the testing, for example, with the saliva kit sent to the consumer; 
the presence of such documents was not investigated in this thesis. However, arguably the 
consumers take a decision to purchase the tests on the basis of the information available before 
placing an order and paying for the testing; therefore, the provision of information (studied 
herein) prior to purchasing the testing is crucial for decision making to undergo the testing. 
Potential presence of additional documents sent to consumers with saliva kit after purchasing 
the test could be relevant and could result in resigning from undergoing the testing. Such a 
practice of obscuring information until after purchase, however, could appear as unfair to 
consumers and precluding from taking informed choice before buying a test. The process of the 
provision information at different stages of purchasing DTC GT (including the role of a HCP, 
if one is involved), as well as validity of the agreements require further investigation. 
Remarkably, the alleged lack of adequate informed consent for sharing consumer’s genetic data 
became a subject of an ongoing lawsuit against one of the companies studied herein, Gene By 
Gene, although in the context of its different service (Cole vs. Gene by Gene LTD, 
https://www.genomicslawreport.com/index.php/2017/07/18/a-constitutional-challenge-to-
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alaskas-genetic-privacy-statute/). The plaintiff alleged that the company had disclosed his data 
without his consent and asserted injury on the basis of Alaska’s Genetic Privacy Act, which 
requires informed and written consent to sharing and disclosure of one’s genetic data. The 
outcome of this ongoing case may have important implications to consumer genomics industry, 
in particular to the practices of provision of information by the DTC companies and modes of 
obtaining informed consent. 
Content of the informed consent documents 
Not only did the manner of obtaining informed consent in the studied companies appeared to 
be inadequate, but the content of these documents itself raised concerns. These related mainly 
to the lack of relevant information and/or presence of potentially misleading descriptions of the 
testing and secondary uses of consumers samples and health-related data. Consequently, 
consumers might not be aware of all the implications of undertaking WGS/WES, including the 
potential benefits and risks, or the usage of their samples and/or health-related data for research 
purposes. Therefore, consumers’ acceptance or the given consent might not be truly informed. 
Additionally, the lack of transparency in provision of information about the usage of 
consumers’ data for research could undermine trust in research practices in general, including 
publicly funded research [4] (Chapter 4).  
Readability of informed consent forms for whole genome sequencing 
One of the observations made when examining companies’ websites was that the language used 
was quite complex, in some instances, to the extent that it could be questioned whether the 
language could be a barrier to understanding rather than an aid. Building on this finding, the 
aim of the follow-up study was to investigate the ease of understanding of consent forms for 
WGS and WES (Chapter 5). The study on readability of informed consent forms for clinical 
WES and WGS (some of which come from companies advertising directly-to-consumers) 
showed that none of the forms studied complied with the recommended reading grade level for 
informed consent forms (that is grade level 8, recommended by Institutional Review Boards of 
U.S. medical schools). This indicates that the forms probably would not be comprehensible for 
many, if not most patients. According to the statements present in the studied informed consent 
forms, the responsibility of explaining the relevant informed consent information to the patients 
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is placed on a HCP (even if the consent form is not easy to comprehend). This may be 
problematic if a HCP does not have sufficient training in genomics to be able to explain the 
information to patients. Therefore, along with developing good examples of informed consent 
forms facilitating the process of informed consent, the adequate training and education 
resources for HCPs (such as GEN-EQUIP, https://www.primarycaregenetics.org) should be 
developed, especially given the predictions that WGS/WES will become part of mainstream 
medical practice [5]. Not only should the achievements of genomics be translated into medical 
practice, but also its language, as a prerequisite for effective and respectful communication 
between healthcare professionals and patients [6]. 
Limitations and the importance of the presented empirical studies 
The studies discussed herein have some limitations. The study of DTC GT companies is limited 
to specific sections of companies’ websites; additional informational materials may be provided 
to consumers by the companies, for example, in the sections of websites not investigated herein, 
which require further examination. Similarly, the analysis of readability of informed consent is 
focused solely on informed consent forms in English available online, excluding those in other 
languages and not available via the Internet. Furthermore, the readability formulas employed 
provide indication, and not exact measure of comprehensibility of the content of consent forms. 
Other approaches, such as contacting the healthcare providers and companies to obtain 
additional information, interviews or surveys of the consumers/patients, healthcare 
professionals, and companies’ representatives, could provide more insights into the current 
offer of WGS. 
Summing up, all the three empirical studies (Chapter 3,4, and 5) reveal concerns regarding 
informed consent for WGS and WES and the use of consumers’ data. The presence of these 
issues in the context of genomic approaches that generate huge amounts of sensitive data is 
particularly worrisome. In order to respect patients/consumers, the compliance with ethical 
standards when offering genetic testing should be strived for, also in the commercial DTC offer 
of WES and WGS. The studies presented herein indicate specific areas in which practices 
should be improved, therefore providing reference and guidance for well-informed and 
potentially policy-relevant discussions between various stakeholders. 
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Changes in the European legislation regarding genetic testing 
Informed consent for genetic testing and pre-test counselling was a subject of heated debate 
during the preparatory stages of the recently adopted Regulation (EU) 2017/746 of the 
European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices, 
which will apply in European Union member states after 5 years transition period.  In the 
preparatory phases, different suggestions were made regarding these aspects, from requiring 
mandatory pre- and post-test genetic counselling for predictive, prenatal and diagnostic genetic 
tests, as well as written informed consent, to the opinions that such provisions would infringe 
the principles of proportionality and subsidiarity and could be difficult to implement in daily 
medical practice [7]. Finally, in its adopted version, the Regulation underlines the importance 
of informed consent for genetic testing and pre-test counselling, however, it provides limited 
and rather general requirements in this regard, as discussed in Chapter 2. Furthermore, these 
provisions are addressed to Member States, therefore their impact will probably be limited to 
the clinical context, having little value for genetic testing sold directly-to-consumers.  
However, importantly, the Regulation sets higher standards for clinical evidence required for 
genetic tests entering European market. The raised bar for requirements of clinical evidence 
included in the Regulation may limit the offer of susceptibility genetic testing for complex 
disorders which have limited clinical validity. Furthermore, the Regulation prohibits misleading 
advertising, and clarifies that companies established outside the European Union should still 
comply with the relevant EU rules when offering their products to consumers residing within 
the EU. Given the ethical concerns related to the offer of DTC genetic testing, not only 
regarding informed consent, but also questionable clinical validity of some tests and misleading 
advertising as discussed in Chapter 2, it seems that the recently adopted IVD Regulation may 
bring some desirable changes to the European DTC GT market. It should be kept in mind, 
however, that compliance of companies based outside of the European Union sending their tests 
to private individuals in the EU may be hard to enforce. The real value of the IVD Regulation 
for DTC GT will, therefore, be largely dependent on its enforcement.  
Given that DTC offer of genetic testing involves processing of sensitive health-related data and 
that DTC GT companies are mostly based on e-commerce business model, other laws in the 
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European context can also be relevant to DTC GT offers. For example, laws concerning unfair 
commercial practices and the General Data Protection Regulation, which will apply in the EU 
in May 2018 setting standards, for example, for informed consent for the use of health-related 
data [8]. The relevance and impact of other laws, such as national laws, on DTC GT require 
further investigation and discussion.  
Interestingly, while the legislation pertaining to DTC GT in Europe seems to limit the 
circulation of DTC GT in Europe, on the other side of the Atlantic, the climate for DTC genetics 
seems to be favourable. In April 2017, the U.S. Food and Drug Administration completed pre-
market review and allowed for marketing of 23andMe direct-to-consumer genetic test - 
Personal Genome Service Genetic Health Risk which provides information about 
predispositions for 10 diseases and conditions [9]. This decision of the FDA seems to be 
surprising, as some of the genetic variants approved for the offer are not advised in clinical 
context by professional recommendations (Chapter 2). The actions of the regulatory authorities 
and law makers, both in Europe and in the USA, should continuously be subject to scrutiny and 
discussions. In particular, it may be interesting to investigate the process of evaluating 
requirements for clinical evidence for the tests allowed for market. Furthermore, decisions and 
recommendations related to the offer of genetic testing could be investigated from the point of 
view of conflict of interest, not only in the context of the activities of regulatory bodies, but 
also advisory committees, and professional societies issuing guidelines in the area of genetics 
and genomics. The aspect of conflict of interest has already brought some attention in the 
literature, in the context of some of the practices of the FDA as well as the National Academies 
of Sciences, Medicine and Engineering [10,11].  
Emerging problems and research issues within ELSI of genomics 
The market of direct-to-consumer genetic testing is dynamically evolving posing novel ethical 
challenges, as discussed in Chapter 2. Next to the well-known and still relevant issues of clinical 
validity of the testing, inadequate informed consent, and potentially misleading advertising, 
new ethical concerns emerged, such as, “monetization” of genetic data and DTC GT targeted 
to (prospective) parents. Given these developments, the empirical studies monitoring the 
current offers and practices of DTC GT companies and related ethical issues are vital. As the 
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discussion presented in this thesis touches upon broader topics within the ELSI of genomics, in 
the following paragraph some indications of the current trends in the industry and indications 
for future research are presented.  
Genomic data have been recognized as precious material for research, with the potential to 
help advance science and improve healthcare; however, they are simultaneously a potential 
source of sensitive information about one’s health and ethnicity, which could be used for 
discriminatory purposes. Being aware of both benefits of usage of genomic data and risks of 
their misuses, numerous organizations and stakeholders (for example, Global Alliance for 
Health and Genomics, American College of Medical Genetics) have been promoting sharing of 
genetic data in a way that adheres to ethical principles such as respect for individuals and 
transparency [12–14].  
Indeed, growing amounts of health-related, including genomic, data are being collected and 
shared. National databases storing health-related information have been created, for example, 
in the UK and in China [15,16]. Numerous mobile applications have been designed to record 
users’ lifestyle and health related data, which may be used by the companies for research 
purposes [17]. Furthermore, portals encouraging consumers of DTC GT to upload their genetic 
data for research purposes emerged; some of these services offer compensation to consumers 
for accessing their data (as discussed in Chapter 2). Genomic and health data has also been 
recognized as assets by big tech companies (Google, IBM), which have been getting access to 
population-derived datasets by paying governments [18,19].  
All these activities raise numerous concerns and issues to investigate, starting with issues of 
informed consent and transparency, which still does not seem to be adequately respected, both 
in the context of collecting data by public entities [15,16], and in the commercial context of 
DTC genetic testing companies, as discussed in Chapter 4. Furthermore, some authors suggest 
that the traditional requirement of specific informed consent needs rethinking in the context of 
novel ways of engaging individuals in research, where digital health data are collected by 
electronic sensors and shared via Internet of things [20]. Another practice, commercialization 
of genomic data challenges the ideals of open science and data sharing based on solidarity, in 
some instances also raising risks of undermining public trust in research. Additionally, the 
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increasing involvement of commercial entities in biomedical research seems to create 
disproportion of powers regarding possibilities of performing research on big datasets [17]. 
Given these concerns, as well as quickly developing activities regarding usage of genomic data, 
the monitoring of the stakeholders’ activities and their implications is essential.  
Genetic testing offered in the context of reproductive choices raises specific issues. 
Legislative frameworks in many countries currently allow the termination of pregnancy on the 
basis of results of genetic prenatal testing6, and more recently, in some places, to select embryos 
based on their genetic makeup [21,22]. These practices, which have their origins in the 1970s, 
has been recognized by some authors as recalling the eugenic approach [23]. It has been argued, 
however, that the current offer of selective abortion is based on accurate science and the value 
of choice, which would distinguish it from the old eugenic practices [23]. The adherence to 
these two criteria in the current clinical genetics practices, however, can be questioned. Firstly, 
the relationships between the phenotypic manifestations of diseases and their genetic 
background, at least in some instances, again are more complex than it was initially thought. 
The interpretation of genetic variants poses challenges and often gives only probabilistic 
indications of their significance; indeed, the cases of misdiagnosis based on genetic information 
have been reported, including in the context of prenatal testing [24,25]. This criticism related 
to adherence to scientific rigor in the offer of prenatal testing (and selective abortions) seems 
to be even more pertinent in the context of recent advancements in prenatal testing and 
proposals to screen foetuses for more conditions as well as to use whole genome sequencing 
for prenatal testing, which can be a source of large amount of genetic information about a foetus 
[26]. Secondly, as shown by studies, ensuring conditions for taking informed choice in the 
context of the offer of prenatal screening, including provision of adequate information, is 
challenging [27,28]. The problem of informed consent and informed choice seems to be further 
problematized in the context of companies advertising prenatal testing directly-to-consumers, 
some of which were shown to present inadequate information about the testing on their websites 
                                                 
6 In some countries abortion is allowed for any reason until certain time (e.g. 12 weeks of pregnancy), after the 
specified time abortions may be allowed under certain circumstances, including a serious genetic condition of a 
foetus (e.g. Czech Republic, Norway). 
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[29]. Finally, the legitimacy and (social) implications of usage of subjective criteria such as 
‘normalcy’ and ‘serious disability’ when deciding whether abortion should be offered based on 
genetic test results are debatable. It is beyond the scope of this section to further explore the 
foundations of current practices of applying genetic knowledge in the context of reproductive 
choices and their relation to eugenics. However, given the concerns indicated above, eugenics, 
values guiding the practice of medical genetics and the limitations of medical knowledge should 
be a subject of further examination. 
Gene editing is a technique which allows to modify DNA of organisms, including humans, 
involving various approaches, for the purpose, for example, of treating diseases.  In 2013 new 
gene editing tool was developed - CRISPR-Cas9 system, allowing for more precise, faster and 
cheaper modification of genomes [30]. This technology can be used to introduce changes in the 
DNA of somatic cells (that is, not inheritable changes) as well as in gametes and embryos in 
vitro (inheritable modifications). In April 2015, in China, CRISPR-Cas9 gene editing 
technology was used for the first time in human embryos, for research purposes [31]. This study 
sparked controversy, prompted debate and extensive media coverage on this issue, as this 
research on embryo seemed to be a step forward to clinical application (involving implantation 
of an embryo in uterus and pregnancy) of this gene manipulation technique. The ability to edit 
genes changes the paradigm in genomics - from diagnosis to treatment or from reading to 
modifying genomes, raising numerous ethical issues, particularly in relation to potential usage 
of this technology in human embryos in the clinical context. These issues include safety 
concerns, implications of introducing heritable changes to human genome, moral status of 
embryos, possibility of using the technology for enhancement purposes, and others. 
Recognizing potentially profound implications related to the applications of CRISPR-Cas9, the 
scientists called for moratorium on its usage in embryos in clinic, and called for research into 
ethical issues of gene editing and public debate, which undoubtfully need to be undertaken to 
guide responsible implementation of this technology.  
Final remarks 
The progress of research and technological developments in genomics reached an 
unprecedented pace in recent decade, opening new possibilities for improved treatment and 
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prevention of diseases. However, the threat of misusing achievements of genomics still exists, 
perhaps is even amplified in some respects, as the technology opens new possibilities, for 
example, to manipulate the human genome, not only in somatic cells but also in germ line cells. 
History teaches us that science can be embraced as a tool serving ideologies and being 
detrimental to individuals. In this era of fast scientific progress, it seems to be essential to stay 
attentive to the ethical dimension of new technologies, learning our lesson from history. 
Research inquires in the ethical, legal and social implications of genomics, based on good 
understanding of the science, recognizing its limits and potential risks, and following rigorous 
methodology should guide the responsible implementation of the technology - in a way that is 
beneficial and respectful of every person.  
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Summary 
Whole genome and whole exome sequencing (WGS, WES) are high-throughput approaches, 
which produce the sequence of (nearly) all the DNA or the protein-coding regions of DNA, 
respectively, in a given organism. WES and WGS generate unprecedented amounts of data, 
from which various types of health-related information may be retrieved, such as diagnostic 
information, results indicating predispositions to diseases, and genetic variants which may 
cause a disease in one’s offspring. Given the amount and the characteristic of genomic 
information, the offer of whole exome and genome sequencing raises ethical, legal and social 
issues. These include, among others, questions about which kind of findings should be obtained 
in genome analysis and returned to patients and how to obtain genuinely informed consent for 
genomic sequencing. Chapter 1 ‘Current ethical issues related to the implementation of whole-
exome and whole-genome sequencing’ provides overview of some of these issues, specifically: 
problems related to opportunistic sceening and unsolicited findings, informed consent and 
commercial offer of genomic sequencing.   
Currently WES and WGS are offered in the context of research, clinical care and direct-to-
consumer genetic testing (DTC GT). Direct-to-consumer genetic testing is a commercial model 
of genetic testing provision where tests are advertised and/or sold directly-to-consumers. 
Chapter 2 provides a timely overview of direct-to-consumer genetic testing market and salient 
ethical issues, as well as an analysis of the impact of the recently adopted Regulation of the 
European Parliament and of the Council on in vitro diagnostic medical devices (IVD) on DTC 
GT. DTC GT companies currently employ new testing approaches, report on a wide spectrum 
of conditions, and target new groups of consumers. Such activities raise ethical issues including 
the questionable analytic and clinical validity of tests, the adequacy of informed consent, 
potentially misleading advertising, testing in children, research uses and commercialization of 
genomic data. The recently adopted IVD Regulation may render many of the predisposition 
DTC GT illegal in Europe as it raises the bar for clinical evidence required for the tests entering 
European market, prohibits misleading advertising, and clarifies that companies established 
outside the European Union should still comply with the relevant EU rules when offering their 
products to consumers residing within the EU.  
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The direct-to-consumer offer of WES and WGS can be perceived as amplifying the already 
identified concerns regarding adequacy of informed consent for both whole exome/genome 
sequencing and the direct-to-consumer genetic testing context. In order to obtain insight into 
how these issues are approached in DTC GT companies offering WGS, a qualitative content 
analysis of websites of companies offering whole exome/genome sequencing directly to 
consumers was conducted. Specifically, information concerning the following elements of 
informed consent was studied: pre-test counselling, benefits and risks, incidental findings, and 
storage and use of consumers’ samples and data (Chapters 3 and 4). The revealed concerns 
include, firstly, the lack of engagement of healthcare professionals in offering of the tests, 
including lack of pre-test counselling. Secondly, some of the companies did not seem to provide 
adequate informed consent documents for genetic testing and for research activities on 
consumers’ samples and data. From the standpoint of medical and research ethics, replacing the 
process of informed consent (which normally consists of a dialogue with a healthcare 
professional and signing IC document) with a ‘clickwrap’ agreement seems to be unacceptable. 
Thirdly, the studies revealed that the content of these documents itself raised concerns. These 
related mainly to the lack of relevant information and/or presence of potentially misleading 
descriptions of some aspects of the testing as well as the secondary use of consumers samples 
and health-related data. Consequently, consumers might not be aware of all the implications of 
undertaking WGS/WES, including the potential benefits and risks, or the usage of their samples 
and/or health-related data for research purposes. Therefore, consumers’ acceptance or the given 
consent might not be truly informed. Additionally, the lack of transparency in provision of 
information about the usage of consumers’ data for research could undermine trust in research 
practices in general, including publicly funded research (Chapter 3 and 4).  
A presence of required elements of information in informed consent documents does not 
guarantee that the patients will understand the descriptions of the complex matters related to 
WGS/WES. To gain insight into how easy to read are IC forms for WGS and WES, the 
readability of IC forms for clinical WES and WGS was evaluated using the SMOG and Flesch-
Kincaid formulas. 36 forms were analysed, most of which were from US providers. The median 
readability grade levels were 14.75 (the SMOG formula), and 12.2 (the Flesch-Kincaid 
formula); these values indicate the years of education after which a person would be able to 
understand a text studied. All forms studied seem to fail to meet the average recommended 
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readability grade level of 8 (e.g. by US medical schools) for IC forms, indicating that the content 
of the forms may not be comprehensible to many patients. The sections aimed at health care 
professionals in the forms indicate that HCPs should be responsible for explaining IC 
information to the patients. However, WES and WGS may be increasingly offered by primary 
care professionals who may not (yet) have sufficient training to be able to communicate 
effectively with patients about genomics. Therefore, to secure an adequate, truly informed 
consent process, the task of developing good, legible examples of IC forms along with 
educating HCPs in genomics should be taken seriously, and adequate resources should be 
allocated to enable these tasks. 
The work conducted for this doctoral degree presents the first empirical studies of the offer of 
whole genome and whole exome sequencing in the direct-to-consumer context (Chapter 3 and 
4). All three empirical studies presented herein (Chapter 3,4, and 5) reveal concerns regarding 
informed consent for WGS and WES and the use of consumers’ samples and data. The presence 
of these issues in the context of genomic approaches that generate huge amounts of sensitive 
data is particularly worrisome. In order to respect patients/consumers, the compliance with 
ethical standards when offering genetic testing should be strived for, also in the commercial 
DTC offer of WES and WGS. To achieve this, it would be constructive to have the community 
of commercial companies weigh in on the development of best practice guidelines for the 
commercial realm along with relevant stakeholders such as consumers, patients and health care 
professionals. The findings presented herein indicate specific areas in which practices should 
be improved providing reference and guidance for well-informed and potentially policy-
relevant discussions between various stakeholders. Furthermore, this research indicates that it 
is important to continue to monitor the behaviour of DTC GT companies and to promote the 
awareness and adherence to the ethical standards currently accepted and/or aspired to by the 
research community.  
 
